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Abstract 
Bone is the most transplanted tissue after blood. As pointed out by the World Health 
Organization, musculoskeletal diseases can potentially rise as the fourth largest cause 
of disability within the next years. Unfortunately, despite the natural ability of bone to 
self-heal it cannot bridge large bone defects without the help of a material. Still today 
the gold standard to restore bone function remains the use of natural bone grafts. 
However, they have several limitations that need to be overcome to accommodate the 
high demands of a global ageing population. 
Calcium phosphate (CaP) bone grafts have been known since the 1970s and stand as 
excellent synthetic candidates due to their composition, similar to the mineral phase of 
bone which consists of approximately 70% of hydroxyapatite (HA). CaPs, and in 
particular HA, possess outstanding intrinsic properties such as biocompatibility, 
bioactivity and the ability to support bone growth. However, HA is chemically stable 
and once implanted it hardly degrades. Ideal synthetic bone grafts should integrate in 
the bone remodeling cycle, balancing implant resorption with its progressive 
replacement by new bone. This can be achieved either by modulating the material’s 
physicochemical properties, or by combining the substrate with biological molecules 
capable of adequately orchestrating the various cells involved in the bone healing 
process. 
The present thesis seeks to explore, on the one hand, the feasibility of modulating the 
physicochemical properties of CaPs towards improving its degradation behavior, and, 
on the other hand, to investigate the potential CaP functionalization with heparin as a 
strategy to improve their biological performance at the various stages of bone healing: 
during the initial phase of inflammation, and during the stages of bone resorption and 
bone growth. 
Chapter 1 offers an overview on bone composition and biology, as well as on bone 
grafting strategies and their potential to heal bone. Chapter 2 deals with the in vitro 
degradation of CaPs in a solution mimicking the osteoclastic environment, focusing 
specifically on the effect of some properties like porosity, specific surface area, 
microstructure and composition. The interrelation of all these parameters sometimes 
masks the relative importance of textural over compositional features, making difficult 
the prediction of their degradation behavior. Chapter 3 explores different strategies to 
incorporate carbonate ions in the crystal structure of HA as a route to obtain materials 
that more closely mimic natural bone.  
To further mimic the biological environment of bone, the second part of the thesis is 
focused on grafting heparin, a highly sulfated glycosaminoglycan present in the bone 
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extracellular matrix, to CaPs. The affinity of heparin for growth factors (GF) makes 
this molecule an excellent candidate to capture endogenous GF bringing many benefits 
in the regulation of cell behavior. It is hypothesized that heparin, given its anti-
inflammatory role, together with the known involvement in osteoblasts differentiation 
(bone forming cells) and osteoclastogenesis (bone resorbing cells formation) could 
enhance the biological performance of synthetic bone grafts. To this aim, CaPs were 
heparinized and their biological performance was assessed using human immune 
system cells, bone forming cells and bone resorbing cells, in an attempt to elucidate 
the synergies of both immune cells and cells of the skeletal system (Chapter 4 and 
Chapter 5). The presence of heparin on the CaPs surface was shown to modulate 
inflammation by down-regulating the expression of pro-inflammatory cytokines, 
which actively provoke acute inflammation resulting in fibrous encapsulation of the 
implant. The immobilization of heparin also contributed to modulate the inflammatory 
response towards a pro-healing stimulation. Additionally, heparin fostered the 
differentiation of mesenchymal stem cells to the osteoblastic lineage, without the 
addition of any exogenous agent. 
Osteoclasts, the bone resorbing cells, are closely related to the immune system since 
monocytes are their precursor cells. The interaction of CaPs, and their heparin-grafted 
analogues were studied in contact with immune cells to determine the capacity of the 
material to foster osteoclast formation, maturation and activity (Chapter 5). The last 
chapter of the thesis, Chapter 6, was devoted to the characterization of the activity of 
osteoclasts on complex materials by cross-sectioning cells on the CaP biomaterials 
using focus ion beam (FIB). This technique allowed investigation of the early stages of 
resorption on materials with complex microstructures, such as CaP cements, which are 
often difficult to evaluate by other techniques. 
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Resum 
L’os és un dels teixits més trasplantats arreu del món desprès de la sang. 
L’organització Mundial de la Salut ha posat de relleu l’increment de les malalties 
musculoesquelètiques, les quals esdevindran la quarta causa mundial de discapacitat 
en el següents anys. Malgrat la capacitat natural de l’ós per autoreparar-se, els defectes 
ossis de grans dimensions necessiten l’ajuda de materials per restaurar-se 
completament. Actualment, l’ús d’empelts naturals és l’alternativa més emprada 
clínicament. Tot i això, els autoempelts comporten certes limitacions que requereixen 
ser adreçades per tal de fer front a les elevades demandes d’una població mundial amb 
un grau d’envelliment creixent. 
Els empelts basats en fosfats càlcics (CaPs) són coneguts des de la dècada del 1970 i 
són uns excel·lents candidats per a la regeneració òssia donada la seva composició, 
similar a la fase mineral de l’os, que consisteix en aproximadament un 70% 
d’hidroxiapatita (HA). Els CaPs, en particular l’HA, posseeixen unes propietats 
intrínseques excepcionals com ara biocompatibilitat, bioactivitat o la capacitat de 
suportar el creixement de nou os. Malgrat la seva semblança amb l’os, l’HA és massa 
estable químicament, i un cop implantada es degrada molt lentament. L’empelt ossi 
sintètic idealment s’hauria d’integrar en el cicle de remodelació òssia, el que requereix 
d’un balanç entre la seva reabsorció i la progressiva substitució per os nou. Aquesta 
capacitat es pot modular mitjançant propietats inherents del material o per mitjà de la 
combinació de substrats amb molècules capaces d’orquestrar adequadament les 
respostes de les diverses cèl·lules implicades en la restauració o curació òssia. 
La present tesis cerca explorar, per una banda, la possibilitat de modular les propietats 
físico-químiques dels CaPs per tal de millorar la seva degradació, i per una altra, el 
potencial per funcionalitzar els CaPs amb heparina, amb la finalitat de millorar les 
interaccions biològiques a les diferents etapes de la restauració òssia, tant durant la 
primera etapa inflamatòria, com durant la resorció i el creixement d’os nou. 
El Capítol 1 descriu l’estat de l’art respecte a les principals característiques de l’os, els 
empelts disponibles i el seu potencial per curar o regenerar el teixit ossi. El Capítol 2 
de la present tesi explora la manera en què la modificació de propietats com la 
porositat, la superfície específica, la microestructura o la composició dels CaPs pot ser 
emprada per regular la degradació d’aquests materials en una solució acídica similar a 
l’emprada pels osteoclasts durant la resorció òssia. La interrelació de totes aquestes 
propietats emmascara de vegades la importància relativa de les propietats texturals, 
molt lligades a les composicionals, dificultant la predicció dels nivells de degradació 
dels materials depenent de cada propietat. El Capítol 3 es centra en les diferents 
estratègies per incorporar ions carbonat en l’estructura cristal·lina de l’HA per tal de 
mimetitzar encara més la composició natural de l’os.  
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Per tal de mimetitzar més l’entorn biològic de l’os, la segona part d’aquesta tesi ha 
estat focalitzada en immobilitzar heparina, un tipus de glicosaminoglicà altament 
sulfonat present en la matriu extracel·lular de l’os, sobre els CaPs. L’afinitat de 
l’heparina per captar factors de creixement fan d’aquesta molècula un candidat 
excel·lent per capturar factors de creixement endògens capaços de regular la resposta 
cel·lular. Així doncs, partint de les propietats anti-inflamatòries de l’heparina, i de la 
seva implicació en els processos d’osteogènesi i osteoclastogènesi, s’ha formulat la 
hipòtesi de que aquesta biomolècula podria contribuir a millorar les prestacions dels 
empelts ossis sintètics. Amb aquest objectiu, s’ha posat a punt un procés 
d’heparinització de CaPs i s`ha avaluat el seu efecte sobre la resposta de cèl·lules 
humanes del sistema immune, cèl·lules osteogèniques i osteoclàstiques, per tal 
d’escatir les possibles sinèrgies de tots dos sistemes, l’immune i l’ossi en la 
regeneració (Capítol 4 i Capítol 5). S’ha demostrat que la presència d’heparina a la 
superfície dels CaPs regula la inflamació per mitjà de la supressió parcial de citocines 
que provoquen processos d’inflamació aguda, conduents a una encapsulació fibrosa de 
l’empelt. Per altra banda, l’heparinització modula la inflamació cap a l’estimulació de 
la restauració natural de l’os. Addicionalment, s’ha observat que l’heparina estimula la 
diferenciació de cèl·lules mesenquimals sense l’addició de cap agent exogen. 
Els osteoclasts, les cèl·lules responsables de reabsorbir os, estan íntimament lligades al 
sistema immune donat que els monòcits en són els seus precursors. En el Capítol 5 
s’ha analitzat l’efecte de l’heparinització en la interacció dels CaPs amb cèl·lules del 
sistema inmune, per determinar la capacitat de fomentar la formació de cèl·lules 
osteoclàstiques, així com la seva maduració i activitat. S’ha observat que la presència 
d’heparina accelera la fusió de precursors per formar osteoclasts madurs. L’últim 
capítol de la tesi, Capítol 6, s’ha dedicat a la caracterització de l’activitat osteoclàstica 
en materials complexos per mitjà del seccionament de les cèl·lules fent ús de la 
litografia per feix de ions. Aquesta innovadora tècnica ha permès l’avaluació d’etapes 
primàries de reabsorció en materials amb microestructures complexes com són els 
CaPs, els quals representen un repte per ser avaluats amb altres tècniques. 
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Scope and aim of the thesis 
Despite the excellent osseointegration potential of CaP bone grafts, the major 
drawback for most apatitic formulations is their limited resorption rates. Consequently, 
CaPs remain at the bony site instead of being gradually replaced by new bone. It is 
fundamental to develop more interactive biomaterials, capable not only of replacing 
bone, but also of stimulating its regeneration. The process of bone regeneration is 
complex and involves many cell types operating simultaneously. Among them, there 
are cells of the immune and skeletal system. Inflammation, which is the first barrier 
faced by the implant, is often overlooked. Recently, the emerging field of 
osteoimmunology has shed light on the importance of the cross-talk between the 
immune and skeletal system in bone regeneration.  
The present thesis focuses on boosting the limited regenerative potential of specific 
CaP formulations through different strategies: i) by modifying its physicochemical 
properties (by changing composition, microstructure, porosity, specific surface area, 
etc.); and ii) through grafting on the CaP surface extracellular matrix molecules, such 
as heparin, known for its anti-inflammatory, osteogenic, and osteoclastogenic effects. 
The materials are analyzed in terms of cell response, using cells of the immune and 
skeletal systems, to understand the contribution of these cell types in bone 
regeneration.   
The specific objectives to achieve the aforementioned goals are: 
Objective 1: Development of calcium phosphate bone grafts with different 
physicochemical properties to control the materials’ degradation behavior and improve 
the biomimicry of bone. 
 Development and characterization of calcium phosphates with different 
physicochemical properties in terms of microstructure, porosity, specific 
surface area, and composition. Assessment of the relative effect of each 
parameter on degradation under conditions similar to the osteoclastic 
resorption.  
 Assessment of different routes for the incorporation of carbonate ions 
into calcium deficient hydroxyapatite through biomimetic and 
hydrothermal synthesis. 
Objective 2: Functionalization of CaPs with heparin, present in the natural 
extracellular bone matrix to mimic cell microenvironment and the evaluation of the in 
vitro cell response to the modified CaPs, focusing on those cell types involved in the 
bone regeneration process: 
 xx 
 
 Immobilization of heparin on the surface of CaPs by different grafting 
procedures (physisorption and chemisorption) and characterization of the 
heparinized surfaces. 
 Study of the immunomodulatory effects of heparin grafted surfaces in 
contact with inflammatory primary human cells. 
 Study of the adhesion, proliferation and differentiation of rat 
mesenchymal stem cells on heparin functionalized CaPs.  
 Study the effects of heparin on the osteoclastogenesis process, and on 
human osteoclast adhesion, proliferation and activity. 
 Evaluation of the resorptive activity of osteoclasts on rough biomimetic 
CaP surfaces by focus ion beam–scanning electron microscopy. 
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Abbreviations 
 
ACP Amorphous calcium phosphate Mϕ Macrophage 
ATPase Adenosintriphosphatase MCPA Monocalcium phosphate anhydrous 
ALP Alkaline phosphatase MCPM Monocalcium phosphate monohydrate 
α-TCP Alpha-tricalcium phosphate M-CSF Macrophage colony stimulating factor 
APTES (3-aminopropyl)triethoxysilane MIP Mercury intrusion porosimetry 
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CDHA Calcium deficient hydroxyapatite OCP Octacalcium phosphate 
CaP Calcium phosphate ON Osteonectin 
CathK Cathepsin K OPG Osteoprotegerin 
COLL Collagen OPN Osteopontin 
CPC Calcium phosphate cement PBS Phosphate buffered saline 
CPF Calcium phosphate foam PG Proteoglycan 
CSF Colony stimulating factor PGE2 Prostaglandin E2 
DBM Demineralized bone matrix PMA Phorbol-12-myristate-13-acetate 
DCPA Dicalcium phosphate anhydrous PMNC Polymorphonuclear cells 
DCPD Dicalcium phosphate dihydrate PTFE Polytetrafluoroethylene 
DNA Deoxyribonucleic acid PTH Parathyroid hormone 
ECM Extracellular matrix RANK Receptor activator of nuclear factor κ B 
FBGC Foreign body giant cell RANKL RANK ligand 
FBS Fetal bovine serum RGD Arginylglycylaspartic acid 
FGF Fibroblast growth factor RNA Ribonucleic acid 
FIB Focus ion beam ROS Reactive oxygen species 
FTIR Fourier transform infrared spectroscopy RUNX2 Runt-related transcription factor 2 
GAG Glycosaminoglycan TCPS Tissue culture polystyrene 
GF Growth factor TGF Transforming growth factor 
HA Hydroxyapatite TNF Tumor necrosis factor 
IGF Insulin-like growth factor SEM Scanning electron microscope 
IL Interleukin SSA Specific surface area 
IL-1ra Interleukin-1 receptor antagonist VEGF Vascular endothelial growth factor 
LPS Lipopolysaccharide XPS X-ray photoelectron spectroscopy 
TRAP Tartrate-resistant acid phosphatase XRD X-ray diffraction 
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1. INTRODUCTION 
Bone tissue is a complex organ which exerts different functions, such as mechanical 
support, protection of soft tissue, calcium and phosphate storage, and hematopoiesis 
among others.[1,2] Bone is one of the most transplanted tissues, and according to the 
World Health Organization (WHO), it is expected that musculoskeletal diseases arise 
as the fourth main cause of disability by the year 2020.[3] These data make relevant the 
importance of designing adequate bone substitutes capable of replacing or stimulating 
the regeneration potential of bone in the coming years.  
The following sections will provide an overview of the basic concepts of bone, its 
hierarchy, features and remodeling processes in order to help understanding the 
necessity and the characteristics of biomaterials for bone regeneration. 
1.1. Bone composition 
Bone is a composite material formed by a main inorganic component and an organic 
matrix. The inorganic part of bone consists of poorly crystalline hydroxyapatite, with a 
structure close to that of hydroxyapatite (HA, Ca10(PO4)6(OH)2), and accounts for 
approximately 70% in weight of its structure; the remaining 30% is constituted by 
collagen (90%) and non-collagenous structural proteins such as proteoglycans, 
sialoproteins, in addition to growth factors and cytokines. Bone also contains cells, 
such as osteoblasts, osteoclasts and osteocytes. Bone hydroxyapatite consists of nano-
sized, plate-like crystals discrete and discontinuously located throughout the organic 
matrix. Hydroxyapatite has an open crystal structure which allows several ionic 
substitutions such as sodium, magnesium, fluoride or citrate, the most common being 
carbonate, which accounts for 4-8wt%.[4] Biological apatites are poorly crystalline 
since they contain several foreign ions, and non-stoichiometric, due to the presence of 
these ionic substitutions.[5] Depending on the type and amount of substitutions, the 
apatite reactivity and chemical behavior becomes altered. The HA crystal structure in 
bone is hexagonal since it allows the habit of foreign ions, whilst monoclinic, which is 
easily destabilized by ions, is more typical of high temperature apatites. 
1.2. Bone structure 
The human skeleton has a total of 213 bones, which are classified in four main 
categories: long bones, short bones, flat bones and irregular bones. In an adult human 
skeleton, 80% of bone consists of cortical bone and 20% of trabecular. Cortical bone is 
dense and surrounds the marrow space, whereas trabecular bone has a honeycomb 
network interposed in the bone marrow compartment.[6] Bone is a highly hierarchical 
connective tissue. The sophisticated architecture of bone and the high organization 
level of the bone matrix not only account for its optimized mechanical performance, 
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but also provide the adequate niche for bone cells and bone marrow, and play a 
significant role in several biological pathways. 
Weiner and Wagner[7] described extensively the hierarchy of bone and established 
seven levels from the nano to the macroscale (Figure 1-1). The hierarchical structure 
of bone is irregular yet highly oriented, making bone a heterogeneous and anisotropic 
composite material.[8] The smallest scale level corresponds to tropocollagen molecules, 
which form fibrils that are later mineralized and self-arrayed, contributing to bone’s 
intrinsic toughness.[9,10] These collagen arrangements are called lamellae, which 
eventually wrap into concentric layers around a central canal called osteon or 
Harversian system. Osteons are around 200 to 250 µm in diameter and run parallel to 
the long axis of bone.[8] Bone hierarchy is responsible for its high mechanical 
performance, and specifically for its inherent capacity to arrest crack propagation. 
 
Figure 1-1. Hierarchical structure of bone.[11] 
1.3. Bone biology 
Bone is an active tissue and hosts several types of bone cells, mainly four subsets: 
osteoblasts (OB), osteoclasts (OC), osteocytes and bone lining cells. Osteoblasts, 
osteocytes and bone lining cells are originated from local osteoprogenitor cells, whilst 
osteoclasts are derived from the fusion of mononuclear precursors, from the monocyte-
macrophage lineage.[12] 
Bone lining cells are present at the bone surface and are usually inactive; they have 
often been named as osteoblasts precursors.[12] Oppositely, osteocytes are active cells 
which are located in the interior of the mineralized matrix. Osteocytes trapped in the 
bone matrix are the most abundant cells in bone and are active mechanosensors 
guiding both osteoblasts and osteoclasts activity during bone remodeling[13] due to an 
extended network of filopodia, connected through bone matrix canaliculi. Osteoblasts 
are derived from stromal cells and their main function is the deposition of collagen 
matrix and its mineralization. Oppositely, osteoclasts are bone-resorbing cells. They 
are able to resorb the extracellular bone matrix by generating an acidic environment to 
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dissolve the mineral phase of bone, and by secreting enzymes (matrix 
metalloproteinases, MMP) to degrade the organic matrix. 
Each type of cell exerts different functions during bone remodeling by a tight cross-
talk among them, based on a complex protein-protein receptor network. These 
biological mechanisms will be described in the following sections. 
1.3.1. Bone remodeling 
The remodeling of bone occurs lifelong by removing old bone from the skeleton and 
forming new bone, firstly described by Frost in 1990.[14] It is a key process during 
which the newly formed bone grows adjusting to the mechanical demands and the 
activity of the person while maintaining its structural integrity and metabolic 
functions.[14] The degree of remodeling of cortical bone ranges from 2 to 5% per year 
whilst trabecular bone is even more actively remodeled, up to 10%, due to the much 
larger surface to volume ratio.[13] 
The bone remodeling process is complex and requires the interaction of many cells 
regulated by a wide range of biochemical and mechanical factors. Proteins and 
receptors in cells orchestrate the biochemical activities according to the 
microenvironmental stimuli. Remodeling can be divided in five phases: activation, 
resorption, reversal, formation, and mineralization; although, some authors described it 
as a four step process regarding fracture repair.[15] The remodeling process starts in 
small packets of cells called basic multicellular unit (BMU) in which activation is 
controlled by paracrine factors (parathyroid hormone, PTH) present in the bone 
microenvironment. Both osteoclasts and osteoblasts have a synergistic activity within 
the BMU. The first event occurring is the activation and consequent resorption by 
transduction pathways established in the cross-talk of the cells in the BMU,[16] as 
depicted in Figure 1-2. 
Paracrine signals such as PTH are responsible for activating the crosstalk by binding to 
receptors in pre-osteoblasts that secrete other proteins signaling for instance 
osteoclasts differentiation and hence starting resorption. Transition signals are 
generated halting bone resorption and stimulating the bone formation process.[17] At 
the termination step, expression of molecules such as sclerostin bind to osteoblasts and 
bone formation ceases. The balance between resorption and formation is influenced by 
several factors as genetic, mechanical, vascular, nutritional, hormonal and local.[18] 
Other mediator proteins participate in bone remodeling, such as bone morphogenetic 
proteins (BMP), endothelial growth factor (VEGF), transforming growth factor (TGF), 
fibroblast growth factor (FGF), and insulin-like growth factors (IGF)[18–20] driving the 
remodeling response. 
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Figure 1-2. Schematic representation of a BMU and the associated bone remodeling process.[21] 
Bone remodeling is of major importance during healing. Any injury starts with the 
formation of a clot of platelets and blood cells which recruit inflammatory cells from 
the immune system to resolve a wound. Eventually, this clot transforms into a ECM-
hematoma,[22] which signals the following revascularization at the injured site by 
means of several interleukins, specific cytokine-proteins influencing immune 
pathways, and further recruits stem cells to promote the formation of soft callus, which 
finally is mineralized.[23] 
As depicted, several orchestrators play a role during the complex bone remodeling 
process. Hence, it is crucial to understand each stage of the process to overcome the 
different necessities during, for instance, a biomaterial implantation. Bone grafting is 
leading to an injury which triggers different biological cascades. Implants interact with 
host tissue, for instance bone, and can integrate in it. The extent of this integration is 
tightly linked to the characteristics of the implant material. In order to understand the 
potential interactions triggered upon an exogenous material implantation, the 
following sections describe the main actors orchestrating the bone remodeling process. 
1.3.1.1. Bone microenvironment: The role of the extracellular matrix 
in bone remodeling 
As described in Section 1.1, the extracellular matrix (ECM) of bone consists mainly of 
secreted products of many cell types that form an organized scaffold for cell support. 
The main structural component is mineralized collagen. However, it contains also 
other molecules like laminins or proteoglycans (PGs) among others, with a 3D 
insoluble ultrastructure. Many of the proteins contained in the ECM are glycosylated, 
partially due to the presence of glycosaminoglycans (GAG). GAGs which are present 
in the ECM assembled into PGs through a core protein, are long negatively charged 
Introduction 
7 
 
heteropolysaccharides that occupy large areas providing many sites for interaction 
with various molecules such as growth factors or cytokines.[24,25] Since all cell types 
are in close contact with the ECM, they benefit from the high affinity of GAGs for 
GFs. It is widely accepted that the ECM can integrate and deliver multiple signals to 
cells through the release of GFs upon ECM degradation or by the degradation of 
GAGs.[25–27] Additionally, GFs can also bind to ECM by GAG-mediated interactions 
through specific protein domains and membrane proteins acting on cells.[23,28] In fact, 
the microenvironment that the ECM creates is fundamental for cells as most 
interactions of cells and proteins are mediated by the ECM components. All the 
functions associated to the ECM have been summarized in Figure 1-3. 
 
Figure 1-3. Main functions of the ECM and its influence in biochemical and mechanical 
processes, adapted.[26] 
1.3.1.2. Inflammation 
Inflammation is necessary to different extents during bone remodeling. Any injured 
site in bone and in any other tissue undergoes inflammation. Thus, a fracture or a bone 
replacement will both be raising an injury. Upon injury, exudation of proteins, fluids 
and blood cells occur at the injured site[29,30] leading to inflammation. Immune cells 
arriving at the injured site are responsible for degrading and phagocytizing any 
pathogen or injured tissue, as well as signaling the pathways for cells to resolve 
inflammation and restore tissue. Leukocytes, connective tissue cells and extracellular 
matrix components are the main factors regulating the chemical signaling to resolve 
inflammation. Initially, a provisional matrix is formed consisting mainly of fibrin 
which furnishes structural and biochemical components to the process of wound 
healing.[29] Neutrophils and monocytes, intravascular cells, arrive at this provisional 
network and release chemotactic factors over different time periods activating in turn, 
different cell functions. The first released chemical factors are reactive oxygen and 
nitrogen species (ROS and NOS, respectively)[31] which generate oxidative stresses 
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into the microenvironment. ROS levels dictate the effect on cellular mechanisms; high 
concentrations are deleterious to cells due to their oxidizing effect on cell proteins, 
lipids and DNA. Low ROS concentrations instead, function as signaling molecules for 
cell growth, adhesion, differentiation and apoptosis. 
Neutrophils are short-life cells and undergo apoptosis within hours or few days. On the 
contrary, when monocytes adhere to tissue, they transform into different types of 
macrophages depending of the microenvironment stimuli. According to these stimuli, 
macrophages release cytokines[32–35] to help address healing by signaling other cell 
types such as fibroblast, endothelial, and mesenchymal cells. Even though 
inflammation is necessary to start healing, an overexposure to inflammatory signals 
can lead to fibrotic tissue encapsulation by chronic inflammation and tissue 
granulation. Thus, a balance between pro-inflammatory and pro-healing cytokines is 
fundamental as depicted from Figure 1-4. 
 
Figure 1-4. Peak expression of cytokines over time during inflammation, adapted.[36] 
Macrophages assume diverse and context dependent phenotypes (known as 
macrophage polarization) between pro-inflammatory and anti-inflammatory 
phenotypes, as summarized in Figure 1-5. They are classified as M1 and M2, 
according to their pro- or anti-inflammatory phenotypes, respectively.[37] The early 
stage of the healing process is dominated by the pro-inflammatory M1 phenotype 
where cytokines such as tumor necrosis factor alpha (TNF-α) or interleukin 1 beta (IL-
1β) are released.[38] In an ideal scenario after the first hours, M1 cytokines would be 
down-regulated by the release of anti-inflammatory cytokines such as IL-10, IL-4, IL-
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13 or TGF-β restraining inflammation and initiating tissue repair.[39] This tight 
interrelation between the immune and the skeletal system has led to a new emerging 
field called osteoimmunology that seeks to understand and benefit from the tight 
crosstalk between both systems.  
As depicted, both the immune and skeletal system share several regulatory, signaling 
molecules and transcription factors which modulate their crosstalk. Leukocytes and 
macrophages release proteins which can activate for instance osteoclast maturation, 
such as IL-1, IL-6 and TNF (osteolytic cytokines) or RANKL[40] or promote 
osteogenesis by the regulation of BMP.[41] Understanding the different pathways 
established between both cell lineage is crucial to develop more integrating materials. 
An adequate inflammatory response is a requisite of successful bone repair since it is 
also coupled with coagulation and angiogenesis, which are also requisite for cells 
survival. 
 
Figure 1-5. Macrophage polarization and their function and cytokines released, adapted.[32,42] 
1.3.1.3. Osteoclastogenesis 
Osteoclasts are responsible for bone resorption. They can degrade both the inorganic 
phase of bone by releasing acidic species, i.e. protons, and the organic phase through 
specific enzymes that degrade the organic components. 
Osteoclasts are multinucleated cells formed by fusion of cells of the monocyte-
macrophage lineage upon stimulation with proteins. These proteins are often secreted 
by bone marrow stromal cells or cells of the osteoblastic lineage.[43] Macrophage 
colony-stimulating factor (M-CSF), receptor activator of nuclear factor kappa B 
(RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) are secreted by 
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osteoblasts or stromal cells and regulate osteoclast activity in what is known as the 
RANK/RANKL/OPG pathway. Specifically, RANK-RANKL interactions lead to 
osteoclast maturation, while OPG is a decoy receptor inhibiting RANK-RANKL 
interactions, as shown in Figure 1-6. Other environmental stimuli can foster osteoclast 
formation such as PTH, prostaglandin E (PGE2), vitamin D, or cytokines such as 
interleukin 11 (IL-11) or tumor necrosis factor alpha (TNF-α).[43–45] 
 
Figure 1-6. Osteoclast differentiation and activation, adapted.[12] 
As previously mentioned, osteoclasts are derived from the monocyte-macrophage 
lineage. Monocytes belong to the immune system and can arrive to bone after an 
injury, where they become macrophages which have the potential to actively 
phagocytize pathogens. Fusion of macrophages under the stimulation with CSF and 
RANKL, among others, generates mature osteoclasts. In fact, during maturation, 
osteoclasts resemble foreign body giant cells (FBGC). Prior to bone resorption, 
osteoclasts attach to bone by polarizing their membrane forming a ‘ruffled membrane’ 
typical from this type of cells. Once attached and sealed by the ruffled membrane, 
osteoclasts transport acidifying vesicles to degrade bone. Thus, bone resorption by 
osteoclasts takes places under acidic conditions, normally at pH around 4.5. 
Adenosintriphosphatase (ATPase) and carbonic anhydrase are some of the proteases 
mediating this acidification which degrades bone mineral, whereas cathepsin K 
(CathK) and MMPs degrade the organic components of bone.[46,47] 
1.3.1.4. Osteogenesis 
There are two paths for bone formation both involving the transformation of a pre-
existing connective tissue (mesenchyme) into bone tissue; intramembranous 
ossification occurs by direct conversion from mesenchyme to bone and takes place 
specifically in flat bones; endochondral ossification occurs by a cartilage intermediate 
which is later replaced by bone.[13] 
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The main actors during osteogenesis are osteoblasts, which are in charge of the 
secretion of the organic component of bone ECM and its subsequent mineralization. 
Osteoblasts differentiate from the mesenchyme; i.e. from mesenchymal stem cells 
(MSC). The microenvironment of MSC will dictate the differentiation into the bone 
lineage cells. Osteoblasts differentiation can be activated by different pathways, being 
the main regulators bone morphogenetic proteins (BMP), firstly identified by Urist in 
1967. BMPs are members of the TGF-β superfamily and are known to be able to 
recruit immature cells and trigger their subsequent differentiation into the bone 
lineage.[19] 
Fully differentiated osteoblasts are typically protein producing cells, both collagenous 
and non-collagenous proteins, and are responsible also for regulating the bone matrix 
mineralization. During OB maturation, typical genes are expressed which are 
associated to different events; proliferation, ECM development and maturation, and 
finally, mineralization. The first stage is related to the secretion of collagen type I 
(COLL1), alkaline phosphatase (ALP), osteopontin (OPN), bone sialoprotein (BSP), 
and RUNX2 that regulates osteocalcin (OCN), which is a later marker during the 
mineralization stage. The osteoblasts trapped in the ECM during mineralization will 
later become osteocytes, as shown in Figure 1-7, by down-regulation of ALP and 
COLL expression. 
 
Figure 1-7. Differentiation of MSC into osteoblasts and osteocytes and the markers at each stage, 
adapted.[48] 
1.4. Synthetic bone grafts 
Bone is the most commonly replaced tissue except for blood. Despite its natural self-
healing ability, large bone defects or critically sized defects cannot heal by themselves 
and the need of bone grafts, either natural or synthetic, to replace or regenerate the 
damaged tissue is fundamental. Autografts harvested from the patient are known to be 
the gold standard; however, their low volume availability and associated morbidity 
limit their application.[49,50] Cadaveric allografts, demineralized bone matrix (DBM) or 
interspecies xenografts are also alternatives but they have also some limitations, such 
as the associated immunogenic response, risk of disease transmission, as well as 
cultural and ethical considerations.[51] For all these reasons, the use of synthetic bone 
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grafts represents a good alternative, although it is necessary to enhance their 
performance in order for them to be truly competitive with the autografts. 
Synthetic bone graft must be biocompatible, and ideally, they should undergo 
remodeling and support new bone formation. However, it is difficult to have synthetic 
bone grafts combining all this features. Calcium phosphates (CaPs), owing to their 
close similarity to the mineral phase are good candidates for this application. However, 
the in vivo performance is uneven, depending not only on the composition but also on 
the processing route used for the synthesis, as described in the following sections. 
1.4.1. Calcium Phosphates 
CaPs as already mentioned, have a composition similar to that of natural bone and 
possesses several of the required properties for optimal bone regeneration since they 
can be bioactive, resorbable, osteoconductive and osteoinductive*.[52–56] However, the 
combination of all these properties into one material requires a tight control and a 
thorough understanding of the material and the biological site. Still now, this control is 
not easy and efficient enough. 
CaPs can be considered as salts of orthophosphoric acid which can be obtained 
through several synthesis methods. The synthesis path usually dictates the final 
physicochemical properties of the compound. There exist eleven known CaPs with 
Ca/P molar ratio within 0.5 and 2.0. Four of them are obtained by solid state reactions 
at high temperature, and the rest through precipitation in aqueous environment by low 
temperature synthesis routes. Additionally to the Ca/P molar ratio, acidity/basicity and 
solubility are the parameters influencing mostly their physicochemical properties,[57] as 
depicted from Table 1-1. In general, the lower the Ca/P molar ratio is, the more acidic 
and water-soluble the calcium orthophosphate becomes. 
 
 
 
 
 
 
* 
Bioactive: the ability to form a bone-like apatite layer on implant surface in the living body. 
Resorbable: the ability to degrade or be resorbed by surrounding tissues. 
Osteoconductive: the provision of a scaffold for the growth of new bone cells on implant surface 
Osteoinductive: the capacity of the implant to stimulate primitive, undifferentiated and pluripotent cells to 
develop into bone-forming lineage.  
Introduction 
13 
 
Table 1-1. Existing Calcium phosphates (CaP).[57] 
Ca/P ratio Compound Chemical formula Solubilitya
0.5 Monocalcium phosphate  
monohydrate (MCPM) 
Ca(H2PO4)2·2H2O ~18 
0.5 Monocalcium phosphate  
anhydrous (MCPA) 
Ca(H2PO4)2 ~17 
1.0 Dicalcium phosphate  
dihydrate (DCPD) 
CaHPO4·2H2O ~0.088 
1.0 Dicalcium phosphate  
anhydrous (DCPA) 
CaHPO4 ~0.048 
1.33 Octacalcium phosphate (OCP) Ca8(HPO4)2 (PO4)4·5H2O ~0.0081 
1.5 α-Tricalcium phosphate  
(α-TCP) 
α-Ca3(PO4)2 ~0.0025 
1.5 β-Tricalcium phosphate  
(β-TCP) 
β-Ca3(PO4)2 ~0.0005 
1.2-2.2 Amorphous calcium 
phosphate (ACP) 
CaXHY(PO4)Z·nH2O N.A. 
1.5-1.67 Calcium-deficient  
hydroxyapatite (CDHA) 
Ca10-X(HPO4)X(PO4)6-X(OH)2-X ~0.0094 
1.67 Hydroxyapatite (HA) Ca10(PO4)6(OH)2 ~0.0003 
2.0 Tetracalcium phosphate (TTCP) Ca4(PO4)2O ~0.0007 
aSolubility in g/L in water at 25°C 
1.4.2. High temperature CaPs 
There are four of the eleven CaP salts which are obtained by solid state reaction at 
high temperatures. One of the most used as synthetic bone graft is tricalcium 
phosphate (Ca3(PO4)2), which exhibits two allotropic forms (α-TCP and β-TCP, 
respectively). β-TCP is obtained by solid-state reaction of calcium and phosphate 
precursors, for instance through the following reaction (Equation 1)[58]: 
2ܥܽܪܲ ସܱ ൅ ܥܽܥܱଷ ൅ ݄݁ܽݐ → ܥܽଷሺܲ ସܱሻଶ ൅ ܥܱଶ               (Equation 1) 
At temperature above 1125°C, β-TCP transforms to α-TCP, which is a metastable 
phase that in contact with water hydrolyses rapidly to calcium deficient hydroxyapatite 
(CDHA). Tetracalcium phosphate (TTCP) is the most basic salt, which possesses a 
higher solubility than HA. It can be obtained at temperatures above 1300°C by 
reaction of DCPA with calcium carbonate (CaCO3). TTCP is not stable in water and 
hydrolyses rapidly to HA and calcium hydroxide (Ca(OH)2).[59] 
HA can be obtained both by solid state reaction at high temperature, and by 
precipitation in aqueous solutions at low temperature. The high temperature HA is 
obtained by solid-state reaction of other calcium phosphates (e.g., MCPM, DCPA, 
DCPD, OCP) with CaO, Ca(OH)2, or CaCO3 at temperatures above 1200 ºC.[57,60] The 
solubility of HA is the lowest among the listed CaPs in Table 1-1. Biphasic CaPs 
(BCP), traditionally mixtures of HA and β-TCP, combine a stable and poorly soluble 
phase like HA with the more soluble β-TCP, and can also be prepared by solid state 
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reaction. The properties of the resulting material lie in between each of the 
components. Due to the higher degradability of TCP, the reactivity of BCP increases 
with the increase in the TCP/HA ratio. Thus, in vivo bioresorbability of BCP can be 
controlled through phase composition.[61,62] 
The microstructure of the high temperature CaPs is dependent on the sintering 
temperature and time. For instance, higher sintering temperatures result in lower 
specific surface area and lower porosity, but improved compression resistance.[61] 
Figure 1-8 shows the typical sintered microstructure of a BCP scaffold. Upon 
sintering, atoms diffuse across the boundaries of the particles fusing them together and 
forming sintering necks which lead to denser and smoother pieces.[63] 
Biological apatites contain several ionic substitutions within the hydroxyapatite 
structure. Chemical modifications can be inserted in high temperature CaPs, 
generating different chemical behaviors, such as higher solubility or reactivity. Pietak 
et al. successfully incorporated silicon ions and proved its effect as an inhibitor of 
grain growth.[64] Several authors have focused their efforts in the production and 
characterization of high temperature doped CaPs with silicon, magnesium or 
carbonate.[65–70] 
 
Figure 1-8. SEM images of a BCP scaffold obtained at different sintering temperatures: A: 1200; 
B: 1150, and C: 1100ºC. Lower sintering temperature results in an increase of micropores and a 
decrease in the crystal size.[71] 
Macroporosity can also be incorporated in high temperature CaPs. Macropores are 
usually formed due to the release of volatile materials, i.e. the incorporation of pore-
creating additives, so-called porogens. The ideal porogen should be non-toxic and, in 
the case of sintered ceramics, should be finally volatilized upon sintering.[60] Porosity 
has been demonstrated to have a great effect on the resorbability of the material.[52,72] 
1.4.3. Low temperature CaPs 
Monocalcium phosphate monohydrate (MCPM), monocalcium phosphate anhydrous 
(MCPA), octacalcium phosphate (OCP), dicalcium phosphate dihydrate (DCPD), 
dicalcium phosphate anhydrous (DCPA), amorphous calcium phosphate (ACP), and 
calcium deficient hydroxyapatite (CDHA) can all be produced by a precipitation 
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reaction in aqueous solutions at low temperature. However, some of them can also be 
obtained through high temperature methods.  
The most relevant low temperature CaP for bone regeneration applications are those 
compounds found in the body (HA, OCP, ACP, and occasionally DCPD). MCPM and 
its anhydrous form MCPA (formed upon heating MCPM above 100°C), for instance, 
are the most acidic CaP and are not naturally found in the body. They are rarely 
employed as substitutes for bone replacement. Similarly, DCPD can be crystallized at 
low pH, pH <6.5, and transformed to the anhydrous counterpart (DCPA) at 
temperature above 80°C. Their minerals are called brushite and monetite, respectively. 
Oppositely to MCPM, DCPD is found biologically in pathological calcifications and is 
proposed as one of the intermediates in bone mineralization.[73] OCP is thought to be 
an unstable transient intermediate during precipitation of hydroxyapatite, and it is 
found as component in human dental and urinary calculi and plays a crucial role in in 
vivo formation of apatitic biominerals.[74,75] Analogously, ACP can be encountered as a 
transient phase during precipitation of CaPs in aqueous systems. Usually, it is 
described as the first phase appearing when precipitation occurs from high 
supersaturated solutions.[74] HA can also be synthesized at low temperature, mainly by 
precipitation, hydrothermal treatments or hydrolysis. 
By far, the most interesting low temperature CaP is HA or its analogous CDHA due to 
their similarity both in structure and composition to the mineral phase of bone. Low 
temperature CDHA is not a stoichiometric compound, but a solid solution with the 
following formula: Ca10−x(PO4)6−x(HPO4)x(OH)2−x, (where x is between 0 and 1). 
Therefore, it has a Ca/P ratio between 1.67 and 1.5. CDHA is crystal structured like 
hydroxyapatite, but possesses cation vacancies (Ca2+) and anion (OH–) vacancies. 
Some of the sites occupied solely by phosphate anions in stoichiometric 
hydroxyapatite are substituted by hydrogen phosphate (HPO42–) anions. It can be 
obtained by precipitation, with poor crystallinity and high specific surface area, which 
enhance their solubility compared to stoichiometric HA. Thermal decomposition of 
CDHA results in its transformation to β-TCP when the Ca/P ratio is 1.5, or to biphasic 
β-TCP/HA if the Ca/P lies between 1.5 and 1.67. 
1.4.3.1. Calcium phosphate cements 
Among the low temperature CaPs, calcium phosphate cements (CPC) stand as a very 
particular type of material that has generated great interest as bone grafts. CPC were 
discovered by Brown and Chow in the 1980s and LeGeros et al.[77,78] CPC are formed 
through a mixture of a calcium orthophosphate salts with a liquid phase, normally 
water or an aqueous solution, and forms a paste able to harden and set through a 
dissolution and precipitation process in physiological conditions. The most commonly 
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used CPCs are based on final products of hydroxyapatite or brushite, as shown in 
Figure 1-9. 
One of the most exciting properties of CPCs consists of their ability to form an 
injectable paste that is able to self-set in physiological conditions. This enables them to 
be handled directly by clinicians and to be injected into bone cavities with minimal 
invasive surgery.[5] One of the first kinds of CPCs to be commercialized was the 
Constanz cement,[79] which consisted of a poorly crystalline carbonated apatite 
(dahllite). Upon implantation, cements have shown to resorb slowly, which causes the 
problematic of mismatch of the resorption rates accomplished naturally in bone. Great 
efforts have been put towards the development of these materials in an attempt to 
achieve better resorption rates, similar to those of bone, coupling bone formation with 
implant resorption. 
 
Figure 1-9. Calcium phosphate cement formulations.[80] 
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Since cementitious reactions involve mixing a powder with a liquid phase, this simple 
reaction offers a wide range of tunable properties depending on the particle size of the 
reactants, liquid phase composition, liquid to powder ratio (L/P), setting environment, 
and setting time. CPCs are intrinsically porous due to the formation of an entangled 
network of crystals during precipitation, resulting in high specific surface areas that 
enhance bioactivity.[81] The use of starting powders with small particle sizes makes 
them more reactive and this favors the formation of many nuclei leading to the 
precipitation of a higher number of smaller crystals.[82] Cements also possess 
nanoporosity due to the voids in between crystals. Moreover, increasing the high liquid 
to powder ratio of the cement formulation leads to microstructures with a higher 
content of micropores caused by the higher distance between particles.[83] 
Despite the intrinsic porous nature of CPCs –with pores in the nano- and micrometric 
ranges, they lack macroporosity, which is crucial for bone ingrowth and to spur 
resorbability. Similarly to the sintered materials, macroporosity can be easily obtained 
through the addition of non-toxic porogens[84] or by surfactants that allow creating and 
stabilizing foamed pastes.[82,85] All porosity levels achievable with CPCs are depicted 
in Figure 1-10. 
 
Figure 1-10. Pore entrance size distribution associated to the microstructure in macroporous 
CDHA CPC; a) crystal entanglement due to setting reaction, b) crystal agglomerated due to L/P 
ratio and c) macropores due to foaming process, adapted.[83] 
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As earlier mentioned, CDHA crystal structure allows many ionic substitutions. In 
order to further mimic biological apatite, CDHA can be synthesized incorporating the 
ion substitutions present in bone, such as carbonate, magnesium, strontium, etc. 
Carbonate represents the major natural ionic substitution, and carbonate ions can be 
placed both at phosphate and hydroxyl positions in the apatite lattice, named as B-type 
or A-type respectively. The B-type substitution is the most frequently found in 
biological apatites, together with charge compensation by a calcium vacancy, and with 
a hydrogen atom which bonds to a neighboring phosphate.[86] 
Ionic substitutions have been shown not only to affect the physicochemical properties 
of CaP bone grafts materials, but also their biological performance which will be 
addressed in the following sections. 
1.5. Biological performance of synthetic bone grafts 
As previously mentioned, bone grafts, and particularly CaPs, have the great advantage 
of being recognized by the body since they have similar composition to that of natural 
mineral bone phase. When properly designed, CaPs can actively participate in the bone 
remodeling process. CaPs can foster new bone formation and are also susceptible to 
osteoclastic degradation, which makes them excellent candidates for bone 
regeneration. During bone remodeling, there is a tight synchronization between bone 
resorption and new bone formation that needs to be taken into account in the design of 
CaP materials. The balance between formation and resorption is complex, and as 
described earlier, there are several different actors guiding the process. The 
modulation of CaPs biological performance has been investigated by different authors 
who have described different routes to enhance the biomaterials output.[87,88] 
It is of paramount importance to approach bone regeneration from a multidisciplinary 
view. It is necessary to understand the interaction of the different material properties 
(chemical, textural, mechanical, etc) with the surrounding cells, in order to identify the 
possible directions to enhance biomaterial’s performance. In addition to chemical 
composition, microstructural properties, grain and crystal size, microporosity, surface 
roughness and specific surface area have also been proposed as crucial parameters 
controlling the biological response of biomaterials. An important property required in 
bone regeneration is osteoinduction. The ability of a material to induce osteogenic cell 
differentiation represents a clear advantage to integrate grafts into tissue.[89] Several 
authors have investigated chemical and textural properties of biomaterials, both in 
vitro and in vivo, in order to understand the biological reactions triggered by each 
feature.[90-92] 
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The following sections summarize the main strategies that researchers have adopted to 
modulate materials properties in views of improving their integration and facilitating 
bone remodeling.  
1.5.1. Physical properties 
Physical properties mainly concern textural properties such as roughness, topography, 
specific surface area and porosity. Biomaterial geometry and topography are crucial 
for cell attachment for instance. It has been shown that nanosized surface features can 
act as a direct physical trigger on MSC osteogenic differentiation, even without 
additional osteogenic supplements.[93,94] Importantly, high specific surface areas have 
been demonstrated to play a key role. High surface areas of low temperature CaP 
allows high adsorption and retention of important proteins for the chemical signaling, 
as depicted from the work of Espanol et al.[95] 
Porosity also has a great influence on the success of biomaterials. Generally, the 
importance of pores is related to the invasion of the materials by blood vessels, 
therefore sustaining the metabolism of cells inside the scaffold.[96] Pore geometry has 
been pointed as crucial by Habibovic et al. demonstrating that bone formation was 
exclusively limited to the inside of concavities of pores which helped to entrap and 
concentrate proteins.[71] Parameters such as pore interconnectivity, pore geometry, strut 
topography and porosity, contribute to modulate the process of osteogenesis. Cell 
survival depends on nutrients and oxygen supply, hence the need of an interconnected 
pore network that allows for vasculogenesis.  
Pore sizes are dictating the extent of bone formation (Table 1-2). It is known that pore 
sizes above 100µm in solid ceramics boost their potential to allow angiogenesis and 
bone growth in vivo.[97] Additionally, smaller pore sizes allow interactions with 
proteins and cells, as well as hosting secretory matrix which provide promoting factors 
such as BMPs. In sintered CaP ceramics, a decrease in sintering temperature while 
keeping composition constant, leads to an increase in the number of micropores, which 
enhanced biological response, and specifically the osteoinductive potential.[98] 
Similarly, Fellah et al. demonstrated that an increased microporosity and specific 
surface area were beneficial for the amount of bone formed in a study in critical-sized 
femoral defects in goats.[99] However, higher porosities lead to decreased mechanical 
strength restricting their application to light load bearing sites. 
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Table 1-2.Biological implications of the different pore sizes in 3D scaffolds.[100] 
Pore size of a 3D scaffold Biochemical effect or function 
<1 µm Interaction with proteins Responsible for bioactivity 
1-20 µm 
Type of cells attracted 
Cellular development 
Orientation and directionality of 
cellular ingrowth 
100-1000 µm 
Cellular growth 
Bone ingrowth 
Predominant function in the 
mechanical strength 
>1000 µm Implant functionality Implant shape 
1.5.2. Chemical properties 
Besides the effect that the physical properties of CaPs have on cell behavior, changes 
in the materials’ composition can also be used to guide the biological behavior. The 
most common strategies to modify CaP composition is to combine soluble CaPs 
phases to improve the remodeling capacity of the material, to dope the CaPs with key 
ions to regulate specific biological cascades,[104] and to alter the surface charge of the 
material to selectively adsorb certain proteins and modulate cell response.  
Biphasic CaP mixtures combining phases with different chemical reactivity or 
solubility is a common strategy to improve the biological performance of scaffolds. 
Several authors have investigated the effect of more soluble phases such as brushite or 
monetite[103–105] and the combination of HA with β-TCP.[62,106] Gisep et al. showed that 
biphasic cements resorb faster than monophasic ones.[107] However, resorbability often 
restricts the structural integrity of scaffolds, so a balanced compromise between 
biological and mechanical properties is mandatory for successful bone grafts. In 
addition to improve resorption, the liberation of calcium and phosphate ions from the 
material into the surroundings may increase the local supersaturation of the biological 
fluid, causing precipitation of carbonated apatite while also entrapping important 
proteins such as BMPs.[71] 
Doping CaPs with specific ions can also be used to influence cellular signaling and 
improve bone remodeling. The release of ions upon dissolution of the scaffold can 
trigger different cell behavior. Boanini et al. reviewed the effect of ionic substitutions 
in low temperature CaPs with respect to their cellular response.[102] Carbonate doping 
of apatites was shown to distort the crystal lattice increasing resorbability compared to 
stoichiometric HA and also to promote osteoclastic activity. Landi et al. achieved 
higher osteoconductive properties and increased the quantity of newly formed bone on 
carbonated HA compared to HA.[108] Spence et al. found enhanced osteoclastic 
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mediated resorption for carbonated HA, which was further triggered by the amount of 
carbonate in the HA structure,[109] and used it as a tool to boost the poor resorption of 
synthetic HA. 
Silicon doped HA have also shown improved bioactivity by stabilizing amorphous 
CaPs and fostering dissolution.[68] Cardenas et al. studied the in vitro cell response to 
α-TCP-based cement containing calcium silicates and showed improved osteogenic 
response.[110] Strontium substituted CaPs have been shown to stimulate bone formation 
and hamper osteoclastic proliferation.[111] Landi et al. demonstrated an enhancement of 
osteoconduction and resorption rate of magnesium-doped HA compared to control 
stoichiometric HA.[112] Webster et al. also studied the osteoblast response to trivalent 
and divalent doped HA such as bismuth or zinc and magnesium.[113] Interestingly, they 
found that bismuth doped HA could enhance osteoblast mineral deposition for longer 
time than divalent cations. Zinc has also been successfully incorporated to CaP 
structures. This element is an essential trace element acting as cofactor for numerous 
enzymes, including DNA and RNA replication and protein synthesis.[114] 
A different way of guiding cell behavior through compositional modification is by 
modifying the surface charge of the materials. The works of Yamashita and Nakamura 
et al. proved an accelerated bone growth on negatively charged surfaces compared to 
positively charged HA.[115,116] In general, the surface charge of CaP varies depending 
on the synthesis method and this causes differences in the electrostatic interactions 
with the surrounding environment influencing cell behavior. According to their charge, 
biomaterials interact differently with proteins driving different cell responses.[117–119] 
To further engineer the biomaterials surface, a rather widely spread strategy is through 
grafting of organic motifs present in ECM or in cell microenvironment on the 
biomaterials surface. This strategy has been shown to greatly modulate biological 
responses as will be shown in the following section. 
1.5.3. Functionalization with biomolecules 
The functionalization of materials with specific biomolecules has attracted great 
scientific interest as an alternative way to tune the biological response to biomaterials. 
During the last decades, this strategy has been exploited in different applications, such 
as engineered platforms for cell proliferation and differentiation or drug delivery 
systems for controlled release of molecules, such as antibiotics, proving effective in 
enhancing the bone regeneration process.[23,80,120–123] 
A vast range of molecules have been explored for immobilization on materials surface. 
Special attention has been paid to GF, and specifically to BMPs, as they are known to 
foster the osteogenic response,[20,124,125] and VEGF, which improves blood vessels 
generation or angiogenesis. Also short peptide sequences with specific functions have 
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been explored, such as RGD, which is a cell adhesion motif able to interact with 
integrins. However, both peptides and proteins have several drawbacks still to 
overcome. Proteins can easily be denaturalized, hence losing their conformation and 
biological activity. On the contrary, peptides possess higher stability to pH and 
temperature changes than proteins, but they are less efficient than proteins and their 
enzymatic stability in vivo is often too low.  
However, since growth factors are naturally occurring in the body, an alternative 
strategy is also possible based on the recruitment of these naturally occurring proteins 
without the need of grafting them on the surface of the biomaterial.[123–130] The 
functionalization of CaP with molecules able to attract GF represents a smart strategy 
to overcome the drawbacks of proteins and peptides. 
An interesting molecule ubiquitous in the body and present in several transduction 
pathways is the family of glycosaminoglycans (GAGs). As previously mentioned, 
GAGs are present in the stem cells niche and in the extracellular matrix and have great 
affinity for proteins and GFs.[131–133] They can bind to core proteins to form 
proteoglycans (PG) or to other proteins and cell receptors.[131] 
Salbach et al. pointed at the potential of GAGs to enhance the regenerative properties 
of biomaterials,[134] due to the wide range of interactions they can exert with different 
cell lineages such as endothelial and fibroblast cells, skeletal, and immune system 
cells.[131,135,136] The GAGs family includes hyaluronic acid, chondroitin, heparan and 
keratin sulphates, and heparin, which is the most sulfated GAG. The sulfonation 
degree of GAGs has been demonstrated to affect their binding affinity with 
proteins.[137–141] Unlike peptides that often bind GFs via specific molecular recognition, 
heparin can bind numerous GF target via less specific electrostatic interactions by 
virtue of the negatively charged sulfate and carboxylate groups on their constituent 
GAG chains. Although heparin has been used for decades as anticoagulant due to its 
capacity to bind antithrombin, its regenerative potential is nowadays attracting much 
attention. 
Indeed, GAGs are able to interact directly with BMP and interleukins, influencing 
osteogenesis, osteoclastogenesis and the immune system, as shown in recent 
works.[142–145] Despite the potential of GAGs, their biological activity has been mainly 
studied on organic materials such as the collagen matrix and polymers, or by direct 
supplementation on the cell culture media.[137,146] Salbach, Hempel and Hintze et al. 
focused their works on unraveling the mechanisms of the interactions between GAGs 
and proteins involved in osteogenesis, mainly BMP-2, BMP-4, sclerostin-Wnt, and 
TGF-β.[137,139,140,147–149] Edlund et al. covalently functionalized heparin and BMP-2 on 
resorbable polymers, showing enhanced bioactivity, growth and proliferation of 
MSC.[122] Among the limited works performed on CaPs, pro-angiogenic GF combined 
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with heparin was used by Lode et al. for the sustained release of VEGF from CaP 
cements.[150] Gittens et al. instead, investigated the feasibility of anchoring heparin on 
HA for drug delivery purposes and proved an increased affinity of b-FGF and BMP-2 
on the heparin modified HA.[128] In the study by Goonasekera et al., it was proved that 
the mechanisms of heparin anchoring to HA affected its interaction with BMP-2 and 
therefore its release profile.[151] 
In the above-mentioned studies, the purpose of combining GAGs with CaP substrates 
were clearly focused towards addressing the release of pre-loaded GF in views of 
improving the bone regenerative potential of CaPs. However, the strategy of using 
GAGs to sequester endogenous GF had so far not been reported for CaPs.  
 
Figure 1-11. Surface interactions between biomaterials and cells; adapted.[152] 
The present thesis seeks to exploit different strategies to improve the regenerative 
potential of CaPs bone grafts either through chemical or physical modification of the 
CaPs, as depicted in Figure 1-11. Particular attention will be paid to characterize the 
material’s response at different stages of the bone healing process using cells of the 
immune and skeletal systems to better understand and predict the in vivo behavior. 
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2. In vitro degradation of calcium phosphates: effect of multiscale 
porosity, textural properties and composition 
 
Scope 
 
The resorption of biomaterials can be achieved actively or passively by means of 
cellular activity (so-called bioresorption) and/or by the inherent physicochemical 
properties of materials, respectively. The following chapter aims to describe the 
physicochemical properties of a wide variety of CaPs and the extent to which each 
parameter can modulate degradation. Multiscale porosity, SSA and composition 
characterization during acidic degradation can shed light on the most effective 
properties to modulate biomaterial degradation and resorption, which is crucial and 
mandatory for the regenerative potential of bone grafts. An accelerated degradation 
method using an acidic media resembling osteoclast resorption environment (pH<4) 
has been used to unravel the extent to which each property affect CaPs degradation. 
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2.1. Introduction 
Bone has a remarkable capacity for self-repair. However, this self-healing 
capacity is not sufficient to bridge critical sized bone defects and moreover it can 
be impaired in some pathological situations. In these cases, the use of bone 
grafts, either natural (autografts, allografts or xenografts) or synthetic, is crucial 
to restore bone function.[1] An ideal bone graft should provide initial strength at 
the implantation site while actively supporting bone remodeling. Therefore, it is 
important to have a tight synchronization between graft resorption and new bone 
deposition to allow a gradual replacement of the bone graft by newly formed 
bone.[2] Although bone autografts remain the gold standard for such applications, 
site morbidity and volume availability are major concerns that limit their use.[3] 
The need for synthetic bone grafts is clear, but their choice and design remain 
still complex due to many considerations such as material composition, 
architecture, mechanical stability, degradation products, etc. that can potentially 
affect the remodeling process.[4] 
Among synthetic bone grafts,[5-7] calcium phosphates (CaP) are very interesting 
for remodeling purposes as they possess a close resemblance to the mineral phase 
of natural bone consisting of ~70 wt% of nanocrystalline hydroxyapatite (HA).[8] 
Owing to the close compositional resemblance of CaP to bone mineral, they can 
induce a biological response similar to that taking place during bone remodeling. 
Indeed, CaP can potentially be resorbed by osteoclastic cells and can also support 
bone formation under the action of osteoblastic cells.[9] However, despite the 
potential of CaP, there is presently no material matching the remodeling rates of 
natural bone. The bottleneck for most CaP formulations, including 
hydroxyapatite-based formulations, is their poor resorption rate, especially for 
sintered HA, which is one of the most commonly used materials.[10] In vivo 
studies have proved that even after 9 months of implantation sintered HA 
remained at the site with hardly any sign of resorption.[11,12] To circumvent this 
problem, HA has been combined with more soluble phases such as β-tricalcium 
phosphate (β-TCP).[13–16] Alternatively, more inherently soluble phases such as 
brushite/monetite have also demonstrated higher resorbability.[17,18] In addition, 
doping the crystal structure of HA with e.g. carbonate ions was found to enhance 
its resorption and to promote osteoclastic activity in vitro.[19–24] 
However, not only composition plays a role in degradation rates. The 
modification of crystallinity, grain size, specific surface area,[25,26] or the porosity 
content[27–29] are relevant physicochemical features which have been shown to 
help tailor resorption rates, hence improving the in vivo performance of such 
implants.[30] Despite the various works proving increased degradation in materials 
with lower crystallinity, high SSA, decreased grain density, and a higher degree 
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of porosity, the extent to which each parameter influences resorption remains 
unclear. The complexity of isolating the contribution of each of these parameters 
lies in the close interrelation between these factors, as changing one can 
potentially affect the other/s.  
One key aspect in the evaluation of the in vitro degradation of biomaterials is the 
selection of the degrading medium. Although degradation of CaP has been 
assessed in different solutions,[31–35] the simulation of the resorption process by 
osteoclasts requires working in solutions at acidic pH. This is because resorption 
by mature osteoclast proceeds through the development of a tight ring-like zone 
of adhesion (i.e. the sealing zone) that delimits the resorbing area onto which 
osteoclasts generate an acid milieu that can reach values below pH 3, resulting in 
the dissolution of the underlying mineral.[36] In this regards, studies performed at 
low pH can be used as predictors of osteoclastic degradation.[37–40] 
The aim of this chapter was to provide quantitative information on the relative 
importance of CaP composition, specific surface area, and porosity in an in vitro 
model of CaP degradation. We took advantage of the possibility offered by the 
fabrication of hydroxyapatite scaffolds using biomimetic routes, i.e., by low 
temperature dissolution–precipitation reactions, to systematically introduce 
controlled levels of porosity at the nano, micro, and macroscale, as well as to 
modify the specific surface area.[41–43] Thus, the porosity at the nano-microscale 
and the specific surface area were modified by varying the L/P ratio and the 
particle size of the starting powder, respectively.[41,42] In turn, macroporosity was 
introduced through a foaming process.[43] Moreover, the effect of doping with 
carbonate ions on the degradation behavior was analyzed. Finally, the 
degradation behavior of the biomimetic scaffolds was compared to that of 
sintered materials, namely β-TCP and sintered HA, obtained after thermal 
treatment of the biomimetic scaffolds, which, in addition to the change in 
composition, exhibited different textural parameters. To facilitate comparison 
between materials and to discard any effect due to the use of different reagents 
(e.g. purity, presence of ionic traces of foreign ions, etc.), all materials were 
prepared from the same Ca and P sources. 
2.2. Materials and Methods 
2.2.1. Preparation of biomimetic calcium deficient 
hydroxyapatite 
α-TCP was used for the preparation of biomimetic calcium deficient 
hydroxyapatite (CDHA) through a cementitious reaction. Briefly, α-TCP was 
obtained by heating calcium hydrogen phosphate (CaHPO4, Sigma-Aldrich, St. 
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Louis, USA) and calcium carbonate (CaCO3, Sigma-Aldrich, St. Louis, USA) at 
a 2:1 molar ratio at 1400°C for 15h and then quenching in air. Subsequently, the 
particles obtained were milled as described elsewhere[41] to obtain two different 
α-TCP powder sizes, coarse (C: 5.2µm median size) and fine (F: 2.8µm median 
size). α-TCP, with 2wt% of precipitated hydroxyapatite (PHA, Merck KGaA, 
Darmstadt, Germany), was mixed with a liquid phase consisting of an aqueous 
solution of 2.5wt% disodium hydrogen phosphate (Na2HPO4, Merck, Darmstadt, 
Germany) which acted as a reaction accelerant. Both phases were mixed in a 
mortar for 1min and the resulting paste was transferred into 15x2mm2 PTFE disc 
moulds where the discs were left to set in water at 37°C for 7 days. CDHA 
samples with different liquid to powder ratios (L/P) were prepared, ranging from 
0.35 to 0.65mL/g. 
2.2.2. Preparation of biomimetic carbonate-doped 
hydroxyapatite 
Carbonated calcium deficient hydroxyapatite (C-CDHA) was obtained by 
performing the setting of the cement in a saturated sodium bicarbonate solution 
(NaHCO3, Sigma-Aldrich, St. Louis, USA) instead of water, for 17 days at 37°C. 
Samples were immersed in the carbonated setting medium once cohesion was 
achieved, i.e., approximately after 5h of preparation. In these specimens, water 
was used as the liquid phase of the cements instead of a disodium hydrogen 
phosphate solution.  
2.2.3. Preparation of biomimetic foams 
To prepare the macroporous scaffolds, the powder phase consisting of 98wt% α-
TCP and 2wt% of precipitated hydroxyapatite (PHA) was mixed with an aqueous 
solution of 1wt% Polysorbate 80 (Sigma-Aldrich, St. Louis, USA) as foaming 
agent.[43] Both phases were foamed with a domestic food mixer for 30s at 
7000rpm and then transferred to 6x12mm2 PTFE cylindrical moulds where they 
were left to set in water at 37°C for 10 days. The L/P ratios for the foams were 
adjusted to 0.55 and 0.65mL/g for coarse and fine α-TCP powders respectively, 
as these proportions produced scaffolds with similar macroporosities for the two 
powders. 
2.2.4. Preparation of sintered hydroxyapatite and 
beta-tricalcium phosphate 
Sintering of CDHA and C-CDHA at 1100°C for 9h resulted in β-TCP and 
sintered HA (SHA). This protocol was applied both to non-foamed and foamed 
cements. The non-foamed specimens corresponding to β-TCP and SHA were 
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obtained from coarse particles since no differences were observed regarding their 
physicochemical features after sintering. Figure 2-1 summarizes the various 
synthesis procedures and the nomenclature assigned to the different materials. 
 
Figure 2-1. Sketch summarizing the various CaP synthesis procedures and sample 
nomenclature. C = carbonated; F = foam; CDHA = calcium deficient hydroxyapatite; 
SHA = sintered hydroxyapatite; β-TCP = beta tricalcium phosphate. C and F subscripts 
denote the size of starting α-TCP. * In this work, the degradation of sintered 
hydroxyapatite (SHAC and SHAF) was only analyzed in foamed samples. ** The effect of 
microporosity on the degradation of non-foamed β-TCP was assessed using the coarse 
samples (β-TCPC). 
2.2.5. Physicochemical Characterization 
2.2.5.1. X-ray Diffraction (XRD) 
Phase characterization of the samples was performed by XRD using a D8 
Advance diffractometer (Bruker) equipped with a Cu Kα anode 
(monochromated, λ=1.5406Ǻ), operated at 40kV, and 40mA. Data were collected 
in 0.02° steps over the 2θ range of 10°-80° with a counting time of 2s per step. 
Prior to analysis, the samples were finely ground into powders. The experimental 
patterns were compared to those of hydroxyapatite (JCPDS 09-0432), α-TCP 
(JCPDS 09-0348) and β-TCP (JCPDS 09-0169). Phase quantification was 
performed using analysis software (DIFFRAC.EVA software, Bruker). The 
analyses were based on reference intensity ratio values. Phase intensities of 
experimental diffractograms were adjusted to those of reference patterns. The 
algorithm calculations are performed taking into account the intensity ratio of the 
experimental phase with respect to a standard pattern (corundum, I/Icor). 
2.2.5.2. FTIR spectroscopy 
Samples were analyzed by ATR-FTIR using a Nicolet 6700FTIR equipped with 
a He/Ne beam, CsI beam splitter and DTGS-CsI detector. 64 scans were acquired 
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with a resolution of 4cm-1 in the range of 4000 to 575cm-1 with a Germanium 
crystal.  
2.2.5.3. Carbonate quantification 
Elemental quantification of total carbon content was performed by bulk 
combustion using a Thermal combustion element analyzer, Thermo EA 
1108(TC/EA), working in standard conditions (Helium flow at 120mL/min, 
combustion furnace at 1000°C, chromatographic column oven at 60°C, oxygen 
loop 10mL at 100kPa). The amount of carbonate was calculated according to the 
following equation: 
Percentage	of	Carbonate ൌ ܯܹ஼ைయమషܯ ஼ܹ ൉ %஼ 
where,	ܯܹ஼ைయమష is the molecular weight of carbonate ion, ܯ ஼ܹ is the molecular 
weight of carbon, and %஼ is the percentage of carbon given by the measurement. 
Prior to analysis, samples were crushed using an agate mortar, and the powders 
were dried at 120°C overnight. 
2.2.5.4. Morphological analysis 
Scanning electron microscopy (Zeiss Neon40dual beam FIB/SEM) was used to 
study the microstructure of the samples. All micrographs were taken from the 
cross-section of samples. Prior to imaging, samples were coated with carbon to 
enhance conductivity. 
2.2.5.5. Specific Surface Area 
The SSA area was determined by nitrogen adsorption using the BET method 
(ASAP 2020, Micromeritics). Prior to measurement, samples were outgassed in 
vacuum conditions (10µmHg) at a holding temperature of 100°C for 2 hours. 
2.2.5.6. Porosity 
The open porosity and pore entrance size distributions were obtained by MIP 
(Autopore IV Micromeritics). Mercury contact angle used was 130 degrees and a 
surface tension of 485 dynes/cm for the measurement analysis. All samples were 
dried at 100°C for 2 hours prior to measurement. Mercury intrusion-extrusion 
curves were recorded from 30 to 30000psia. 
2.2.5.7. Skeletal density and compression tests 
The skeletal density of samples was measured by helium picnometry (AccuPyc 
133, Micromeritics) for the different compositions CDHAC, CDHAF, C-CDHAC, 
β-TCP and HA. The compressive strength of the different compositions and L/P 
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ratios for non-foamed formulations were measured using a Universal Testing 
Machine (Instron 8511) at a cross-head speed of 1mm/min until fracture. Twelve 
cylindrical samples (6mm diameter by 12mm high) were analyzed for each 
composition and L/P. Foam specimens for the different compositions were 
analyzed for compression strength using a Bionix (MTS, Universal testing 
machine) and 20 cylindrical samples were tested. 
2.2.6. Accelerated degradation study 
An accelerated degradation study was performed by immersing the samples in an 
acidic solution consisting of 0.01M hydrochloric acid (HCl, PanreacAppliChem) 
and 0.14M sodium chloride (NaCl, PanreacAppliChem) at 37°C, based on 
previous studies.[36,44] Prior to degradation, samples were dried at 120°C 
overnight until a constant weight was achieved. Since the solution was not 
buffered, to prevent any change in the solution pH that would alter the 
degradation behavior, the samples were immersed in a large volume of acidic 
medium (15mL) to keep the pH constant. The solutions were placed in sterile 
polypropylene tubes (50mL) over 8h under static conditions. Every hour, 
samples were transferred to new vials with fresh medium. After degradation, 
samples were rinsed thrice with distilled water and dried overnight at 120°C until 
constant weight. The weight loss percentage (n=3) was obtained by calculating 
the difference in weight according to the equation: 
Percentage	of	weight	loss ൌ ௠బି௠೑௠బ ൉ 100	ሾ%ሿ                   (Eq.2) 
where, m଴ is the initial sample mass and m୤ is the final mass after drying. 
Supernatants at each time point were collected and pH values were measured 
using a pHmeter (MultiMeter MM 41). 
2.2.7. Statistical analyses 
The degradation experiments were conducted with three samples. The results are 
presented as the average and standard deviation. Statistical significance with a 
level of p<0.05 was evaluated for dense and foamed samples. One-way ANOVA 
was used for dense samples since they presented a normal distribution. The 
analyses of foamed versus non-foamed specimens were carried out using the 
non-parametric Mann Whitney test since no normal distribution was found. 
Compressive strength is presented as mean and standard deviation. All statistics 
were performed using SPSS software (IBM). 
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2.3. Results 
2.3.1. Physicochemical Characterization 
Figure 2-2A shows the X-ray diffraction results for the different samples. The 
XRD profile of the biomimetic samples differed significantly from the sintered 
ones in terms of peak sharpness as a consequence of the low crystallinity of 
biomimetic CDHA. Lower crystallinity was more pronounced in CDHAF than in 
CDHAC. The three CDHA samples contained traces of unreacted α-TCP (3wt%). 
It is noteworthy that the addition of carbonate altered the CDHA conversion 
kinetics, and 17 days were required for conversion of C-CDHA samples into 
similar levels as those of CDHA coarse and fine. Similarly, the absence of 
accelerant in the liquid phase, as is the case of foamed specimens required 10 
days of setting. This was confirmed by the similar unreacted α-TCP levels. Upon 
sintering CDHA at 1100°C, pure β-TCP was obtained, whilst sintering of C-
CDHA resulted into stoichiometric HA. 
The ATR-FTIR spectra of the different materials studied are shown in Figure 
2-2B. Similar to what was observed by XRD, sintered samples showed better 
resolved bands than biomimetic materials. This was particularly evident when 
comparing CDHA with SHA. Typical phosphate (PO43-) bands in HA appear at 
570, 600, 960, 1030 and 1090cm-1, corresponding to vibrational modes ν4, ν1, ν3 
respectively.[45]-[47] The stoichiometric high temperature SHA showed well 
defined and sharper bands than CDHA for the phosphate groups. The hydroxyl 
band, at 630 cm-1 appeared also sharper in SHA (Ca10(PO4)6(OH)2) than in 
CDHA, consistent with the non-stoichiometric nature of the apatites obtained by 
hydrolysis of α-TCP (i.e., Ca9(PO4)5(HPO4)(OH)).[47] The presence of HPO42- in 
CDHA was proved by an additional band appearing at 870 cm-1. Typical 
carbonate bands (CO32-) at 1414 and 1471cm-1, and at 871cm-1 were visible in C-
CDHA, which are representative of ν2 vibrational mode accounting for a B-type 
carbonated apatite (i.e. phosphate substitution).[48,49] The β-TCP spectrum 
showed typical phosphate bands at 551, 604, 945, 970, 1024, 1042, 1080 and 
1118cm-1.[46,50] 
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Figure 2-2. XRD patterns (A) and ATR-FTIR spectra (B) of all materials studied, 
prepared with a L/P ratio of 0.55mL/g 
The skeletal density of the biomimetic compositions slightly differed. CDHAC 
and CDHAF resulted in 2.70±0.02g/cm3 and 2.67±0.02g/cm3 respectively, while 
the value for C-CDHAC decreased to 2.54±0.03g/cm3 consistent with the 
incorporation of carbonate in the crystal structure. As expected, sintered β-TCP 
and HA compositions, showed the highest values of density with 3.08±0.02 and 
3.18±0.04g/cm3 respectively. TC/EA analyses of carbonate-containing samples 
are summarized in Table 2-1. The carbonate levels were similar for all samples 
regardless of their porosity, ranging from 11 to 13%wt. Control samples of 
CDHAC and CDHAF were included and proved no carbonation occurring from 
ambient carbon dioxide or from precursor chemicals.  
Table 2-1.Carbonate content of the different carbonated CDHA samples 
 L/P ratio Carbonate level 
[mL/g] [%wt] 
C-CDHAC 0.35 12.25 ± 0.78 
0.45 13.30 ± 1.27 
0.55 12.33 ± 0.25 
0.65 13.23 ± 0.04 
Foam-C-CDHAC 0.55 11.33 ± 0.39 
Foam-C-CDHAF 0.65 12.58 ± 0.32 
CDHAC/F 0.55 0.05± 0.07 
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Scanning electron micrographs of the different compositions are shown in Figure 
2-3. The different biomimetic substrates showed microstructures consisting of 
aggregates of nano-micrometric crystals. For CDHAC, the aggregates consisted 
of plate-like crystals. CDHAF instead consisted of needle-like crystals due to the 
smaller particle size of α-TCP used for its synthesis. The introduction of 
carbonate resulted in a plate-like morphology of the crystals, both for the C-
CDHAC and C-CDHAF samples, which showed a very similar microstructure. 
The high temperature CaPs, β-TCP and SHA, showed the typical polyhedral 
grain structure of sintered samples.  
 
Figure 2-3. Scanning electron micrographs showing the microstructures of the different 
samples prepared with L/P ratio of 0.55mL/g (scale bar: 500nm). 
Micrographs taken at a lower magnification of the CDHA and β-TCP non-
foamed samples obtained at different L/P ratios and micrographs of the foamed 
samples revealed significant differences according to the processing methods of 
the materials (Figure 2-4). The increase in the L/P ratio led to more open 
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structures, consistent with an increase in the separation between the starting α-
TCP particles, due to the higher amount of liquid. Foaming resulted in the 
formation of larger macropores, with pore interconnections, i.e., openings 
between adjacent macropores.  
 
Figure 2-4. Scanning electron micrographs at low magnification of the non-foamed 
CDHAC and CDHAF and β-TCPC samples obtained with different L/P ratios (0.35 and 
0.65mL/g), as well as of the foamed counterparts. The scale bar in the two first columns 
corresponds to 5µm, and in the third column (foams) to 100µm. 
The specific surface area and total open porosity values for all materials are 
shown in Figure 2-5. Figure 2-5A displays the values for non-foamed materials 
and Figure 2-5B, for foamed analogues. Materials synthesized at high 
temperature showed low SSA values (<1m2/g) whilst low temperature 
biomimetic substrates showed higher SSA values. Specifically, CDHAF with 
needle-like structure possessed the higher SSA values (40m2/g) whereas CDHAC, 
consisting of bigger plate-like crystals, showed lower values (15m2/g). 
Carbonated samples (C-CDHAC) showed values between those of CDHAC and 
CDHAF (27m2/g). Carbonated CDHA fine (C-CDHAF) was not analyzed since 
porosity, microstructure and SSA was equal to the coarse counterpart. 
The L/P ratio did not have a significant effect on SSA values. Oppositely, L/P 
ratio had a great influence on porosity values. The increase in L/P ratio resulted 
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in higher percentages of open porosity, significantly evident after the foaming 
process, as assessed by MIP. The opening structure correlated to the increase in 
L/P ratio was also demonstrated by the decrease in mechanical properties. 
Compression strength showed a linear decrease upon L/P increase, independently 
from composition. Sintered β-TCP exhibited the highest compression strength, 
whilst biomimetic substrates showed similar resistance. 
 
Figure 2-5. Specific surface area (SSA) and percentage of open porosity values for 
biomimetic and sintered non-foamed compositions (A) and for the corresponding foamed 
formulations (B). Note that for the foams two L/P were studied, 0.55 and 0.65mL/g, 
corresponding to coarse and fine formulations, respectively. Compression strength of the 
non-foamed samples for each L/P and for each different composition (C). Values 
corresponding to CDHAC and CDHAF were taken from reference [41]. Compression 
strength for the different foamed formulations (D). 
Interestingly, in the non-foamed compositions, the increase of L/P ratio not only 
resulted in an increase in the total porosity, but also shifted the pore size 
distributions to larger sizes, as illustrated in Figure 2-6. All biomimetic samples 
(CDHAC, CDHAF and C-CDHAC) showed bimodal pore populations. Larger 
pores account for the pores in between aggregates (micrometric range), and the 
smaller pores relate to the distance between crystals (nanometric range). In 
contrast, sintered β-TCP samples exhibited a large peak centered around 1µm, 
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and an almost total disappearance of the nanoporosity, as a consequence of 
nanocrystal coalescence during the sintering process. 
The effect of the foaming process on the pore size distribution is illustrated for 
biomimetic and sintered foams in Figure 2-6E and F, respectively. Biomimetic 
foams (Figure 2-6E) maintained the trend regarding nano-microporosities, with a 
superimposed macroporosity up to 100µm. Upon sintering, the macroporosity as 
well as the microporosity around 1µm were maintained, whereas no nanoporosity 
was observed as a result of the aforementioned coalescence of the nanocrystals 
(Figure 2-6F). 
 
Figure 2-6. Pore entrance size distributions of the different samples, as determined by 
MIP. 
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2.3.2. Accelerated degradation study 
The results of the accelerated degradation study are illustrated in Figure 2-7. 
Figure 2-7A depicts the degradation of the different non-foamed materials 
depending on their L/P ratio while Figure 2-7B shows the degradation of the 
foamed samples (non-foamed counterparts are included as control samples). 
Overall, when the liquid to powder ratio increased, the degradation increased for 
all samples but to varying degrees depending on their composition, 
microstructure, and textural properties. For a given L/P, CDHAF experienced a 
larger weight loss than the similar CDHAC, and the degradation was more 
sensitive to the increase in L/P than the coarse counterpart. Surprisingly, the 
carbonated apatite (C-CDHA) exhibited the lowest degradation values of all 
samples, whereas β-TCP, despite being the most soluble phase, showed 
degradation values between CDHA and C-CDHA. 
 
Figure 2-7. Accelerated in vitro degradation for biomimetic and sintered samples (n=3). A) 
Non-foamed samples groups identified by the same superscripts are not statistically 
different (P > 0.05). Letters indicate differences between different L/P within the same 
formulation; numbers identify differences between compositions for the same L/P 
(p<0.05); B) Degradation for foamed samples and non-foamed counterparts. According to 
subscripts, coarse samples have L/P of 0.55mL/g and fine analogues 0.65mL/g. * denotes 
statistically significant differences (p<0.05) between samples, dense and foamed, 
respectively, C) pH values for L/P ratio 0.35 and 0.65mL/g. 
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The incorporation of macroporosity in the foamed samples resulted in 
remarkable increases in degradation, compared to their non-foamed analogues 
(see Figure 2-7B). However, the extent of the increase was strongly dependent on 
the substrate. Thus, biomimetic CDHA showed the highest increase (three- and 
four-fold weight loss for the foamed CDHAC and CDHAF compared to their non-
foamed counterparts). In the carbonated samples, C-CDHA, the impact of the 
macroporosity was smaller resulting in a three-fold weight loss increase 
irrespective of the α-TCP particle size. In the sintered β-TCP, the impact of 
foaming in the degradation was again dependent on the size of the starting α-
TCP, being two or three-fold for β-TCPC and β-TCPF respectively. SHA foams 
showed the lowest degradation among all foamed materials, yielding similar 
resorption as non-foamed materials. Figure 2-7C shows the pH values measured 
during the degradation experiment. Steady values in pH were observed for all 
samples throughout the experiment, irrespective of sample composition and 
porosity. 
Figure 2-8 combines the degradation results obtained for each material as a 
function of porosity. Despite that non-foamed formulations exhibited a linear 
increase with L/P (differences in slope were observed depending on sample 
type), the introduction of interconnected macropores in the foamed formulations 
led to marked changes in the degradation behavior. Degradation increased 
exponentially (exponential growth function) on the biomimetic samples with 
correlation coefficients (R2) of 0.986, 0.799, and 0.855 for coarse, fine, and 
carbonated CDHA respectively, but remained linear for the sintered β-TCP (R2= 
0.938). 
The samples were analyzed after degradation, to investigate possible changes in 
composition and morphology. The results for representative samples of each 
composition at a fixed L/P (0.55mL/g) are shown in Figure 2-9. XRD (Figure 
2-9A) proved that no additional phases were re-precipitated. SEM images (Figure 
2-9B) taken of the surface of the materials clearly demonstrated the degradation 
of the pristine plate and needle like crystals in the biomimetic CDHA samples, 
whilst images of β-TCP exhibited a less-obvious degradation only visible at the 
grain boundaries. The microstructure of the non-foamed samples cross-sections 
remained intact indicating that the acid was not penetrating the sample bulk. 
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Figure 2-8. Degradation of the different samples as a function of the open porosity 
depicted in Figure 2-5. Insets for each type of material corresponds to dense formulations 
(including 4 different L/P ratios), while full graphs combine dense with the foamed 
specimens. C-CDHAC and β-TCP include the foamed coarse and fine specimens. 
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Figure 2-9. XRD (A) and SEM (B) images for different compositions with L/P of 0.55mL/g 
before (solid line) and after degradation (dashed line). SEM images of the surface of the 
specimens for the biomimetic CDHA (coarse and fine) and β-TCP, before and after 
degradation (scale bar: 1µm). 
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2.4. Discussion 
The present study analyses the degradation behavior of different calcium 
phosphate biomaterials. The simple in vitro model used here does not capture all 
the complex mechanisms occurring during the degradation process of a 
biomaterial once implanted in the body. Therefore, the results obtained cannot 
directly be translated to material performance in vivo. However, this model 
facilitates comparison of the sensitivity to acidic degradation of different 
synthetic calcium phosphate ceramics, and, most importantly, it makes easier 
analyzing the relevance of some textural properties, i.e. specific surface area and 
porosity, during the acidic degradation of synthetic calcium phosphates. 
The use of cementitious reactions in the formulation of biomimetic samples was 
vital to control the level of nano- and microporosity of the samples.[40] Indeed, 
the hydrolysis of α-TCP at body temperature results in the precipitation of an 
entangled network of crystal aggregates responsible for the presence of 
nanoporosity in the samples (Figure 2-4 and Figure 2-6). Increasing the L/P ratio 
during sample preparation gradually introduced an additional level of porosity 
within the micron range, due to an increase in the distance between crystal 
aggregates(Figure 2-4 and Figure 2-6).[40] Furthermore, the foaming process 
allowed introducing an interconnected network of macropores in the material 
(Figure 2-4 and Figure 2-6). This provided a platform to systematically assess the 
role of the multiscale level of porosity in the degradation behavior of calcium 
phosphates. On the other hand, the change in the starting α-TCP powder size 
from fine (F) to coarse (C) led to a change in the morphology of the nanocrystals 
from needles to plates -regardless of the L/P ratio- with a consequent change in 
SSA. The SSA was controlled by the surface area of the crystals which was 
readily available due to porous nature of cements (crystals precipitate forming an 
open entangled network) and was not affected by the L/P ratio. Modification of 
the cements composition was achieved either by incorporation of carbonate ions 
during precipitation or by a sintering process. 
The degradation behavior of the different materials can be analyzed in two 
separate blocs: the degradation of the non-foamed samples, i.e. 
micro/nanoporous samples, versus the degradation of the foamed formulations, 
i.e., macroporous samples. Although all samples were inherently porous, non-
foamed specimens possessed a maximum pore size below 3µm, whilst foamed 
formulations presented a superimposed macroporosity, typically above 10µm. 
Regarding the non-foamed CDHA materials, despite the similar porosity values 
of biomimetic coarse and fine samples at a fixed L/P ratio, fine samples yielded 
higher resorption (Figure 2-7A), thus revealing the effect of SSA (the only 
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exception was for L/P 0.35). Thus, for a given porosity, CDHAF degraded more 
than CDHAC. However, the difference in weight loss was small, and depended 
on the porosity and pore size of the specimens. Changing the L/P from 0.35 to 
0.65mL/g led to a linear increase in the degradation of biomimetic C and F 
samples. This was due not only to the increase in total porosity with L/P, but also 
to the displacement of pore sizes to larger values, due to the increase in 
interaggregate spaces.[40,41] This led to the appearance of an interconnected pore 
network around 1-2µm (Figure 2-6A and B) through which the acidic media 
could improve penetration even if this was limited to the nearby surface. As 
shown in Figure 2-8, the increase of degradation with microporosity was more 
pronounced for the CDHAF than for CDHAC (from 5wt% to 6.5wt% and 8wt% 
respectively), leading to a three times larger slope (0.13 vs. 0.04). This can be 
associated to the higher SSA and is in agreement with the trend observed by Kuo 
et al. using calcium sulphate based materials.[51] 
However, for the less porous formulations: CHDAC and CDHAF at L/P of 0.35, a 
similar degradation of around 5wt% was observed even if CDHAF doubled the 
SSA of CHDAC. The lower packing efficiency of coarse samples results in 
interaggregate spaces slightly larger than those observed for fine samples (pores 
centered at 50nm and 30nm in Figure 2-6A and B, respectively) allowing more 
liquid penetration and the subsequent degradation of the exposed volume. 
It is worth mentioning that in calcium phosphate cements the L/P ratio and the 
particle size of the starting powder, which determine the SSA and micro-
nanoporosity (Figure 2-5 and Figure 2-6), are usually adjusted in order to 
optimize the mechanical and rheological properties, but their effect on the 
degradation rate is often overlooked. The results obtained show that they also 
influence the sensitivity to acidic degradation, and therefore, this should be taken 
into account in the design of the cement formulation.   
The setting of the α-TCP cement in a carbonate solution produced a carbonate-
doped calcium deficient apatite. Interestingly, despite the comparable values in 
SSA between carbonated doped HA (C-CDHAC) and the non-carbonated 
substrates (CDHAC, CDHAF), the degradation behavior was significantly lower 
for the carbonated samples (p<0.05). This was unexpected, since the 
incorporation of carbonate ions in the hydroxyapatite lattice is known to 
markedly disturb the crystal lattice[52] increasing its solubility.[53–55] 
Quantitatively, C-CDHAC resorption was reduced by a 30-50% compared to 
CDHAF, regardless of the L/P ratio. Figure 2-7C and Figure 2-9 showed that the 
carbonate ions released during degradation did not increase the pH of the 
degrading media, which could have altered the degradation behavior. 
Additionally, the ions released did not cause re-precipitation of secondary phases 
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either. Moreover, although in the present work high percentages of carbonate 
were obtained; those values were comparable to other reported works.[56] Most 
importantly, the position of the carbonate bands in the FTIR indicated the 
incorporation of carbonate ions in the phosphate positions as shown in Figure 
2-2B. Typical bands of CO32- at 1414 and 1471cm-1 [21,48,49] gave evidence of a 
preferred B-type substitution. However, due to the broad bands in carbonate 
region υ2 region (871cm-1) further analysis are necessary to discard some 
adsorbed or interstitial carbonate.  
The reason for the unexpected decrease in degradation can be linked to the fact 
that in the present study, the degradation behavior of the carbonated samples was 
compared to calcium deficient hydroxyapatite instead of stoichiometric 
hydroxyapatite, as most authors do. The former, i.e. Ca9(PO4)5(HPO4)(OH), is 
inherently more soluble than stoichiometric HA, i.e.Ca10(PO4)6(OH)2,[57] with 
solubility products of 85.1 (-log KPS) and 116.8 (-log KPS) respectively,[11] due to 
its distorted lattice and consequently lower crystallinity. The results obtained 
suggest that the incorporation of carbonate ions in this kind of pre-distorted 
lattice does not have the same effect than in stoichiometric HA; rather than 
increasing the solubility the opposite happens. 
Figure 2-7A also displays the results for the degradation behavior of β-TCP 
samples at the different L/P. It is interesting to note that, in spite of having a 
much higher solubility, with a solubility product of 28.9 (-log KPS)[11,58] and 
larger pore sizes (Figure 2-6), its degradation was lower than that of CDHA, 
which can be explained by the much smaller SSA. Similar to what was already 
observed for the biomimetic samples, the increase in L/P led to a gradual 
increase of the degradation of sintered β-TCP samples from 4% to 6% for L/P 
0.35 to 0.65, respectively, with a slope similar to that of CDHAF.  
The second part of the study aimed to discern the effect of macroporosity on the 
degradation rates of biomimetic and sintered samples. Since not all L/P could be 
foamed, only one L/P per material was selected to assess the effect of 
macroporosity on degradation, that being the one that allowed obtaining similar 
values of macroporosity in the different materials (Figure 2-6B). For biomimetic 
CDHA samples, foaming resulted in an increase of the extent of degradation to 
levels between a 20-30wt% (Figure 2-7B). The carbonated samples showed a 
smaller increase, in agreement with the decreased degradation observed in the 
non-foamed specimens. For the sintered samples, foaming led to a maximum of 
15% of mass loss. The degradation values for β-TCP obtained upon sintering 
CDHAC were rather low if compared to β-TCP obtained from CDHAF. This can 
be explained by the low porosity of the former formulation (Figure 2-5B).For 
comparison purposes, Figure 2-7B also included the degradation of a 
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stoichiometric HA foam. As expected, SHA presented the lowest degradation 
among all foams comparable to the non-foamed materials (5-7wt%) due to its 
low solubility and low SSA.  
The benefits of having an open porous structure in the degradation of CaP was 
also observed by Schaefer et al. using 2D dense disks and 3D porous scaffolds 
consisting of sintered HA and β-TCP.[14] Figure 2-8 combines the degradation 
behavior obtained for the non-foamed and foamed materials as a function of 
porosity. The graph for each composition shows that for the biomimetic 
substrates, foaming results in an exponential increase in degradation, which can 
be explained by the large available area that becomes exposed to the acidic 
medium, and therefore is susceptible to degradation. The relevance of the SSA, 
in this respect, was highlighted by the observation that the introduction of similar 
levels of macroporosity resulted in a significantly higher increase in degradation 
for the fine than for the coarse CDHA foams (29% vs 19% weight loss), 
corresponding to a SSA of 30 and 14m2/g respectively. Thus, similar levels of 
added macroporosity represented a 3-fold increase in degradation for the coarse 
CDHA, whereas for the fine CDHA the increase was 4-fold.  
Interestingly, for the sintered β-TCP, the impact of the macroporosity introduced 
by foaming on the degradation was much lower, as it only resulted in a linear 
increase in degradation. On one hand, this can be explained by its low SSA, and 
on the other, by the larger size of the micropores already present in the substrate 
which may help to improve penetration of the acidic solution within the material, 
even in absence of macropores, therefore reducing the impact of the 
macroporosity. In spite of having a high SSA, an intermediate behavior was 
found for the carbonated hydroxyapatite samples that did not experience such a 
large increase in degradation upon foaming as did the CDHA samples, probably 
due to the low solubility already found in the non-foamed samples. 
One important aspect to check was whether the degradation of the calcium 
phosphates generated any by-products due to the acidic environment during the 
experiment. Indeed, in previous works, where degradable polymers like 
polylactic acid or derivatives were incorporated[59,60] to increase the degradation 
of CaP, the precipitation of brushite was reported due to the acidic environment 
caused by the degradation of these polymeric phases.[61] As demonstrated by the 
XRD patterns (see Figure 2-9A), the composition of all samples remained 
unaltered after degradation, while SEM images evidenced the microstructural 
changes post-degradation (Figure 2-9B). However, whereas the microstructure of 
the CDHA surface appeared clearly degraded due to the acidic environment, the 
dissolution on sintered β-TCP was noticeable mainly at the grain boundaries, 
which induces the formation of cracks and irregularities on the grain surfaces and 
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was also highlighted by Koerten et al.[38] Despite the visible effects of 
degradation, the penetration degree of the acidic medium was limited to a few 
micrometers from the surface (e.g. up to 10µm for a L/P=0.55) for the non-
foamed samples. In the case of the foamed samples, the presence of 
interconnected macropores allowed the penetration of the acidic medium 
throughout all material. 
Overall, this study demonstrates the importance of textural properties, which can 
modulate or even outweigh the effect of other intrinsic properties such as the 
solubility of the compounds. The tuning of porosity and SSA at a multiscale level 
(nano, micro and macroporosity) is a powerful tool to control the degradation of 
CaPs, which can even exceed the effect of the intrinsic solubility of the material.  
2.5. Conclusions 
The in vitro degradation behavior of different CaPs was compared in terms of 
composition, SSA, and multiscale porosity (nano, micro, and macroporosity) 
using an isotonic acidic solution of pH 2 to emulate the acidic osteoclastic 
environment during bone remodeling. The SSA played an important role in the 
degradation as shown by the comparison between biomimetic samples with 
different SSA and a range of porosities at different length scales. In this respect, 
it is important to stress the advantage offered by the biomimetic processing of 
CaP, which allows tuning the SSA in a much higher range than the high 
temperature sintering methods. However, the effect of SSA on degradation was 
dependent on the porosity and pore size, which conditioned the extent of acid 
penetration within the samples. The combination of SSA and porosity (nano-, 
micro- and macro) resulted in an exponential increase in the degradation for high 
SSA materials but to a linear increase in sintered materials with low SSA. 
Varying these parameters allowed tuning degradation from 3wt% up to 30wt%. 
Without the foaming step, degradation could not go beyond the 8wt%. In contrast 
to what happens with stoichiometric hydroxyapatite, doping with carbonate did 
not result in an increase of the chemical degradation of biomimetic CDHA, 
indicating that carbonate did not have the same effect, probably due to the lower 
crystallinity and the already distorted network of CDHA compared to 
stoichiometric hydroxyapatite. 
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3. Carbonation of low temperature macroporous calcium 
phosphates 
 
Scope 
 
Carbonate is the major substituting ion found in biological apatites. It has been 
attempted to be incorporated into synthetic bone grafts, as a strategy to further 
enhance their biological performance. Mimicking biological apatites composition can 
render several advantages towards the recognition and integration of bone grafts. The 
present chapter investigates different routes to dope low temperature CDHA with 
carbonate as a tool to enhance their biological performance. The carbonation routes 
have been applied to macroporous CDHA, preserving their macrostructure and 
controlling micro and nanostructure, separately from the carbonation content. 
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3.1. Introduction 
The development of biomimetic macroporous scaffolds, with a chemical composition 
and nanostructure close to the mineral phase of bone remains a major challenge. 
Biomaterials for bone regeneration need to adapt to the bone turn-over to help 
preserving the biological and mechanical characteristics of the bony site. This can be 
accomplished using macroporous scaffolds made of materials that closely mimic bone. 
It is widely accepted that biological apatites have a greater solubility than traditionally 
sintered calcium phosphate ceramics due to the nano-metric size of the crystals, their 
poor crystallinity and the presence of foreign ions where carbonate accounts for the 
major substitution (4-8%wt.).[1] Carbonate inclusion has indeed a major role in bone 
remodeling where bone resorbing cells, i.e. osteoclasts, have been closely associated to 
the selective resorption of regions of high carbonate inclusion[2] or by stimulating 
osteoblast activity.[3] This explains why biomimetic precipitation routes which provide 
nanosized crystals similar to those found in bone have been extensively investigated.[4–
7] Unfortunately, in these studies the consolidation of nanoparticles into bulk samples 
require a sintering step negating any benefit of the nanoparticles.[8–10] Calcium 
phosphate (CaPs) cements are bulk bodies formed through biomimetic routes. One 
typical formulation is that of α-TCP that hydrolyses into a CDHA under physiological 
conditions, according to equation (1).  
3CaଷሺPOସሻଶ ൅ HଶO → CaଽሺHPOସሻሺPOସሻହሺOHሻ                    (Eq. 1)	
The setting reaction results in an entangled network of nano/submicron crystals with 
an intrinsic nano and microporosity and large SSA.[11] Additionally, CaP cements can 
be further modulated by the addition of macroporosity.[12,13] Variations in the local 
ionic environment during CDHA precipitation offer a suitable platform to incorporate 
foreign ions into the hospitable crystal structure of CDHA.[14] 
Attempts to develop carbonated CPCs have been made by introducing sources of 
carbonate such as vaterite or calcite accomplishing high carbonation ratios.[15–20] The 
major side-effect of performing carbonation during the setting reaction was observed 
in the change of the rheological properties of the cement paste and the concomitant 
delay of the setting reaction. Unfortunately this requires re-adjusting the cement 
formulation to have setting times adequate for implantation. Del Real et al. added 
sodium bicarbonate in a CPC formulation as a method to create macropores due to the 
decomposition of CO32- to CO2.[21] However, while those formulations cannot be made 
injectable because of the risk of embolism, they have the added drawback that both 
carbonate and macropore content are coupled and cannot be adjusted separately.  
The goal of the present chapter is to decouple carbonation from macropore formation 
by exploring different strategies for the carbonation of macroporous scaffolds based on 
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the hydrolysis of α-TCP. Carbonation was carried out either by introducing the 
carbonate during the setting reaction, i.e., simultaneously to the precipitation of 
CDHA, or by a post-treatment of the pre-set scaffolds. In both cases the macroporous 
structure of the scaffold was preserved. The extent of carbonate incorporation was 
investigated for the different methods varying the amount of carbonate and studying its 
textural and chemical implications. 
3.2. Materials and Methods 
3.2.1. Carbonation methods 
Calcium phosphate foams (CPF) were prepared by mixing a powder phase consisting 
of α-TCP and 2wt% of precipitated HA with an aqueous solution containing 1wt% of 
polysorbate (Tween 80®, Sigma Aldrich, St.Louis, USA) that acted as surfactant.[22] 
Both phases were foamed at 7000rpm for 30s using a domestic food mixer, and the 
paste was transferred into 6x12mm2 moulds. Three different carbonation routes were 
explored (Figure 3-1): i) carbonation during setting: the α-TCP foams were immersed 
in a NaHCO3 solution (Sigma-Aldrich, St. Louis, USA) as setting medium, and either 
kept at 37 ºC for 17 days (coded as BC-S, standing for carbonation during biomimetic 
setting) or ii) subjected to an hydrothermal treatment by autoclaving at 121ºC and 1 
bar for 30 minutes (HC-S, hydrothermal carbonation during setting). Prior to 
immersion in the carbonate solution the samples were left for 8h in a humid 
atmosphere at 37oC to gain initial cohesion; and iii) post-setting carbonation: the 
hydrothermal treatment described above was applied to previously set CDHA foams, 
immersed in a NaHCO3 solution (PS-HC, post-setting hydrothermal carbonation). 
Three different NaHCO3 concentrations were used (2.5, 5 and 10wt% NaHCO3). A 
control sample was prepared following method, using water as setting medium. 
Controls for BC-S and PS-HC were left 10 days for setting prior to carbonation 
treatment, whereas HC-S controls were autoclaved in water after 8h in humid 
atmosphere. After the treatment all samples were thoroughly rinsed with double 
distilled water to remove all dissolved salts. The schematic representation of the 
different carbonation methods is shown in Figure 3-1. 
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Figure 3-1. Schematic description of the different carbonation methods: i) BC-S, ii) HC-S and 
iii) PS-HC. 
3.2.2. Characterization 
The presence of carbonate was analyzed by ATR-FTIR (Nicolet 6700). Data was 
acquired in 64 scans with a resolution of 4cm-1 from 4000 to 575cm-1 with a 
Germanium crystal. The content of carbonate for the scaffolds processed using the 
highest concentration of carbonate (10wt% NaHCO3) was analyzed by bulk 
combustion using a Thermal combustion element analyzer (Thermo EA 1108). The 
amount of carbonate was calculated according to the following equation (2). 
Percentage	of	Carbonate ൌ ெௐ಴ೀయమషெௐ಴ ൉ %஼                        (Eq.2) 
where, ܯܹ஼ைయమష and ܯ ஼ܹ are the molecular weight of carbonate and carbon, 
respectively, and %஼ is the percentage of carbon given by the measurement. Samples 
were grinded and dried at 120°C overnight prior to analysis. 
Phase composition was identified by XRD (D8 Advance diffractometer, Bruker) with 
a Cu Kα anode (monochromated, λ=1.5406Ǻ), operated at 40kV, and 40mA. Data 
were acquired in 0.02° steps over the 2θ range of 10°-70° with 2s per step. For 
multiple phase quantification EVA software was used (Bruker). The textural properties 
of the foams were analyzed by scanning electron microscopy (SEM, Zeiss Neon40). 
Samples were coated with carbon to gain conductivity prior to imaging. The specific 
surface area of the scaffolds was determined by nitrogen adsorption using the BET 
(Brunauer-Emmett-Teller) method (ASAP Micromeritics).  
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3.3. Results and Discussion 
3.3.1. Carbonation level and textural properties of the 
foams 
The presence of carbonate as observed by FTIR (Figure 3-2) was highly dependent on 
the carbonation method. Carbonate bands specific for carbonate incorporation into 
CDHA were visible at 1471 and 1419cm-1, corresponding to a B-type substituted 
apatite. The band at 874cm-1can be assigned to both, HPO42-or to a B-type carbonate 
substituted apatite.[4,23,24] The remaining bands were all attributed to typical vibrational 
modes of phosphate in apatite (stretching at 1030cm-1, 964 and 1093cm-1 and the O-P-
O bending modes at 604 and 563cm-1).[25] 
The PS-HC resulted in lower levels of carbonate compared to the other methods, as 
observed from the lower intensity of the carbonate bands. This result was expected, as 
carbonate ions needed to diffuse into the CDHA crystal structure. Increasing the 
carbonate content in the solution resulted in better defined bands by ATR-FTIR as 
observed with the increase in intensity of the ν3 CO32- vibration mode (Figure 3-2). 
However, the maximum content of carbonate achieved by this method was 2.5wt%, 
obtained after immersion in 10wt% NaHCO3 solution (Table 3-1). On the contrary, 
carbonation during setting, i.e. during precipitation of CDHA, either at 37oC (BC-S) or 
by the hydrothermal treatment (HC-S), increased the yield of carbonation (Figure 3-2). 
Moreover, increasing the content of carbonate in the setting medium increased the 
intensity of the carbonate bands in the precipitated apatite. The maximum levels of 
carbonate, obtained with the 10wt% NaHCO3 solution, were 12.3% for BC-S method 
and 13.0% for HC-S method, similar to previous works.[26,27] The following table 
summarizes the maximum carbonate contents (using 10%wt. NaHCO3) for each 
method, together with their SSA compared to control samples. 
Table 3-1. SSA and maximum carbonate content for the different synthesis methods using 
10%wt. NaHCO3. 
Method CO3
2- 
[%wt.] 
SSA 
[m2/g] 
Control Carbonated 
BC-S 12.3 20 30 
HC-S 13 17 32 
PS-HC 2.5 20 17 
 
 
Chapter 3 
66 
 
 
Figure 3-2. ATR-FTIR spectra for the samples obtained by the different carbonation methods, 
using carbonate solutions with different concentrations. 
One fundamental aspect shared by all carbonation methods was their ability to 
preserve the structural integrity of the foams as shown in the low magnification SEM 
images of the foams cross-sections (Figure 3-3). BC-S method had a great impact on 
the microstructure of the precipitated crystals. When the dissolution of α-TCP and 
precipitation of CDHA took place in a carbonate-containing medium, a significant 
decrease in the crystal size was observed. The micrometric plate-like crystals found in 
the foams set in water (Figure 3-3A and inset) turned into smaller plates (Figure 3-3B 
and inset) in presence of carbonate, thus increasing the SSA from 20m2/g to 30m2/g 
respectively (Table 3-1). Similarly, HC-S method in water resulted in needle-like 
structures, whereas fine plate-like crystals were formed when the same treatment was 
done in presence of carbonate (Figure 3-3C inset and Figure 3-3D inset, respectively), 
the SSA increasing from 17 and 32m2/g, respectively. Finally, no changes in the 
microstructure were observed for PS-HC method, i.e. in CDHA foams (Figure 3-3E 
inset and Figure 3-3F inset), as in this case carbonate had to diffuse in pre-existing 
crystals. The SSA also showed no modification, with values of 20 and 17m2/g for 
control and carbonated samples, respectively. 
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Figure 3-3. Representative SEM images of the pristine and carbonated foams at low 
magnification showing the interconnected macroporous geometry (scale bar: 500µm), and 
insetsat higher magnification (scale bar: 2µm) showing the representative micro-nanostructure 
of the crystals. The immersion solutions for the control and carbonated samples were water and 
10%wt. NaHCO3 respectively. 
3.3.2. Composition of foams after carbonation 
The presence of carbonate ions during setting can affect the setting kinetics, hence the 
importance of assessing total conversion to carbonated CDHA for each carbonation 
method. BC-S method required 17 days of setting to achieve the same degree 
conversion than the control samples after 10 days (Figure 3-4, grey solid line). Slight 
variations were found according to the amount of carbonate in solution. Unreacted α-
TCP in control samples was slightly lower than in carbonated samples. According to 
the carbonate amount different contents of unreacted α-TCP were found (3 and 6% for 
the lowest and highest bicarbonate concentrations, respectively). Broader peaks were 
found as the carbonate content increased, owing to the crystal distortion provoked by 
carbonate incorporation into the CDHA and to the smaller size of the resulting 
Chapter 3 
68 
 
crystals. Importantly, no additional phases were found due to the incorporation of 
carbonate. 
HC-S method considerably reduced the time required for the synthesis of carbonated 
apatite from days to hours. However, when the setting of control α-TCP foams, i.e. 
autoclaved in water, was performed in the autoclave, it resulted in a biphasic calcium 
phosphate consisting of 92% CDHA and 8% β-TCP (black dashed line), due to partial 
transformation of α-TCP into its allotropic phase. This transformation is in accordance 
with previously reported hydrothermal synthesis of α-TCP, where β-TCP appeared as 
an intermediate during the conversion to CDHA.[28,29] In contrast, hydrothermal setting 
in the presence of carbonate stabilized α-TCP instead of β-TCP. For the highest 
carbonate content solution (10wt% NaHCO3) the resulting phase composition was 1% 
β-TCP, 9% α-TCP and 90% CDHA. Similar observations in terms of peak broadening 
were observed, in agreement with the lattice distortion caused by the incorporation of 
carbonate and the smaller size of the precipitated crystals. An additional non-identified 
phase appeared overlapped with the main peaks of hydroxyapatite (31.2º, 2θ) which 
was not possible to identify. 
Interestingly, PS-HC method did not induce any alteration in XRD results in terms of 
peak broadening, as it would have been expected from the introduction of carbonate 
within the crystal lattice. This suggests that carbonate could be mostly concentrated in 
the hydrated layer rather than entering the crystal structure.[24] The lower carbonate 
content in PS-HC method is also consistent with the prominent shoulder at 630cm-1, 
similar to control samples. Such behavior was also observed in the work by Combes et 
al. during carbonation of brushitic cements.[16] Slightly higher α-TCP was found as the 
bicarbonate concentration increased, possibly due to the α-TCP stabilizing effect of 
carbonate. 
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Figure 3-4. XRD patterns of the pristine and carbonated foams obtained using the different 
carbonation methods investigated. Patterns are shown at the bottom of each graph 
corresponding to HA (JCPDS 09-0432), α-TCP (JCPDS 09-0348) and β-TCP (JCPDS 09-0169). 
Chapter 3 
70 
 
3.4. Conclusions 
The present chapter proves that is feasible to carbonate macroporous cements without 
compromising their three-dimensional integrity by decoupling carbonation from 
macropore structure formation. Three different strategies were explored which not 
only allowed controlling the carbonation degree but also the microstructure, phase 
composition and setting reaction. Controlling the carbonation degree of porous 
scaffolds without compromising the 3D network is fundamental for several biological 
events as it allows cell colonization, vascular tissue ingrowth and facilitates scaffold 
remodeling. The fact that the carbonate content can be tuned enables exploring how 
the degree of carbonation intervenes in the various biological events. 
3.5. Appendix. Controlled biphasic calcium phosphate 
mixtures 
Traditionally, BCP are obtained by sintering at high temperatures different calcium 
phosphate compounds with a specific Ca/P ratio. The composition of the biphasic 
formulations, which has great influence on the in vivo performance of CaPs 
implants,[30] can be adjusted through the Ca/P ratio.[31] The incorporation of controlled 
amounts of carbonate substituting phosphate groups in any of the carbonation 
processes earlier described (section 3.2.1), causes an alteration in the Ca/P ratio which 
could be used to prepare BCPs. The combination of macroporosity to allow 
angiogenesis, together with a source of calcium and phosphates prone to reprecipitated 
in the implant surrounding, has demonstrated to foster osteoinduction. Yuan et al. 
defined microporosity also as a requisite in bone formation.[32] 
To prove the potential of obtaining BCP from carbonated samples, HC-S foams with 
different carbonate contents were prepared and sintered. For this purpose sodium 
hydrogen carbonate was first dissolved in water using different carbonate solution 
concentrations (0.1, 0.5, 1, 1.25, 1.5, 2.5, and 5%wt.) where CDHA foams were 
immersed and autoclaved (Figure 3-5). After hydrothermal setting, samples were 
sintered at 1100ºC for 9h and the phase composition was studied by XRD (D8 
Advance diffractometer, Bruker). Phase quantification was performed using EVA 
software (Bruker), as previously described. 
Depending on the amount of carbonate, the sintering process led to different 
compositions (Figure 3-6). Sintering of CDHA turns into pure β-TCP. The addition of 
0.1wt% of sodium hydrogen carbonate already leads to a BCP composition consisting 
mainly of β-TCP (85%). The increase in carbonate further increases the content of HA 
phase, evidencing the carbonate substitution for phosphates. The decreasing in the 
phosphate content increases the Ca/P ratio, achieving a closer stoichiometric 
composition. Finally, 2.5wt% of carbonate addition transforms into pure HA. The 
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excess of carbonate might be detrimental since calcium oxide (Figure 3-6, red arrow) 
appears for carbonate contents above 2.5wt%, as is the case of 5wt% bicarbonate 
addition. 
 
Figure 3-5. Hydrothermal carbonation setting of CPF and sintering process to obtain BCP. 
 
Figure 3-6. XRD data for foams autoclaved with different carbonate contents and sintered 
afterwards showing the phase composition of the BCP. 
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4. Heparinization of Beta Tricalcium Phosphate: 
Immunomodulatory effects and osteogenic potential 
 
Scope 
 
Surface functionalization has become a powerful tool to modulate the biological 
interactions of biomaterials. Ideally, surfaces mimicking the cellular 
microenvironment can help to enhance or stimulate specific cell responses of 
paramount importance during bone healing. Heparin is the most sulfated member of 
GAGs family. They are present in stem cells niche as part of the ECM and interact 
with several GF involved in inflammation, osteogenesis and osteoclastogenesis. The 
following chapter is devoted to the study of the functionalization of CaP substrates 
with heparin as a tool to modulate the response of inflammatory cells and 
mesenchymal stem cells. 
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4.1. Introduction 
The implantation of synthetic bone grafts in a host triggers a complex cascade of 
events, which ideally should lead, either to the graft’s osseointegration or to its 
progressive resorption and replacement by new bone. The interaction of the 
biomaterial with different cells involved in these events is of paramount importance. 
However, the attention that has been paid to the different stages of this process has 
been uneven. Whereas most engineering approaches focus on the osteogenic potential 
of the material, other crucial events such as their immune response are often 
overlooked. The vital role of immune cells in regulating bone dynamics has been 
emphasized in recent years by the emerging field of osteoimmunology, which has 
identified the relevant role of immune cells during osteogenesis.[1,2] 
After implantation, biomaterials cause a foreign body reaction that can critically 
determine the success or failure of the material. Briefly, the immune cascade starts 
with the formation of a transient protein layer on the surface of the biomaterial, 
followed by extravasation of cells such as neutrophils, monocytes or mast cells that try 
to phagocytize the biomaterial. At this stage, neutrophils and monocytes release 
proteolytic enzymes and reactive ROS to degrade the implant. Within a few days, 
neutrophils undergo apoptosis while monocytes, which have adhered to the substrate, 
turn into macrophages. These macrophages may develop distinct dynamic phenotypes, 
known as M1 or M2, with pro-inflammatory or anti-inflammatory functions 
respectively.[3–6] M1 releases chemokines and cytokines that enhance inflammation 
while M2 secrete anti-inflammatory cytokines, and promote bone remodeling and 
repair, by regulating osteogenesis and osteoclastogenesis.[7] The polarization of 
macrophages can be influenced by materials properties. Thus, features such as 
topography,[8–11] surface chemistry,[12–17] mechanical stimuli,[18,19] or porosity[20,21] are 
known to determine immune cells fate.  
GAGs are interesting as modulating molecules for both immune and skeletal systems. 
GAGs are ubiquitous in tissues (e.g., as part of stem cells niche and the extracellular 
matrix) and are known for their potential to interact with growth factors.[22–24] GAGs 
assembled into proteins (PG) are highly present within injured sites. After injury, 
GAGs are released from their PG back-bone, become soluble and initiate the healing 
cascade.[25,26] GAGs can bind chemo- and cytokines that alter leukocyte migration, 
endothelial extravasation or cytokine expression.[25,27–30] Decades ago, the anti-
inflammatory effect of the most sulfonated GAG, heparin, was demonstrated by 
Dandona et al., showing an inhibitory effect on ROS release by leucocytes.[31] In more 
recent studies, Zhou et al. also found the down-regulation of inflammatory cytokines 
such as IL-1β in presence of GAG multilayers.[32] 
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Due to their ubiquitous nature, GAGs not only interact with the immune system, but 
also with bone cells.[33] Their ability to bind proteins such as GF has been used by 
several authors to regulate cell behavior. The degree and position of sulfate groups on 
GAGs has been shown to influence the affinity for BMPs,[34,35] and to foster osteoblast 
differentiation[36] by blocking sclerostin which is an inhibitor of Wnt signaling for 
osteoblast differentiation.[37] In a similar manner, GAGs can foster osteoclastogenesis 
by blocking OPG, which competes with RANKL, necessary for osteoclast maturation. 
[38–40] 
Overall, the studies performed using GAGs have mostly focused on their 
supplementation in cell cultures but little has been done using them as substrates or as 
surface platforms in combination with biocompatible substrates, besides their 
application as artificial ECM in combination with collagen or other organic 
molecules.[23,24,41–45] We hypothesize that the combination of bioactive, 
osteoconductive and inductive substrates such as calcium phosphate (CaP) materials 
with the regenerative potential of GAGs can result in an enhancement of their 
biological performance. 
β-TCP as a member of CaP family is similar to natural bone’s mineral phase and has 
been used successfully in the clinic for decades. Nevertheless, the main focus of many 
investigations has been their osteogenic potential, while their interaction with the 
immune system has often been overlooked. Chen et al. have recently made a step 
forward towards unraveling the tight link between osteogenesis and immunology on 
ceramic substrates,[16,46,47] mainly β-TCP or porous alumina. However, the studies 
performed were limited to the evaluation of the effect of β-TCP extracts on cells rather 
than involving direct cell seeding on the material. The importance of 
osteoimmunology in the design of bone grafts, and the involvement of GAGs both in 
inflammatory and osteogenic processes has encouraged the present work. Some 
studies have previously explored the functionalization of CaP with heparin, as a 
strategy for the controlled delivery of growth factors.[48–50] The focus of this study is 
different, as it aims at investigating the functionalization of β-TCP with heparin as a 
method to modulate the response of inflammatory cells (i.e. human neutrophils, 
monocytes and macrophages), and mesenchymal stem cells.  
4.2. Materials and Methods 
4.2.1. Preparation of calcium phosphates 
β-TCP was obtained by sintering CDHA. CDHA discs were obtained by hydrolysis of 
α-TCP through a self-setting reaction. α-TCP was prepared by solid state reaction of 
calcium hydrogen phosphate (CaHPO4, Sigma-Aldrich, St. Louis, USA) and calcium 
carbonate (CaCO3, Sigma-Aldrich, St. Louis, USA) mixed at a 2:1 molar ratio and 
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heated for 15h at 1400°C followed by quenching in air. Subsequently, the particles 
obtained were milled to a final median size of 5.2µm[51] and mixed with 2wt% of 
precipitated hydroxyapatite (PHA, Merck KGaA, Darmstadt, Germany). This powder 
was then mixed for 1min in a mortar with distilled water at a liquid to powder ratio 
(L/P) of 0.35mL/g, resulting in a paste that was transferred into two different size 
moulds: 15x2 and 5x1mm2 (diameter x thickness) PTFE moulds. The discs were 
immersed in water at 37°C for 10 days, to allow for complete hydrolysis to CDHA. 
The discs were subsequently subjected to a sintering process at 1100°C for 9h to 
obtain the final β-TCP. 
4.2.2. Heparinization 
Heparin immobilization on the surface of β-TCP was performed using two different 
routes, either physical adsorption or chemisorption, i.e. chemical covalent binding 
(Figure 4-1A and B, respectively). Freshly prepared heparin (BioIberica S.A.U. 
Barcelona, Spain) solutions in PBS (phosphate buffer saline, Thermo Fisher Scientific) 
were used. Physical adsorption was carried out by immersing the samples in the 
heparin solution for 2 hours under gentle agitation (100 rpm). Heparin covalent 
binding was accomplished via a 2-step functionalisation method: i) First, silanization 
with aminopropyltrietoxysilane (APTES, Sigma-Aldrich, St. Louis, USA) was 
performed using a modified procedure from previous work.[52] Discs were immersed in 
a solution of APTES (2% vol., i.e. 80mM) in absolute Ethanol (Panreac,AppliedChem) 
in the presence of distilled water (3% vol.) and left for different times (1 hour or 
overnight) under agitation. Afterwards, the discs were removed and sonicated in an 
ultrasonic bath (Ultrasons-HD, J.P. Selecta, Barcelona) in absolute ethanol solution for 
5min, followed by three ethanol rinses to remove any unbound APTES; ii) The second 
functionalization step consisted in the covalent immobilization of heparin onto the 
aminated surfaces of the materials. Carbodiimide (1-(3-dimethylaminoporpyl)-3-
ethylcarbodiimide, EDC, Sigma-Aldrich, St. Louis, USA) and N-hydrosuccinimide 
(NHS, Sigma-Aldrich, St. Louis, USA) were used to couple heparin via its carboxyl 
groups to the amino groups of the silane. Freshly prepared solutions of heparin in PBS 
at different concentrations were firstly activated for 15min at pH ~6.5 in presence of 
EDC/NHS (100 and 150mM, respectively). Upon activation, pH was raised to 7.5 and 
the silanized discs were immersed in the activated heparin solution (1mL) for 2h under 
agitation (100rpm). 
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Figure 4-1. Diagram of the two heparin immobilization methods. A) physisorption and B) 
chemisorption. 
The heparin saturation curves were determined on the overnight silanized surfaces by 
immersing the samples in activated heparin solutions with different concentrations (10, 
25, 50, 75, 100, 150, and 200µg/mL) for 2h. Supernatants were collected, and the 
amount of heparin was determined using a colorimetric assay modified from the 
literature.[53] Briefly, a solution of 0.005wt% Toluidine blue (Sigma-Aldrich, St. 
Louis, USA) was prepared in 0.01M hydrochloric acid (HCl, Panreac AppliChem) and 
0.2wt% sodium chloride (NaCl, Sigma-Aldrich, St. Louis, USA). Heparin supernatants 
were mixed with the Toluidine solution at a 1:1 ratio using vortex and centrifuged for 
5min at 15000 relative centrifugal force (rcf). Afterwards, 200µL of the sample 
solutions were placed in a 96-wellplate and the absorbance was read at 631nm (Infinite 
200 PRO Microplate reader, TECAN). A standard calibration curve was made, 
measuring solutions with known heparin concentrations up to 25µg/mL. 
4.2.3. Materials characterization 
SSA of the discs was measured by nitrogen adsorption using the BET method (ASAP 
2020 Micromeritics). The porosity and pore size distribution were obtained by MIP 
(Autopore IV Micromeritics). Phase composition was assessed by XRD (D8 Advance, 
Bruker) using a Cu Kα anode (monochromated, λ=1.5406Ǻ) operated at 40kV and 
40mA. Data were collected in 0.02° steps over the 2θ range of 10°-80° with a counting 
time of 2 per step. Phase identification was accomplished comparing the resulting 
patterns to that of β-tricalcium phosphate (JCPDS 09-0169). 
SEM (FIB Zeiss Neon40) was used to study the microstructure of the samples. Prior to 
imaging, samples were coated with carbon to enhance conductivity. The 
microstructure of the samples was studied before and after functionalization to 
investigate possible morphological changes. X-ray photoelectron spectroscopy (XPS) 
was used to analyze surface composition of the pristine (control) and functionalized 
samples. Spectra were acquired in ultra-high vacuum (5 10-9mbar) with an XR50 Mg 
anode source operating at 150W and a Phoibos 150 MCD-9 detector (D8 advance, 
SPECS Surface Nano Analysis GmbH, Germany). Spectra were recorded at pass 
energy of 25eV with a step size of 0.1eV for C1s, N1s, O1s, Si2p, Ca2p, P2p, and S2p. 
C1s peak was used as a reference. CasaXPS software (Casa Software Ldt, UK) was 
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used for the determination of atomic elemental composition applying the manufacturer 
set of relative sensitivity factors. 
4.2.4. Cell isolation 
The inflammatory response was evaluated using primary human cells isolated from 
blood obtained from anonymous volunteer donors at the Uppsala University Hospital. 
Monocytes and neutrophils were isolated from buffy coats by two different separation 
procedures. Firstly, monocytes were isolated from blood (15mL) which were then 
diluted in 1xPBS at a 1:1 ratio and mixed gently by inversion. Afterwards, diluted 
blood (30mL) were gently poured onto Ficoll-Paque Plus (15mL) (GE Healthcare, 
Chicago USA) followed by centrifugation at 400rcf for 30min. The upper human 
plasma layer was collected and kept at 4°C for later use. The monocytes layer was 
pelleted and resuspended in 1xPBS (10mL) and centrifuged at 100rcf for 15min for a 
total of 3 washes. Next, the monocytes pellet was resuspended in PBS (2 mL) and the 
cells were counted by Trypan blue exclusion method (1:5) in a cytometer. Finally, 
cells were diluted in cell culture medium (4PBS/1RPMI-1640/100mM glucose) 
containing 10% of human plasma. 
Secondly, to extract the PMNC, the blood pellet layer obtained after centrifugation and 
removal of plasma and the mononuclear layer was resuspended in 20mL of 3% 
Dextran (Sigma) in 0.9% saline solution and incubated for 25min. The supernatant was 
collected and centrifuged at 250rcf for 10min. Afterwards, the supernatant was treated 
with 20mL of 0.2% saline for 20s, followed by 20mL more of 1.6% saline in order to 
lyse erythrocytes. The cell suspension was then centrifuged at 250rcf for 10min. The 
PMNC pellet was resuspended in PBS and cells were counted using acetic acid (6%) 
in a cytometer. Finally, cells were diluted in cell culture medium (4PBS/1RPMI-
1640/100mM glucose) with 10% of human plasma. 
4.2.5. Chemiluminescence study 
A luminol amplified chemiluminescence assay was used to quantify the reactive 
oxygen species (ROS) generated by both monocytes and neutrophils under phorbol-
12-myristate-13-acetate (PMA, Sigma Aldrich) activation[54,55]. Prior to the analyses, 
the 5x1mm2 discs were sterilized in 70% ethanol for 3h, followed by three PBS rinses 
of 15min each. 200µL of cells were seeded on the pristine and heparinized β-TCP 
discs at a cellular density of 106cells/mL, followed by the addition of 100µL of 
luminol solution (500µM). Previously, a luminol solution was prepared by adding 1% 
of luminol stock solution and 0.2% horseradish peroxidase (1mg/mL, Jackson Immuno 
Research) as signal amplifier. The luminol stock solution was obtained by dissolving 
luminol (Fisher Scientific) to 50mM in 0.2M NaOH. Both cell types and positive 
controls (TCPS+) were activated with 1µM PMA, which was added into the cell 
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suspension solution. A negative control consisting of non-activated cells seeded on 
tissue culture polystyrene was added (TCPS). Luminescence was monitored in a 
microplate reader (Infinite M200, Tekan, Männedorf, Switzerland) at 37ºC every 2 
min up to 2h. Measurements were conducted using triplicates for each material type 
(n=3). The experiment was then repeated with two independent blood donors. 
4.2.6. Macrophage cell culture 
Macrophage cell culture assays were performed using 15x2mm2 discs. Upon isolation, 
monocytes were resuspended in complete RPMI cell culture medium supplemented 
with 10% fetal bovine serum (FBS, Thermo Scientific Hyclone), 2% HEPES (Sigma-
Aldrich, St. Louis, US) and 1% Penicillin/streptomycin (Thermo Scientific). Prior to 
seeding, pristine and heparinized β-TCP discs were sterilized as previously described 
and immersed overnight in 1ml of complete medium. Seeding was performed by 
adding 1ml of cells in complete medium at a cell density of 2·105cells/mL. All 
substrates were supplemented with 1ng/mL of lypopolysaccharide (LPS, Sigma-
Aldrich, St. Louis, US) including a positive control (TCPS+). The negative controls 
(TCPS) consisted in cells without LPS supplementation. Cells were cultured for 3 
days. Supernatants of macrophage cultures were collected at 6, 24, 48, and 72h and 
analyzed with ELISA kits to detect Tumor Necrosis Factor (human TNF-α, KHC3012, 
Invitrogen), Interleukin 1 (human IL-1β, KHC0012, Invitrogen) and Interleukin 10 
(human IL-10, KHC0103, Invitrogen). Duplicates were used for each single 
experiment and three biological replicas were conducted with three independent blood 
buffy coats. 
Cell viability at each time point was quantified by lactate dehydrogenase release (LDH 
KitMAK066, Sigma Aldrich, St. Louis, US). 400µL of 1% Triton-X100 (Sigma 
Aldrich, St. Louis, US) solution in PBS was used to lyse cells followed by three 
freezing and thawing steps. Cytokines values were normalized to the obtained cell 
number at each time point and to the values of TCPS+ at 6h. 
Cell morphology was assessed by scanning electron microscopy (SEM, Zeiss 1530, 
Germany) at 6, 24, 48, and 72 h. Cells were fixed using a 2.5% glutaraldehyde solution 
in PBS at 4°C for 2 h, followed by 3 rinses in PBS of 15 min each. Afterwards, a 
series of ethanol dehydration steps were carried out for 15 min each (10-30-50-70-90-
99%). Finally, samples were vacuum dried and coated with Au/Pd to enhance 
conductivity. Image analyses of macrophage morphology were processed by FIJI 
(ImageJ software) to investigate the elongation ratio (n=30 except for β-TCP at 6h and 
TCPS at 72h where n=10). 
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4.2.7. Mesenchymal stem cell culture 
Rat mesenchymal stem cells (rMSCs) extracted from young Lewis rats and used at 
passage 3 were used to investigate the osteogenic potential of the heparinized surfaces. 
All samples were sterilized as previously described. Afterwards, 15x2mm2 discs were 
left overnight in supplemented cell culture medium as preconditioning prior to 
seeding. rMSCs were cultured on the pristine and heparinized β-TCP discs 
(8·104cells/mL, 1mL) with Advanced DMEM (AdvDMEM) supplemented with 10% 
FBS, 2% HEPES and 1% of penicillin/streptomycin and L-glutamine (Invitrogen). 
Tissue culture polystyrene (TCPS) was used as control. Cells were cultured over 6h, 3, 
7 and 14 days refreshing medium every day. At day four, osteogenic medium 
consisting of supplemented advDMEM with 50µg/mL ascorbic acid, 10mM β-
glycerophosphate and 100nM dexamethasone was used as cell culture medium for all 
substrates. At each time point, samples were rinsed thrice with PBS and lysed with M-
PER® (Mammalian Protein Extraction Reagent, Thermo Scientific, Waltham, MA, 
USA; 300µL). Cytotoxicity Detection Kit LDH (Roche Applied Science, Penzberg, 
Germany) was used to quantify cell proliferation. The results were expressed as a 
relative fold change compared to the cell number obtained on TCPS after 6h and to the 
area of the discs. The alkaline phosphatase (ALP) activity was quantified as a marker 
of osteogenic differentiation (SensoLyte®pNPP Alkaline Phosphatase Assay Kit, 
AnaSpec). 
4.2.8. Statistics 
Data are presented as mean values and standard deviation for ROS experiments 
including triplicates for each material and two different donors. Cytokines and 
elongation ratio are expressed as mean values and standard errors out of duplicates for 
each material type and three independent donors. One way ANOVA was used to 
analyze statistical differences (p<0.05) followed by Tukey post-hoc analysis for all 
experiments using SPSS statistics software (IBM). T-test for independent samples was 
applied to evaluate statistical differences between neutrophils and monocytes for the 
ROS integrated values. 
4.3. Results 
4.3.1. Material characterization 
XRD analysis revealed that the ceramic substrate consisted of phase-pure β-TCP, with 
all peaks matching those in the JCPDS 09-0169 card (Figure 4-2A). The samples were 
porous, as evidenced by MIP, with interconnected pores below 1μm (Figure 4-2B). 
The specific surface area of β-TCP discs was low and typical of high temperature 
sintered ceramics (Figure 4-2C). The microstructure observed by SEM showed the 
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porous nature of the discs and was consistent with the low SSA values from the 
polyhedral grain microstructure after the sintering process (Figure 4-2D).  
 
Figure 4-2. Physico chemical properties of the β-TCP discs. A) X-ray diffraction pattern; B)Pore 
entrance size distribution measured by MIP; C) Specific surface area measured by nitrogen 
adsorption, and total open porosity according to MIP; and D) SEM image of the surface of the 
material (scale bar: 2µm). 
4.3.2. Heparin immobilization 
The effect of the immobilization method on the amount of heparin retained on the 
surface is depicted in Figure 4-3A. The percentage of immobilized heparin 
(100µg/mL, 1mL) after 2h increased drastically when the surface was previously 
silanized, compared to physical adsorption. Moreover, the silanization time allowed 
tuning the final amount of immobilized heparin. One hour of silanization followed by 
two hours of immersion in a heparin solution resulted in approximately 10% of the 
heparin in solution becoming immobilized on the surface. Overnight silanization 
boosted this percentage up to 30%. Heparin surface saturation studies were performed 
to investigate the maximum amount of heparin bound to the substrate in two hours, 
after overnight silanization (Figure 4-3B). As the concentration of heparin in solution 
increased, the surface reached a saturation value of ~25µg of adsorbed heparin for 
concentrations of 50µg/mL and above. From XPS results, the composition of the 
substrates displayed mainly calcium, phosphorous and oxygen which is in agreement 
with the chemical composition of pristine β-TCP (Figure 4-3C). The detected carbon 
was attributed to ambient hydrocarbon contamination. The presence of silicon and 
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nitrogen, together with decreased Ca and P in the overnight silanized sample (β-TCP-
Sil) proved the success of this step. The increase in carbon content on the silanized 
substrate was associated with the ethoxy groups present in APTES. The presence of 
heparin on the heparinized samples (β-TCP-H) was evidenced by the presence of 
sulfur. The decrease in the ratio of silicon and calcium was associated with the 
covering of both the substrate and the silane layer by heparin. The SEM micrograph 
displayed in Figure 4-3D shows that surface functionalization did not induce any 
morphological change in the substrate. 
 
Figure 4-3. Characterization of the heparin-functionalized surfaces. A) Effect of the 
immobilization method on the amount of heparin immobilized on the surface after 2 h 
immersion in a 100µg/mL heparin solution. Pristine samples, where heparin was adsorbed by 
physisorption, are compared to silanized samples, with two different silanization times, 1h or 
overnight (o.n.); B)Saturation of heparin onto the β-TCP surface. The silanized discs (overnight 
silanization) were immersed for 2h in solutions with different concentrations of heparin; C) XPS 
spectra of the pristine material (β-TCP), overnight silanized β-TCP (β-TCP-Sil) and heparinized 
β-TCP (β-TCP-H), this last prepared by 2h immersion of o.n. silanized samples in a 150μg/mL 
heparin solution; D) SEM morphology of the surface of β-TCP-H, after heparin 
functionalization. 
Taking into account the results described above, the heparinization protocol selected 
for the cell culture studies consisted of overnight silanization followed by 2h 
immersion in a 150µg/mL heparin solution. 
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4.3.3. Cell culture studies 
4.3.3.1. Reactive oxygen species generated by monocytes and 
neutrophils in vitro 
The results of ROS (specifically hydrogen peroxide) release kinetics and total ROS 
released by monocytess and PMNCs obtained from blood from two donors, following 
cell activation with PMA are depicted in Figure 4-4. The data for two cell types was 
normalized to the maximum value reached by the positive control (TCPS+) and 
expressed as percentage. PMNC showed a delayed release compared to monocytes. β-
TCP-H down-regulated inflammation 15% for monocytes and 20% for neutrophils 
compared to positive control. Moreover, the total amount of ROS released by both 
types of cells when cultured on the heparinized surface, measured as the area below 
the curve and expressed as unit fraction, was lower than when cultured on bare β-TCP 
or on TCPS+ (Figure 4-4B).  
 
Figure 4-4. ROS release study on PMA-activated cells. Non-activated cells were used as negative 
control (TCPS). A) H2O2 release evolution profiles over time; B) Integration of the total area 
under the curves (N=6 from two independent buffy coats, from two donors). * indicates 
statistically significant differences compared to the negative control TCPS (p<0.05) and # 
indicates statistically significant differences with respect to β-TCP (p<0.05). 
4.3.3.2. Macrophage cell culture assays 
MNCs were seeded on the different substrates, where they adhered turning into 
macrophages. The release of pro-inflammatory cytokines by macrophages, specifically 
TNF-α, IL-1β and IL-10, normalized to cell number at each time point, and expressed 
as fold change with respect to TCPS+/6h (relative fold change) is represented in 
Figure 4-5, in three graphs corresponding to independent buffy coats. The results were 
compared with controls with/without LPS stimulation (TCPS+ and TCPS, 
respectively). In general, for TNF-α and IL-1β, the cytokine release pattern from 
macrophages confirmed a lower inflammatory response of β-TCP and heparinized β-
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TCP-H compared to the positive control TCPS+. β-TCP-H led to lower TNF-α level 
compared to pristine β-TCP, irrespective of the donor. Interestingly, in donors 2 and 3, 
the amount of TNF-α released by macrophages cultured on β-TCP-H was lower than 
that of the negative control (TCPS). Similar results were observed for IL-1β secretion, 
which was lowered upon contact with heparinized surfaces for all buffy coats, which 
showed slightly lower values than those of control without stimulation (TCPS). IL-10 
was not detectable for any of the groups. Due to the variability in native and acquired 
immune systems between donors, data are presented individually for each donor. 
 
Figure 4-5. Cytokine release by macrophages cultured on substrates for 6, 24, 48 and 72h. The 
three graphs correspond to buffy coats from three different donors. Tumor necrosis factor 
alpha(first row) and Interleukin 1 beta (second row). TCPS+ and TCPS correspond to the 
positive and negative controls, with/without LPS stimulation respectively.* indicates statistical 
difference compared to positive control TCPS+ and # to β-TCP (p<0.05).  
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Macrophage morphology on the different substrates was evaluated by SEM at each 
time point (Figure 4-6). All substrates promoted macrophage adhesion over time. 
Some of the cells retained the original round shape whereas others had a more 
elongated shape. This is relevant since macrophage morphology can be used to assess 
phenotype polarization.[56] Cell elongation was observed on both β-TCP and β-TCP-H 
substrates, whereas TCPS and TCPS+ were prone to form cell clusters. TCPS at 72h 
(Figure 4-6G) showed flattened cells with no filopodia (Figure 4-6G inset) which 
suggests apoptosis, whilst TCPS+ exhibited cell clusters (Figure 4-6H) with 
connecting filopodia (Figure 4-6H inset). Higher cell elongation was found on β-TCP-
H compared to bare β-TCP substrate, which at 72h showed still rounded cells (Figure 
4-6E and F, red colored). Image analyses of macrophage morphology showed a higher 
elongation ratio for the cells adhered on β-TCP-H (Figure 4-6I), especially at 72h, with 
a 25% higher elongation rate compared to TCPS. 
 
Figure 4-6. Representative SEM images of macrophages on β-TCP at 6h (A) and 72h (E); β-
TCP-H at 6h (B) and 72h (F); TCPS at 6h (C) and 72h (G); TCPS+ corresponding to LPS 
stimulated cells at 6h (D) and 72h (H). Scale bar in images A, B, E, F: 10µm; C, D: 2µm; G, H: 
20 µm, inset scale bar: 2µm. Red colored cells represent round macrophages and purple ones 
represent elongated ones. I) elongation ratio of cells at 6 and 72h (* denotes statistically 
significant differences from TCPS and TCPS+ at 72h, and # statistically significant differences 
between time-points). 
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4.3.3.3. Mesenchymal stem cell proliferation and differentiation 
Cell culture with rMSCs showed a slow but sustained proliferation on all β-TCP 
substrates over 14days measured by lactate dehydrogenase (LDH), (Figure 4-7A). Cell 
proliferation studies exhibited no statistically significant differences between β-TCP 
and β-TCP-H. Lower adhesion on heparinized substrates was found at 6h as well as 
significantly lower proliferation at 7 days comparing both calcium phosphate 
substrates. Nevertheless, no differences were found at 14 days, where cell proliferation 
rates were similar, irrespective of functionalization. Both substrates promoted lower 
proliferation than TCPS, which increased over 7 days until a plateau was reached. The 
measurement of ALP activity demonstrated earlier differentiation on the heparinized 
substrate β-TCP-H (Figure 4-7B). In the absence of exogenous supplementation, β-
TCP-H induced higher differentiation than TCPS at 6 hours and 3 days. After the 
addition of osteogenic medium (day 4), TCPS exhibit higher differentiation rate (7 
days) compared to calcium phosphate substrates, which decreased at 14 days. 
 
Figure 4-7. Cell proliferation and early differentiation of rMSCs cultured on β-TCP, β-TCP-H 
and TCPS as control. A) cell proliferation over time (14d) measured by LDH; data has been 
normalized to area and to cell number of TCPS at 6h and expressed as relative fold change. B) 
ALP activity over culture time. On day 4, the cell culture medium was replaced by osteogenic 
medium. * indicates statistically significant differences compared to control TCPS for the same 
time point (p<0.05) and # indicates statistically significant differences with respect to β-TCP for 
the same time point (p<0.05). 
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4.4. Discussion 
Calcium phosphates are widely used in clinical procedures. However, although their 
close resemblance to the composition of bone and other advantages such as 
bioactivity, osteoconduction and osteoinduction make them good candidates for bone 
grafting, they are not able to outperform autologous grafts in highly demanding 
situations. The design of new strategies to foster the interaction with the host tissue 
during the whole process of bone remodeling may lead to the development of 
materials with superior performance.   
The bone healing cascade is orchestrated by the cells of both the skeletal and the 
immune system through different shared mediators such as cytokines, receptors, 
signaling molecules and transcription factors. Recent studies have demonstrated that 
some ubiquitous biomolecules that are involved in the cross-talk between the immune 
and skeletal system, can be used to tune osteogenesis and osteoclastogenesis to 
achieve proper bone regeneration rates.[1,2,16,57] 
In this context, the present work explores the immune and osteomodulatory effect of 
heparin immobilized on β-TCP substrates. Previous works have proved the potential of 
heparin applied on model glass surfaces as an anti-inflammatory molecule.[32] 
Moreover, heparin is known have great affinity to growth factors, and this has been 
exploited with collagen, polyacrylamide, chitosan and other organic substrates as a 
way to stimulate bone regeneration.[24,42,44,54]  The high affinity of heparin for growth 
factors is highly relevant in the case of  β-TCP because, even though numerous 
proteins have high binding affinity to calcium phosphates via amino acids with 
phosphate- or carboxylate-terminated side chains, most growth factors lack a specific 
mineral-binding domain.[43] The functionalization with heparin can help to circumvent 
this limitation. However, studies pertaining to the heparinization of calcium 
phosphates are scarce, and limited to its use as an anchoring molecule for the 
immobilization of growth factors on the surface of the biomaterial, for its subsequent 
delivery.[43,49] 
Heparin can bind to CaP by physical adsorption or by covalent attachment, as 
demonstrated in other works with HA.[49] Physical adsorption of heparin takes place 
through electrostatic interaction between the charged sulfate/carboxylate groups in 
heparin with exposed Ca ions on the crystal surface of the CaP. Covalent binding is 
typically accomplished through a silanization step to covalently graft amine groups 
that can react with the carboxylate groups from heparin through amide bond 
formation.[49,66] Heparin binding through covalent bonds is more stable than physically 
adsorbed heparin. It has been reported that in complex environments like body fluids, 
the presence of other charged molecules can compete for binding, thus displacing 
electrostatically bound heparin from the surface of the CaP.[58] The results obtained in 
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the present work for β-TCP show that a covalent binding yielded higher amounts of 
heparin than mere physical adsorption. Figure 4-3A shows increased heparin grafting 
densities following covalent immobilization than physical adsorption, and this was 
further improved with increased silanization time. The maximum amount of heparin 
that was adsorbed on the surface of β-TCP was around 25µg, but this dose could be 
tuned depending on the concentration of heparin used during binding (Figure 4-3B).  
To assess the osteogenic and immunomodulation ability of heparin on β-TCP, covalent 
attachment was preferred for stability reasons as well as to test heparin’s ability to 
recruit endogenous GF which can help modulate cell function.[59,60] During the early 
inflammation process, immune cells can signal the following biological cascades. 
Neutrophils and monocytes interacting with materials release H2O2, which act as anti-
inflammatory signaling molecule. H2O2 can cause cell dysfunction and tissue injury 
depending on the concentration.[61] High concentrations of H2O2 and other ROS are 
deleterious to cells; optimal concentration is required to properly modulate the 
inflammation cascade by stimulating the balance between pro and anti-inflammatory 
cytokines. In the present work, primary human cells were used to assess the 
inflammatory response of the materials as they reflect better the in vivo scenario upon 
biomaterial implantation. Lower hydrogen peroxide levels were detected after contact 
with heparinized β-TCP surfaces compared to the non-heparinized ones (Figure 4-4). 
The release kinetics were different for the two cell types; whereas neutrophils 
exhibited a clear monomodal pattern, monocytes showed an acute release within the 
first 5min followed by a second raise after 80min. Nevertheless, β-TCP-H (Figure 4-4, 
blank squares) still displayed the lowest percentage of release. The role of GAGs on 
inflammation has been previously studied by local administration.[25,30,62] Campo et al. 
found a down-regulation of ROS and inflammatory cytokines in LPS-induced mouse 
chondrocytes by several GAGs.[30] The highest inhibitory effect was exerted by 
chondroitin sulfate and heparan sulfate supplementation. Nevertheless, the effect of 
GAGs has been mainly studied as a supplement in cell culture. Although in the present 
work the reduction of ROS is low, probably due to low heparin concentration, the 
trend observed for the heparinized β-TCP surfaces confirm the anti-oxidative activity 
of heparin.  
Activated macrophages secrete cytokines, which also modulate the inflammatory 
response depending on the interaction with the biomaterial and the implant 
environment.[63] Mantovani et al. extensively described the cytokine system derived 
from macrophage polarization[3,4] and highlighted the dynamism of this polarization. 
Even though for decades M1 pro-inflammatory macrophages were seen as mediators 
of fibrous encapsulation, nowadays it is widely accepted that both M1 and M2 
subtypes promote degradation of implants and healing.[64] In the present work, pro-
inflammatory (TNF-α, IL-1β), pro-wound healing (IL-1β) and anti-inflammatory 
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cytokines (IL-10) were investigated using primary human cells, which although 
entailing a certain degree of variability between donors, mimic more closely the in 
vivo scenario. The cytokine release profiles (Figure 4-5) showed similar trends to those 
of ROS release. TCPS+ exhibited the highest levels of cytokine release upon LPS 
stimulation. Neither β-TCP nor β-TCP-H caused cells to secrete more cytokines than 
LPS-activated TCPS (TCPS+). Similarly to previous works with β-TCP particles,[65,66] 
β-TCP substrates induced higher release of TNF-α and IL-1β than TCPS. 
Functionalization with heparin of these substrates resulted in a reduction of TNF-α and 
IL-1β release, which was below the levels of TCPS in all three donors for IL-1β, and 
in two donors for TNF-α. IL-10, an anti-inflammatory cytokine, was not detected by 
ELISA in any of the substrates. Overall, the reduction in the inflammatory response 
caused by heparin on the surface of the β-TCP substrate was in agreement with 
previous results obtained in GAG multilayer substrates by Zhou et al.[32] 
Besides the cytokines release profile, cell shape can provide information on 
macrophage phenotype which can also be supported by immunostaining techniques for 
specific markers on macrophages. Sridharan et al. concluded that macrophage 
elongation can be associated to a pro-healing phenotype (M2), whereas pro-
inflammatory macrophages (M1) present more rounded shapes.[63] Similarly, 
McWorther et al. found elongated shapes being compatible with an expression of M2 
phenotype on patterned TCPS.[56] SEM images showed early elongation on β-TCP 
substrates at 6h (Figure 4-6A and B), which continued up to 72h, more pronounced on 
heparinized β-TCP-H (Figure 4-6E and F). Image analyses of cell morphology 
revealed significantly higher elongation ratio for β-TCP-H at 72h (Figure 4-6I), which 
can be related to M2 polarization, in agreement to the lower cytokine release (Figure 
4-5).  
Osteogenic cell proliferation and differentiation are required to continue the healing 
process. Some studies have determined that the binding affinity between GAGs and 
osteogenic markers such as osteocalcin, osteonectin or osterix, is necessary for 
osteoblast maturation.[67,68] However, these studies took a direct stimulation approach 
by supplementing GAGs into the cell media or by attaching them on TCPS. The use of 
osteoconductive substrates such as CaPs in combination with GAGs can further 
enhance their biological response. β-TCP and TCPS showed similar rMSCs adhesion, 
while a slightly lower cell adhesion was found for heparinized β-TCP-H, even no 
significant differences were depicted from statistics analyses (Figure 4-7A). 
Noteworthy, early differentiation was stimulated by the presence of heparin as there 
was increased ALP activity compared to pristine β-TCP (Figure 4-7B). Although after 
osteogenic stimulation (7 and 14 days) ALP expression was higher on TCPS, this 
might be influenced by cell confluence, as denoted by the plateau reached in cell 
proliferation for TCPS (Figure 4-7B). Additionally, ALP expression occurred at 
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shorter times on CaPs substrates, but at lower levels even the osteogenic stimulation. 
Hence the platform proposed here presents a novel step forward in the design of 
osteoimmunomodulatory biomaterials taking advantage of the intrinsic properties of 
CaPs together with immobilized GAGs on their surface. 
4.5. Conclusions 
Heparin was covalently attached on β-TCP substrates by a silanization process and 
achieved significantly higher grafting densities compared to physisorption. The 
presence of heparin clearly influenced the response of both immune and osteogenic 
cells. Heparinization decreased the levels of hydrogen peroxide and inflammatory 
cytokines released from human immune cells in contact with the material. Cells 
elongation ratio was found higher on heparinized β-TCP-H, which denote a M2 or pro-
healing phenotype correlated to the down-regulation of pro-inflammatory cytokines. In 
addition, heparinized substrates resulted in higher ALP expression in rat mesenchymal 
stem cells after 3 days of culture in the absence of osteogenic medium, compared to 
non-heparinized substrates. This may indicate that heparinized surfaces enhance 
osteogenic differentiation, but this would need to be validated in further studies. 
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5. Effect of heparinization on the inflammatory response and 
osteoclastogenesis of biomimetic CDHA 
 
Scope 
 
In the previous chapter it was demonstrated that the use of ECM molecule, like 
heparin, on conventional synthetic bone grafts was a promising strategy to enhance 
the materials’ biological interactions. The purpose of this chapter is to explore the 
functionalization of more complex samples, i.e. biomimetic calcium phosphates, and to 
focus the biological screening to  the early stages of healing where immune cells and 
osteoclasts (OC) modulate the inflammation and resorption potential of the 
biomaterial, respectively. 
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5.1. Introduction 
The success of synthetic bone grafts upon implantation is usually related to their 
ability to favorably modulate the host response. The biological cascade triggering 
the success or failure of a biomaterial depends on its interactions with the host 
tissue. These interactions mainly involve the immune and the skeletal systems in 
what nowadays is known as osteoimmunology.[1,2] The immune system plays a 
role in the inflammatory response upon implantation/injury while the skeletal 
system will orchestrate the osteogenic/osteoclastogenic response to interact with 
the biomaterial[3,4] The resolution of this first inflammatory response is related to 
homeostasis, inflammation and the consequent tissue repair and regeneration.[5] 
The main actors during inflammation are blood cells arriving to the injured site 
by extravasation. Neutrophils (polymorphonuclear cells, PMNC), monocytes and 
monocyte-derived cells, such as macrophages, are the first interacting cells, 
which will trigger the biological cascade by releasing reactive species, such as 
ROS and NOS, respectively, chemokines and cytokines.[6–8] Hence, the 
modulation of this early response has recently drawn the attention in the effort to 
enhance the tissue regeneration potential of biomaterials.  
Reducing or switching-off inflammation upon implantation is one desired 
mechanism which can foster the success of an implanted material.[9] One 
interesting approach is the use of GAG as anti-inflammatory molecules. 
Hyaluronic acid, chondroitin sulphate and heparin have shown good anti-
inflammatory properties by binding to chemo- and cytokines.[10] As an example 
of how GAGs interact with the pro-inflammatory chemokine, interleukin–8 
(CXCL8)/neutrophil-mediated inflammation has been recently described.[11] In 
addition, GAGs are part of the extracellular matrix (ECM),and they are known to 
interact with several signaling proteins involved not only in the immune system 
but also in the skeletal pathways.[12,13] Recent works have highlighted the affinity 
of GAGs for osteogenic proteins such as bone morphogenetic proteins 
(BMPs),[14–17] thanks to the presence of heparin binding domains in BMPs.[13] 
Hempel et al. pointed to the degree of sulfonation of GAGs as a key to control 
such interactions.[18,19] Likewise, Hintze et al. reported a higher binding affinity 
of oversulfated GAGs with human BMP-4 compared to the absence of 
sulfonation.[20] Even though the osteogenic potential of GAGs, and specifically 
heparin has been reported, it is still controversial whether GAGs enhance or 
inhibit osteoclast maturation.[21–23] 
In this chapter, we propose to exploit the capacity of GAGs to interact with the 
bone remodeling cascade at different stages, by combining them with a calcium 
phosphate substrate. CaPs are ideal candidates to support bone regeneration. 
Moreover, they possess a close resemblance to mineral bone phase, i.e. HA. 
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Some authors have investigated engineered routes to enhance their biological 
interactions. Lode et al. improved the angiogenic response of endothelial cells in 
vitro by functionalization of CaPs with heparin.[24] Likewise, König et al. 
investigated the effect of heparinized collagen-HA matrices on fibroblast, 
endothelial cells and mesenchymal stem cells resulting in improved biological 
interactions compared to non-heparinized matrices. [25] However, one of the main 
drawbacks of synthetic HA is its poor resorption rate. Hence, promoting their 
resorption is also a good strategy to develop successful bone grafts, able to be 
transformed in new bone.  
In fact, the control of the materials’ resorption is a key aspect during the bone 
remodeling process. Promoting osteoclastogenesis and the bi-directional 
crosstalk between osteoclasts (OC) and osteoblasts (OB) is crucial for bone tissue 
regeneration, and GAGs have been shown to be a good tool to foster these 
interactions. Thus, Salbach et al. studied the effect of sulfonation of GAGs to 
promote OB and OC activity. They found that GAGs were preferentially binding 
OPG, a decoy receptor of RANKL which blocks the interactions RANKL-
RANK, crucial pathway to OC maturation.[26] Similarly, Irie et al. investigated 
the effects of heparin on osteoclasts formation, highlighting as well the heparin 
interaction with OPG.[17]In their study, osteoclast formation was promoted due to 
the dual exposure to RANKL and OPG. Heparin bound to OPG thus increasing 
the RANKL available for OC maturation. Ling et al. also described the 
interfering ability of GAGs to modulate RANKL-induced osteoclastogenesis by 
solubilizing GAGs on cell culture media using RAW murine cells.[27] 
The aim of the present chapter was to use heparin as a tool to tune the 
inflammatory response and osteoclastogenesis of a CaP which are crucial events 
at early stages of bone remodeling. The effect of heparin functionalization ona 
CDHA substrate was analyzed using primary human cells. A widely known 
synthetic bone graft, β-TCP was used as control, together with tissue culture 
polystyrene (TCPS).  
5.2. Materials and Methods 
5.2.1. Preparation and characterization of calcium 
phosphates 
CDHA was obtained by hydrolysis of α-TCP. α-TCP was produced by solid state 
reaction at 1400°C of calcium hydrogen phosphate (CaHPO4, Sigma-Aldrich, St. 
Louis, USA) and calcium carbonate (CaCO3, Sigma-Aldrich, St. Louis, USA) at 
a 2:1 molar ratio for 15h and then quenched in air. The α-TCP was milled to a 
final median size of 5.2µm.[28] α-TCP containing 2wt% of precipitated HA (PHA, 
Chapter 5 
104 
 
Merck KGaA, Darmstadt, Germany) was mixed with a liquid phase consisting of 
distilled water at a liquid to powder (L/P) ratio of 0.35mL/g, resulting in a paste 
that was transferred into PTFE moulds to fabricate discs of either 15 mm 
diameter x2 mm thickness or 5mm diameter x1mm thickness. The discs were left 
to set at 37°C for 10 days in water to allow for complete hydrolysis to CDHA. β-
TCP discs were obtained by sintering the previously obtained CDHA discs at 
1100ºC for 9h and cooling down in air. 
Phase identification was performed by XRD (Bruker, Cu Kα,  λ=1.5406Ǻ, 40kV, 
40mA). Data were collected in 0.02° steps over the 2θ range of 10°-80° with a 
counting time of 2s per step. The experimental patterns were compared to those 
of hydroxyapatite (JCPDS 09-0432), α-TCP (JCPDS 09-0348) and β-TCP 
(JCPDS 09-0169). Pore size distribution was investigated by MIP (Autopore IV 
Micromeritics) recording intrusion-extrusion curves from 30 to 30000 psia. The 
SSA was assessed by nitrogen adsorption using the BET method (ASAP 2020, 
Micromeritics). Finally, the microstructure of the substrates was investigated by 
SEM (FIB Zeiss Neon40). 
5.2.2. Surface functionalization with heparin 
Heparin immobilization was performed through an amidation reaction using a 
first step of silanization with aminopropyltrietoxysilane (APTES, Sigma-Aldrich, 
St. Louis, USA) followed by (1-(3-dimethylaminoporpyl)-3-ethylcarbodiimide, 
EDC, Sigma-Aldrich, St. Louis, USA) and N-hydrosuccinimide (NHS, Sigma-
Aldrich, St. Louis, USA) adapted from literature[29] to couple heparin by its 
carboxyl groups. CDHA discs were immersed in absolute ethanol solution with 
2%v/v APTES and 3%v/v distilled water and left for overnight agitation at 100 
rpm in order to obtain aminated surfaces. Afterwards, the discs were rinsed in 
absolute ethanol and sonicated for 5 minutes. Subsequently, different 
concentrations of heparin were activated to study the saturation onto discs 
surface. Heparin solutions in phosphate buffer saline (PBS, Gibco) were prepared 
and activated by dropping pH to 6.5 for 15 minutes in presence of EDC/NHS. 
Immediately after, pH was raised to 7.5 and 1mL of activated heparin solution 
was poured onto the aminated discs and left under agitation for 2 hours for 
coupling. Supernatants were collected for heparin quantification through an 
indirect colorimetric method based on toluidine blue, adapted from literature.[30] 
Finally, the heparinized discs (CDHA-H) were rinsed in PBS and sonicated for 5 
minutes in order to remove non-covalently attached heparin. 
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5.2.3. Inflammatory response 
Monocytes and PMN were isolated in two steps from human buffy coats from 
volunteer donors at Uppsala University Hospital similar to previously reported. 
[31] Briefly, for monocytes isolation, 15mL of human blood diluted in PBS (1:1) 
were layered onto Ficoll-Paque Plus (GE Healthcare) and monocytes were 
isolated by density gradient centrifugation. The upper plasma layer was collected 
and kept at 4ºC for later use. Mononuclear ring was collected and washed 3 times 
with PBS. Cells were resuspended in PBS and counted by exclusion method 
using Trypan blue (1:5) in a cytometer. PMN underwent a second separation step 
using 20mL of 3% Dextran in 0.9% saline solution. After 25 minutes of 
incubation, supernatant was centrifuged and treated with 0.2% saline solution 
over 20 seconds and 1.6% saline solution to remove erythrocytes. Cell 
suspension was further centrifuged and resuspended in PBS. A solution 
containing 6%wt. acetic acid was used to count cells in a cytometer. 
Luminol amplified chemiluminescence was used to study the inflammatory 
response of cells in contact with 5x1mm2 discs by monitoring the release of 
reactive oxygen species over a time of 2 hours. Cells were activated with 1µM 
phorbol-12-myristate-13-acetate (PMA, Sigma Aldrich) in a luminol solution as 
signal amplifier. A negative control consisting of TCPS was used without PMA 
stimulation. Luminol solution was prepared from stock (50mM of luminol in 0.2 
M NaOH) with 1% luminol stock and 0.2% horseradish peroxidase (1mg/mL) 
and activated with 1µM phorbol-12-myristate-13-acetate (PMA, Sigma Aldrich). 
Prior to luminol kinetic study, 5x1mm2 discs were placed in opaque white 96 
well-plates (Perkin Elmer) and sterilized with 70% ethanol for 3 hours, followed 
by thrice rinsing with PBS for 15 minutes each prior to cell seeding. Both cell 
types were diluted in cell culture media (4PBS/1RPMI-1640/100Mm glucose) at 
a density of 1·106cells/mL. For the plasma containing studies, 10% of human 
plasma was added to the cell medium. 200µL of cells were added to opaque 96 
well-plates (Perkin Elmer) followed by the addition of 100µL of Luminol 
solution (500µM). Luminescence was monitored at 37ºC every 2 min over 2h of 
total kinetic study as previously described.[32] Triplicates for each material were 
used (n=3) and the experiment was repeated twice with independent donor buffy 
coats. 
5.2.4. Osteoclast cell cultures 
Peripheral blood MNC (PBMC), containing the precursors of human osteoclasts, 
were isolated from buffy coats of healthy voluntary blood donors to the National 
Blood Transfusion Service. Donation was anonymous, and institutional review 
board (IRB) approval was not required. Density centrifugation with Ficoll-
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Histopaque gradient (Sigma–Aldrich) was used to isolate the mononuclear cells 
as described in previous work.[33] Cells were resuspended in Dulbecco’s 
Modified Eagle’s Medium–High Glucose (DMEM, Euroclone, Milan, Italy) 
supplemented with 10% fetal bovine serum (FBS, Euroclone) and 1% 
Penicillin/Streptomycin (complete DMEM). CDHA, CDHA-H, β-TCP and TCPS 
were sterilized using 70% ethanol for 3h, followed by three rinses with PBS for 
15min each. Complete medium was added after the sterilization and kept 
overnight prior to cell seeding to minimize ionic exchange as preconditioning 
treatment.  
Mononuclear cells were resuspended in complete DMEM and seeded on discs 
and TCPS at a density of 6·106 cells/cm2 and 3·106 cells/cm2, respectively. After 
2h of incubation, non-adherent cells were gently removed and complete DMEM 
supplemented with 25% RANKL-containing human osteoblast supernatant 
(differentiation medium) was added to induce the differentiation of osteoclast 
precursors (OCP).[34,35] Cell cultures were performed up to 28 days and 
differentiation medium was refreshed every 3 days.  
5.2.4.1. Osteoclast morphology 
Osteoclast morphology at 14, 21 and 28 days of culture was investigated using 
Scanning Electron Microscopy (SEM, FIB Zeiss Neon40). At each time point, 
cells were rinsed with PBS and fixed using 2%paraformaldehyde/2% 
glutaraldehyde in 0.1M cacodylate buffer overnight at 4ºC. Afterwards, samples 
were dehydrated in ethanol series and dried. A thin carbon layer was sputtered 
prior to imaging to impart conductivity. 
Tartrate-resistant acid phosphatase and Hoechst staining (TRAP-Hoechst) at 14, 
21 and 28 days was used to study OC morphology and differentiation. At each 
time point, cells were fixed using 3% paraformaldehyde-2% sucrose for 30 min. 
Afterwards, cell membrane was permeabilized with Triton 0.5% in HEPES for 5 
min at room temperature, and finally stained using naphthol AS-BI phosphoric 
acid and tartrate solution (Acid Phosphatase kit, Sigma–Aldrich) for 60 min at 
37ºC for the cytoplasm and with 2.25µg/mL of Hoechst 33258 (Sigma–Aldrich) 
for 10 min in the dark to for the cell nuclei. TRAP-Hoechst stained samples were 
analyzed by optical fluorescence microscopy at 360nm excitation and 470nm 
emission. ImageJ software was used to perform a semi-quantitative analysis of 
the multinucleated cells found by optical microscopy. Duplicates of 5x1mm2 
material discs were used for the staining study and duplicates of plastic chamber 
slide were used as controls. 
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5.2.4.2. Osteoclast activity 
In order to assess OC differentiation, tartrate-resistant acid phosphatase (TRAP) 
activity was quantified both in cells and culture supernatants at the end of the 
experiment (28 days). Briefly, cells grown on material substrates were rinsed in 
PBS and lysed with 0.1% Triton X-100/1M NaCl (Sigma-Aldrich). 50μl of the 
cell lysate were transferred to a new plate and 50μl 4-nitrophenyl phosphate 
(4.61 mg/ml)/40mM Na-tartrate/50mM Na-acetate (pH 4.8) were added. After 1 
hour incubation at 37 ºC, the reaction was stopped with 50μl of sodium 
hydroxide (NaOH, 0.2M), and the absorbance was measured at 405nm in a 
spectrophotometer (Infinite F200 Pro Microplate Reader; TECAN, Mannedorf, 
Switzerland).  
Bicinchoninic acid colorimetric assay (BCA, Pierce BCA Protein Assay Kit, 
Rockford, USA) was used to quantify the total protein in lysates according to 
manufacturer’s instructions. Material substrates without cells (blank) were 
measured and subtracted from cell-seeded materials. TRAP activity was then 
normalized by the total protein content after blank subtraction.  
Tartrate-resistant acid phosphatase isoform 5b (TRAP5b) activity was 
investigated after 28 days of culture. Cell supernatants were collected, 
centrifuged at 400g for 5 min and assayed using the BoneTRAP® Assay kit 
(Pantecs.r.l., Torino, Italy), according to the manufacturer's instructions. The 
concentration of TRAP5b protein in the supernatants was determined by reading 
the absorbance at 405nm in a spectrophotometer. Data are expressed as mean 
concentration (units/L) after subtraction of the corresponding cell-free readout 
(blank). 
Calcium release and pH were monitored over the experimental time at 0, 3, 7, 14, 
21 and 28 days. At each time point supernatants were collected, centrifuged at 
2800rpm for 5 minutes and kept at 4ºC until measurement. Calcium release was 
measured using a colorimetric method based on ortho-cresolphthalein 
complexone (OCPC, Sigma-Aldrich) adapted from previous works[36,37] and the 
absorbance was measured at 570nm using a UV-vis spectrophotometer (Infinite 
M200 Pro Microplate Reader; TECAN, Manndorf, Switzerland). The values of 
pH were measured using a pH-meter (MultiMeter MM 41). Triplicates of 
15x2mm2 material discs were used for all experiments. 
5.2.5. Statistics 
Data were obtained using triplicates for each experiment. Data are represented as 
mean value ± standard error of the mean. Data groups for TRAP measurements 
and multinucleated cells counting were normally distributed (homogeneous 
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variance, Levene>0.05) and were analyzed using one way ANOVA and post-hoc 
Tukey test was used to assess significant differences. The differences in the 
number of nuclei were not normally distributed and non-parametric Kruskal-
Wallis was used to assess significant differences. Values of p<0.05 were 
considered as significant. All statistics were performed using IBM® SPSS® 
Statistics 24 software. 
5.3.  Results 
5.3.1. Physicochemical properties of CaP substrates 
Phase composition as measured by XRD (Figure 5-1A) showed that CDHA 
consisted of a poorly crystalline hydroxyapatite phase (JCPDS 09-0432), as 
indicated by the broad peaks. A small amount of unreacted α-TCP was detected 
(JCPDS 09-0348), amounting a 2wt%, as quantified by EVA Software. β-TCP 
samples were phase-pure and showed the sharp peaks typical of crystalline 
sintered materials (JCPDS 09-0169). According to MIP analysis (Fig. 1B), 
CDHA exhibited a broad pore size distribution ranging from 10 to 100nm. In 
contrast, β-TCP specimens presented larger pores, centered around 1µm, 
although they exhibited also some nanoporosity. The total porosity was similar 
for both substrates (Figure 5-1C). The microstructure of the two ceramic 
substrates was clearly different. Whereas CDHA consisted of an entangled 
network of plate-like crystals, β-TCP presented a smooth polyhedral grain 
microstructure (Figure 5-1C,a and b), which resulted in very different values of 
SSA, i.e. 24m2/g for CDHA and 0.4 m2/g for β-TCP. Finally, the results of the 
heparin adsorption isotherms are displayed in Figure 5-1D. The maximum 
covalent attachment yield was achieved with 500µg/mL, which allowed for the 
immobilization of approximately 200µg of heparin on the material surface. 
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Figure 5-1. Physicochemical properties of CaP substrates. A: XRD patterns of CDHA and 
β-TCP; B: pore entrance size distribution; C: Specific surface area (SSA) and porosity 
values with representative SEM microstructures for CDHA and β-TCP (a and b, 
respectively, scale bar: 2µm); D: heparin adsorption isotherms on CDHA after 2h 
incubation in heparin solutions. 
5.3.2. Inflammatory response 
The release of ROS by PMN and monocytes upon contact with the surface of the 
different materials activated with PMA is depicted in Figure 5-2 and Figure 5-3. 
The inflammatory response of PMN with and without plasma is shown in Figure 
5-2A and B, respectively. CDHA exhibited the lowest ROS release among all 
substrates either with or without plasma (black and grey curves, respectively), 
followed by CDHA-H and β-TCP. All PMA-stimulated substrates showed a peak 
within the first 5 minutes, shorter times than those presented on Chapter 4 
(Figure 4-4A), which could be related to the handling of PMA activation and 
measurement. Plasma containing studies showed a slight increase in ROS signal 
compared to the absence of plasma. No release of ROS was observed in the 
negative control (TCPS) without PMA activation. 
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Figure 5-2. Kinetics of ROS release by neutrophils in contact with substrates over 2h. A: 
ROS release in presence of 10% human plasma, and B: ROS release without plasma. 
ROS kinetic release upon contact with monocytes in absence of plasma showed 
higher values than PMN Figure 5-3A, however ROS peaks were shifted to longer 
time (20min). TCPS activated (TCPS+) showed a bimodal kinetic, with two ROS 
peaks at 20 and 50min.Biomimetic substrates CDHA and CDHA-H exhibited the 
lowest ROS signals, approximately 60% and 30%, in the presence and absence of 
plasma respectively, showing a mean peak at 20min in all substrates (Figure 
5-3A and B). The presence of plasma increased the signal of ROS for both 
CDHA and CDHA-H, which was though diminished after 1h to half of its value 
(Figure 5-3A). No effect of plasma was found for β-TCP which yielded 
approximately 70-80% of ROS for both absence and presence of plasma.  
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Figure 5-3. ROS release kinetic of monocytes in contact with substrates over 2h. A: ROS 
release in presence of 10% human plasma, and B: ROS release without plasma. 
5.3.3. Osteoclast morphology 
The evolution of osteoclast morphology was qualitatively evaluated by SEM. 
Figure 5-4 shows the OC morphology on substrates at 14, 21 and 28 days. On 
TCPS, round cells were found at 14 days, which became bigger and more spread 
after 21 and 28 days. At 28 days, protuberances surrounded by a flat halo were 
visible for all cells, compatible with mature OC morphology. β-TCP substrate 
showed a high number of round cells at 14 days which spread and showed 
several connecting filopodia at 21 days and 28 days. Biomimetic substrates, 
CDHA and CDHA-H, also supported OC adhesion as shown in the results at 14 
days. After 21 days, cells appeared more elongated on CDHA-H than on CDHA 
at 28 days the presence of cell clusters were observed in some regions of the 
sample particularly for CDHA-H 
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Figure 5-4. SEM images of osteoclasts cultured on substrates at different time points (14 
days, first column; 21 days, second column, and 28 days, third column) Scale bar: 20µm. 
Higher magnification images of CDHA-H at 28 days showed regions with 
degraded crystals compared to pristine plate-like microstructure of the material. 
This was compatible with OC resorption and was especially evident close to the 
cells (Figure 5-5). Figure 5-5B shows that the plate-like crystals typical from 
CDHA appeared degraded at the adjacent zones of OC. 
The differentiation of OC was monitored using TRAP-Hoechst staining at each 
time points (14, 21 and 28 days). Few adherent cells were observed on the 
biomimetic substrates compared to sintered β-TCP. At 14 days, multinucleated 
cells were evident only on TCPS and CDHA-H (Figure 5-6D and J, black 
arrows). This aspect was maintained over 21 and 28 days for both substrates 
(Figure 5-6E and F for CDHA-H, and Figure 5-6K and L for TCPS). Only at 28 
days few multinucleated cells were found on CDHA and β-TCP, even if some 
cell clusters were visible already at 21 days for CDHA (Figure 5-6B). 
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Figure 5-5. SEM images of CDHA-H at 28 days showing distorted crystals from OC 
activity. A: low magnification image showing a covered surface by OC (scale bar:10µm), 
and B: higher magnification image showing degraded plate crystals (white arrows) 
compared to the pristine crystal morphology (*) at the adjacent zone to cells (+), (scale 
bar:2µm). 
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Figure 5-6. TRAP-Hoechst staining showing OC differentiation over time on CDHA (A, B 
and C), on CDHA-H (D, E and F), on β-TCP (G, H and I) and on TCPS (I, K and L).). 
Scale bar:25µm. Black arrows indicate multinucleated cells (OC). 
Image analyses based on TRAP-Hoechst optical images disclosed different cell 
behaviors (Figure 5-7A). A higher number of multinucleated cells was found on 
TCPS since 14 days, which was increasing with time (21 and 28 days). CaPs 
substrates displayed lower number of multinucleated cells compared to TCPS. 
For CDHA, the presence of heparin (CDHA-H) produced higher number of 
multinucleated cells at all-time points, whereas β-TCP and bare CDHA showed 
similar number of multinucleated cells but with less nuclei. A more in-depth 
study on the morphology of the nucleated cells revealed different fusion patterns 
over time. Figure 5-7B illustrates the comparison of the number of nuclei in the 
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multinucleated cells counted in Figure 5-6A. The substrates yielding higher 
number of multinucleated cells, i.e. CDHA-H and TCPS, showed also a higher 
number of cells with 3 to 5 or 6 to 10 nuclei regardless of time.  
 
Figure 5-7. A) Number of multinucleated cells on the different substrates at different time 
points. Groups identify by the same superscripts are not statistically different (p>0.05). 
Numbers indicate differences between the time points within the same sample. Letters 
identify differences between different substrates at each time point. B) Distribution of 
multinucleated cells according to the number of nuclei at the different time points. Letters 
indicate differences between the number of nuclei for each type of sample. All calculations 
correspond to sample triplicates cultured using one single donor osteoclasts precursor 
cells. 
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5.3.4. Osteoclast activity 
The number of OC and their activity on the different substrates was investigated 
by TRAP5b isoform and TRAP activity respectively after 28 days of culture, and 
normalized by the total protein content. Figure 8A shows the total protein in the 
lysates at 28 days. Heparinized CDHA-H showed the highest protein content, 
followed by CDHA and β-TCP, TCPS showing the lowest protein content. The 
TRAP activity normalized by the protein content led to similar levels for the 
different CaP substrates (Figure 5-8B). The presence of heparin resulted in a 
decrease of TRAP activity, although the difference with the pristine CDHA was 
not statistically significant. The concentration of the TRAP5b isoform released 
by the cells cultured on the CaP substrates was smaller than in the control TCPS, 
and similar for all the materials (Figure 5-8C).  
 
Figure 5-8. OC activity and number on substrates at 28 days in terms of TRAP activity. A: 
Total protein in the cell lysates measured by BCA. (#) indicates statistically significant 
differences compared to CDHA-H; B: TRAP activity normalized by total protein in the 
cell lysates (*) indicates statistically significant differences compared to control TCPS; C: 
TRAP5b isoform measured by ELISA (*) indicates no statistically significant differences 
compared to TCPS. Statistical significance of p<0.05. 
Osteoclast activity can also be analyzed in terms of calcium release and pH 
change due to the resorptive activity of OC, although caution needs to be taken 
when studying CaP substrates, as dissolution-precipitation events can affect these 
data. For this reason, experiments were performed using substrates with and 
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without cells. Figure 5-9A represents the mean values of Ca2+ release at each 
time point. The highest Ca2+ concentration was registered when OC precursors 
were cultured on β-TCP. Both biomimetic substrates showed an uptake of 
calcium from the medium, showing similar Ca2+ values irrespective of heparin 
functionalization (Figure 5-9B). Yet, in presence of cells, the concentration of 
Ca2+ in the culture medium increased. The values for TCPS, both with and 
without cells, exhibited a decrease up to 28 days. In contrast, the cell culture 
medium showed a slight acidification in presence of cells for all substrates, 
which was more pronounced on the CaP substrates, especially at early time 
points (Figure 5-9C). Due to the presence of carbon dioxide in incubator which 
can be diffuse into cell culture medium, all samples showed slightly higher pH 
than physiological conditions. The variation of pH comparing the presence and 
absence of cells showed higher acidification for CDHA-H and β-TCP maintained 
over time (Figure 5-9D).  
 
Figure 5-9. Evolution of the extracellular calcium concentration (A) and pH values (C) in 
the cell culture medium in presence (full symbols) or absence of cells (hollow symbols) 
from 0 to 28 days. Each time point values represent the average of three samples. The 
variations of calcium and pH in the culture medium with cells compared to that without 
cells are represented in B and D, respectively. 
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5.4. Discussion 
The engraftment of any material in the human body is bound to cause tissue 
damage, thus evoking an inflammatory response. The study of human neutrophils 
(PMN) and monocytes, with their oxidative and hydrolytic activities, as well as 
of macrophage functions is crucial during injury, as a predictor of the 
inflammatory cascade evolution. Typical inflammation occurs by early 
recruitment of monocytes and neutrophils to the injured site, which will drive the 
host response. This in turn, will lead to either healing or chronic inflammation by 
sustained immune response, with over expression of inflammatory molecules and 
fibrous tissue encapsulation of the material.[3,4,38] Recently, it has been shown that 
the immune system plays a central role in tissue repair and regeneration, also 
when biomaterials/scaffolds are introduced.[39–41] 
The initial cellular responses are firstly modulated by the ROS release activating 
signal transduction pathways.[6] ROS are known to be signaling molecules 
regulating a number of physiological functions, such as gene activation, cellular 
growth, and modulation of chemical reactions in the cell.[42,43] Too high 
concentrations of ROS can lead to cell death by apoptosis/necrosis.[44] On the 
contrary, low ROS levels can stimulate cell signaling to, for instance, enhance 
phagocytosis.[45] Moreover, it has been recently shown that, regardless of the 
sources of ROS, osteogenic and adipogenic differentiation of mesenchymal 
stromal cells (MSC) are partly ROS dependent, so establishing a pivotal role for 
ROS in MSC differentiation.[8] 
CaP ceramics, such HA and β-TCP, are widely used as bone substitutes or 
prosthesis coatings because of their osteoconductive properties, and are known to 
evoke a consistent inflammatory cell response when tested as particles[46] or 
following the resorption of calcium-containing biomaterials.[47] 
In this chapter, we investigated whether the functionalization of CDHA with 
heparin had an effect on the inflammatory response of neutrophils and 
monocytes. The grafting density of heparin onto high SSA CDHA yielded 10-
fold higher heparin compared to smooth sintered β-TCP (Section 4.3.2 Heparin 
immobilization, p. 85) 
PMNs functions must be appropriately regulated in order to avoid excessive or 
unresolved inflammation with ROS-dependent tissue and material damage. 
Recently, some authors have explored the immune response to GAGs. The 
claimed anti-inflammatory effect of some GAGs[48–53] such as heparin in 
reducing the PMA-induced ROS release from neutrophils was not confirmed in 
the present study, where, in fact, lower ROS levels were observed on pristine 
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CDHA than on CDHA-H. In addition, the anti-oxidant effect of human plasma, 
attributed to the scavenging role of proteins was not observed.[52] Although the 
neutrophil response was not particularly affected by the presence of plasma, 
monocytes presented the opposite trend, with lower percentages of ROS in the 
absence of plasma. Among the different CaP substrates, biomimetic CDHA and 
CDHA-H induced the lower ROS release under PMA activation, irrespective of 
the presence or not of heparin (Figure 5-2 and Figure 5-3), which confirms that 
no specific response was activated upon monocytes or PMN in contact with 
heparin. Sintered β-TCP yielded the higher oxidative stress among all CaP 
substrates, in agreement with previous results reported by other authors.[54] 
Macrophages and osteoclasts are known to be tightly related, as in fact OC are 
derived from specifically stimulated macrophages. Three main molecules play 
pivotal roles in the OC maturation from OCP or macrophages, which are 
RANKL, OPG and M-CSF.[55] These molecules are secreted by stromal cells and 
osteoblasts, which have been pointed as necessary for osteoclast precursors 
maturation, as investigated by Udagawa et al.[56] RANKL and OPG are tightly 
linked since OPG is a decoy receptor which competes with RANK for RANKL. 
The balance between these two molecules usually dictates osteoclastogenesis.[57] 
Inhibition of osteoclastogenesis has been found to occur when OPG binds to 
RANK receptor; on the contrary, stromal cells and osteoblasts can secrete higher 
doses of RANKL to enhance bone resorption.[58] With regards to OPG-RANKL 
balance, some authors have pointed to GAGs to interact with OPG.[59] Irie et al. 
found that the addition of heparin in the culture medium of mouse bone marrow 
cell–osteoblast co-cultures promoted osteoclastic activity.[21] This was due to the 
interaction of heparin with OPG, leading to higher RANKL rates to bind to 
RANK receptors in osteoclasts.  
One of the limiting factors of apatitic CaPs is their poor resorption rates. Hence, 
our hypothesis was that heparin functionalization could be used to enhance 
osteoclast formation and resorption onto CaP substrates by interactions in the 
RANKL and OPG balance. This was tested by culturing osteoclast precursor 
cells on the surface of a biomimetic CDHA covalently functionalized with 
heparin (CDHA-H), and comparing the cell response with that on pristine CDHA 
(CDHA).  
The effect of heparin was clearly demonstrated by the TRAP-Hoechst staining 
(Figure 5-6). Even macrophage fusion and OC formation on CaPs was lower in 
number than on control TCPS, the presence of heparin (CDHA-H) highly 
increased the number of multinucleated cells compared to pristine CDHA (Figure 
5-7A). An important aspect that has to be further investigated is whether the 
substrates could lead to the formation of foreign body giant cells (FBGC), which 
Chapter 5 
120 
 
are related to OC and are also multinucleated cells. FBGC are usually TRAP-
positive, but nevertheless they possess higher number of nuclei (>10).[60] The 
formation of multinucleated cells with less than 10 nuclei was evident on all 
substrates, except for β-TCP at 14 days (Figure 5-7B). Multinucleated cells (>3 
nuclei) were found on CDHA-H at 14 days (Figure 5-6D), while on the pristine 
substrates similar OC were found only after 21or 28 days (Figure 5-6B and C), 
and in smaller amounts. Sintered β-TCP and CDHA had similar number of OC 
formed at 28 days (Figure 5-6I and C, respectively). 
Overall, the presence of heparin on CDHA-H demonstrated an enhancement in 
osteoclastogenesis, similar to TCPS but in lower cell number, probably due to the 
CDHA roughness which might hamper higher cell adhesion. Webster et al. found 
OC maturation after 10 to 13 days; conversely, they emphasized that this 
maturation was achieved preferably on nanostructured alumina and HA over 
microstructured surfaces using rat bone marrow cells.[61] However, some other 
authors have pointed to an opposite behavior. Costa et al. found that OC attach 
and mature preferably on smooth surfaces since rough surfaces might hamper the 
formation of sealing zones necessary for OC resorptive activity.[62] Likewise, 
Costa-Rodrigues et al. disclosed that an increase in the surface area, 
microporosity and wettability, resulted in less OC differentiation and function, 
compared to microsized grain topography.[63] 
Recently, in a previous work, we showed that rough surfaces, such as biomimetic 
CDHA with different nanotopographies were permissive for OC formation after 
21 days.[33] Even if no resorption pits were clearly evident, it has been reported 
that using focus ion beam (FIB) to transversally section cells and observing both, 
the cells and the underlying substrate, it was possible to detect early stages of OC 
activity.[64] In the present study, no clear resorption pits were observed in the 
SEM images of OC on the CaP substrates, irrespective of their roughness (Figure 
5-4). Only on the CDHA-H substrate, regions with damaged nanostructure were 
found (Figure 5-5) compatible with a resorptive OC activity, as observed by 
Leeuwenburgh et al. on biomimetic coatings[65] and by Schilling et al. on CaP 
cements.[66] Both authors found similar morphological changes in the 
microstructure of their substrates upon contact with OC. 
To assess OC number and their functionality, TRAP5b isoform and TRAP 
activity were investigated. No significant differences were found among CaP 
substrates at 28 days neither in TRAP activity (Figure 5-8B) nor in TRAP5b 
(Figure 5-8C). Therefore, no conclusive information can be drawn from these 
analyses. Since OC were already formed after 14 days for CDHA-H or 21 days 
for the other CaP substrates, one possible explanation could be that OC at 28 
days had already exceeded the peak of TRAP5b expression. Remarkable 
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differences in TRAP and TRAP5b were noticed only when CaP substrates were 
compared to TCPS.  
An indirect information on OC activity can be inferred from the extracellular 
calcium and pH measurements, being both parameters indicative of OC 
activity.[66] Osteoclastic resorption of the substrate should lead to an increase in 
Ca2+ concentration in the culture medium. However, this can be masked by the 
variations in calcium merely caused by cell culture medium in contact with the 
CaP substrates, even in absence of cells compared to TCPS. The three CaPs 
analyzed in this study were prone to uptake calcium from cell culture medium, 
although this uptake was more pronounced for biomimetic CDHA, as recently 
reported.[67] In presence of OC, calcium concentration increased for all 
substrates, which can be associated to OC activity. This increase was more 
marked for β-TCP (Figure 5-9B), probably due to its inherent higher solubility 
compared to CDHA.[68] Also for CDHA, the presence of cells led to an increase 
in calcium concentration in solution, which was more sustained for heparinized 
CDHA-H samples. Additionally, acidification, which is related to OC activity, 
was demonstrated for all CaP substrates in the presence of cells compared to 
TCPS (Figure 5-9D). β-TCP showed the highest pH variations, followed by 
CDHA-H, which were maintained over the time points of the experiment. 
Overall, we can conclude that heparin plays an important role as 
osteoclastogenesis modulator due to the high number of multinucleated cells. 
Additionally, SEM images supported the OC activity by degraded 
microstructures adjacent to cells in accordance as well with calcium and pH 
variations. Similarly to recent literature, we hypothesize the heparin effect on OC 
maturation is due to the interactions in the OPG/RANKL pathway, even these 
conclusions cannot be extended to all bone PGs.[69] 
This behavior, together with heparin participation in other stages of wound 
healing and tissue regeneration,[70,71] support the development of heparin-
mimicking materials in tissue engineering and treatment of various diseases.[72] 
5.5. Conclusions 
Biomimetic CDHA substrates showed a lower inflammatory response in terms of 
ROS release when compared to sintered β-TCP substrates; however, no further 
reduction of the inflammatory reaction was observed when the surface of CDHA 
was functionalized with heparin. On the contrary, OC were highly stimulated by 
the presence of heparin. Heparin immobilized on CDHA-H induced an earlier 
OC precursors fusion and maturation at 14 days, similar to that found on control 
TCPS, whereas the number of multinucleated cells on the pristine CaPs was 
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significantly lower at 14 days, and remained smaller also at longer times. Even if 
TRAP activity and TRAP5b at 28 days did not demonstrate clear differences in 
the OC activity, morphological assays (SEM and TRAP-Hoechst) showed well 
spread and mature OC on the surfaces of CDHA-H. Material degradation was 
found on CDHA-H due to OC activity as depicted from microstructural changes 
of the typical plate-like crystals. Overall, we can conclude that heparin binding to 
CDHA plays a important role as osteoclastogenesis modulator due to the high 
number of multinucleated cells. This could have an impact in the control of the 
resorption of bone grafts, and could represent a useful tool to integrate the 
biomaterial in the bone remodeling cycle. 
5.6. Appendix. Osteogenic response to heparinized 
CDHA 
In vitro cell studies with MSC on CDHA and heparinized CDHA were 
performed to further investigate the osteogenic potential of the substrates. CDHA 
discs were cultured in presence of rat MSC (2.85·104cells/mL) up to 3 days. 
Gene expression in terms of ALP, BMP-2, COLL and osteonectin (ON) was 
investigated at 6h, 1 and 3 days. TCPS was included as control. After the first 
time point (6h), osteogenic media (om) consisting of 50µg/mL ascorbic acid, 
10mM β-glycerophosphate and 100mM dexamethasone, was supplemented to all 
substrates, except to TCPS control. 
RNA was extracted at each time and quantified by spectrophotometer (NanoDrop 
ND-1000,Thermo Fisher Scientific Inc., Waltham, USA). QuantiTect Reverse 
Transcription Kit (Qiagen GmbH, Hilden, Germany) was used for the synthesis 
of 150µg of complementary DNA. DNA templates were amplified using the 
primers shown in Table 5-1 using QuantiTect SYBR Green RT-qPCR Kit 
(Qiagen GmbH, Hilden, Germany) in an RT-qPCR StepOnePlus (Applied 
Biosystems, Thermo Fisher Scientific Inc., Waltham, USA). RT-qPCR runs for 
specificity of primers was determined by melt curves analyses. Data was 
normalized by the expression of housekeeping gene (β-actin) and relative fold 
changes were calculated related to TCPS control at 6h, according to the 
following equation:  
Etarget∆Cq target (TCPS 6h – sample) / Ehousekeeping∆Cq housekeeping (TCPS 6 h – sample)(Eq. 1) 
where Cq represents the median value of the quantification cycle of the triplicate 
of each sample and E corresponds to the efficiency of amplification and is 
determined from the slope of the log-linear portion of the calibration curve, as 
E=10(-1/slope). 
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Table 5-1. Sequences of the primers used for quantification of gene expression (fw: 
forward; and rv: reverse). 
Gene Gene 
symbol 
Primer’ sequences 
(5’ to 3’) 
β-actin ACTB fw:CCCGCGAGTACAACCTTCT 
rv:CGTCATCCATGGCGA ACT 
Bone morphogenetic 
protein-2 
BMP-2 fw:CCCCTATATGCTCGACCTGT 
rv:AAAGTTCCTCGATGGCTTCTT 
Alkalinephosphatase ALP fw:GCACAACATCAAGGACATCG 
rv:TCAGTTCTGTTCTTGGGGTACAT 
Collagen COLL fw:GCAGCTGACTTCAGGGATGT 
rv:CATGTTCAGCTTTGTGGACCT 
Osteonectin ON fw:GTTTGAAGAAGGTGCAGAGGA 
rv:GGTTCTGGCAGGGGTTTT 
 
The presence of heparin on CDHA (CDHA-H) demonstrated to increase the 
ALP, COLL and ON at earlier time points (6h) compared to pristine CDHA and 
TCPS, maintaining their expression after 1d and finally decreasing at 3d (Figure 
5-10). Surprisingly, BMP-2 was not enhanced on CDHA-H, since pristine CDHA 
registered higher expression levels. However, whilst BMP-2 expression for 
CDHA and TCPS followed a peak expression with a subsequent decay, in 
CDHA-H, the expression of BMP-2 was maintained throughout the experimental 
time. Overall, these results provide some preliminary data that suggest the 
presence of heparin surfaces on CDHA may produce a stimulatory osteogenic 
effect, but this require further study. 
 
Figure 5-10. Gene expression of CDHA and heparinized CDHA-H, together with controls 
TCPS and osteogenic medium-stimulated TCPS, cultured with rMSC for 3 days. 
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6. Focus Ion Beam-Scanning Electron Microscopy 
Characterization of Osteoclastic Resorption of Calcium 
Phosphate Substrates 
 
Scope 
 
Osteoclastic activity is of paramount relevance to evaluate the capacity of bone grafts 
to be implemented in the bone remodeling process. Bone regeneration requires 
implants that are placed temporarily and slowly resorbed integrating them in the 
regenerative process. The active resorption by osteoclasts is crucial to allow new bone 
formation while implant is degraded. The study of OC activity in rough materials is 
often tricky due to the inherent irregularities in materials surface. The present chapter 
is devoted to the study of OC activity by focus ion beam (FIB). This novel technique 
allows cross-sectioning OC to investigate the cell underlying structure. CaP 
substrates, having similar compositions but different microstructures, have been 
cultured in presence of OC and their activity in terms of resorption pits formation and 
degradation of the subjacent microstructure have been investigated by FIB-SEM. 
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6.1. Introduction 
In recent years, Focus Ion Beam (FIB) systems have gained interest as a technique for 
the evaluation of biological samples. Although microscopic evaluation of biological 
matter is challenging, FIB equipped with scanning electron microscopy (SEM) or 
energy dispersive X-ray spectroscopy (EDX/EDS) provides an enhanced working 
environment for studying biomaterials. [1] 
The regenerative potential of bone substitute materials is usually evaluated in vitro by 
assessing how cultures of relevant cells interact with them. Briefly, at the early stages 
of implantation, inflammation occurs and a cascade of chemical signals which drive 
the monocyte/macrophage phenotype are triggered.[2] In an ideal scenario, these cells 
will fuse to form osteoclasts (OC), that is, bone resorbing cells.[3,4] Recent research 
indicates that osteoclasts can establish a cross-talk with osteoblasts leading to 
subsequent bone remodeling.[5] 
Several pre-clinical studies of bone substitutes have focused on these early interactive 
stages and, particularly, on the biomaterial-osteoclasts interactions in terms of OC 
adhesion, gene expression and evaluation of resorption pits.[6-8] Usually, these 
investigations require, on the one hand, the study of OC differentiation and activity, 
such as gene expression or marker identification, and on the other hand, the evaluation 
of morphological changes in the substrates, which implies staining or removal of cells 
in order to visualize the underlying structure. In this context, FIB-SEM technique 
offers the possibility of evaluating both cells and subjacent microstructural changes 
simultaneously. Various studies have used FIB for biological sample evaluation,[9-15] 
and the interest in the field has been increasing over recent years. Nevertheless, studies 
on osteoclast resorption on substrates of challenging topography are lacking. Thus, this 
chapter aims to assess the potential of FIB-SEM technique as a tool to evaluate cell 
morphology together with the microstructural changes caused by OC-mediated 
degradation beneath the cells. Three substrates with similar composition and different 
nano-microstructures are investigated to disclose to what extent FIB-SEM analysis 
may allow assessing the resorption activity of the cells on substrates with different 
topographies. 
6.2. Materials and Methods 
Three types of calcium phosphate substrates were prepared. Low temperature 
biomimetic CDHA was obtained through the hydrolysis of α-TCP (α-Ca3(PO4)2) 
powders at 37oC. Powders with two different particle sizes, coarse (C: 5.2 µm median 
size) and fine (F: 2.8 µm median size), were mixed with a 2.5wt% solution of sodium 
hydrogen phosphate (Na2HPO4, Merck) at a liquid to powder ratio of 0.35mL/g, to 
produce materials with microstructure consisting of an entangled network of plate-like 
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(CDHA-C) and needle-like (CDHA-F) CDHA crystals (both with a Ca/P ratio of 1.5) 
respectively.[16] High temperature stoichiometric sintered HA (sin-HA) was obtained 
by solid state reaction of a mixture of calcium hydrogen phosphate (CaHPO4, Sigma–
Aldrich C7263) and calcium carbonate (CaCO3, Sigma–Aldrich C4830) with a 
calcium to phosphorous ratio of 1.67 at 1100°C for 11h. All materials were produced 
into discs of 14mm diameter and 0.25mm thickness. 
Cell cultures were performed using human peripheral blood mononuclear cells 
(PBMC), from healthy 30-35 year old male voluntary blood donors. Donations were 
anonymous, so institutional review board (IRB) approval was not required. 
Mononuclear cells were isolated by centrifugation with Ficoll-Histopaque (Sigma-
Aldrich) and seeded at a density of 6·106 cells/cm2 on calcium phosphate discs. PBMC 
were differentiated into osteoclast precursors with RANKL-containing cell culture 
medium (DMEM) from human osteoblast supernatants. Cells were seeded on two 
discs for each substrate. The experiment was repeated twice using cells from two 
independent donors. OC precursors were cultured for 21 days. Afterwards, the cells 
were rinsed with PBS (Gibco, UK), fixed with paraformaldehyde/glutaraldehyde in 
0.1M sodium cacodylate buffer, and post-fixed in 2% osmium tetroxide (OsO4) at 
room temperature for 2 hours in order to achieve higher contrast. Then, samples were 
dehydrated in an ethanol series followed by hexamethyldisilazane (HMDS) drying to 
preserve osteoclasts morphology.[17,18] A thin gold-palladium film was sputtered before 
FIB-SEM examination to impart conductivity to samples. 
SEM in combination with FIB (Zeiss Neon 40) was used to examine both the surface 
of cells/materials and the microstructural features underneath the cells. As a first step 
conventional SEM was used to evaluate both the microstructure of the substrates and 
the morphology of the cells. Two representative cells were then selected for FIB cross-
sectioning using gallium ions (Ga+). Prior to cutting, a thin layer of protective 
platinum (Pt) was deposited on the surface by ion-beam assisted deposition in order to 
reduce the curtaining effect. This effect can result in image artefacts due to changes in 
the sputtering yield, as the beam passes over different composition regions, resulting in 
the appearance of parallel patterns in the ablated zones. The deposition of Pt helps 
obtaining smoother cross-sections, thus minimizing the curtaining effect.[13] 
Afterwards, a rough (coarse) milling was performed with a maximum current of 10nA 
to quickly remove most of the material up to a depth of approximately 20 µm nearby 
the region of interest. Finally, a polished cross-section was attained by subsequently 
reducing the Ga+ beam current from 2nA down to 500pA when approaching the Pt 
layer. This procedure reduces the ion beam damage on the sample and any re-
deposition effect, and allows the observation of smoother cross-sections of the cell and 
the underlying microstructure with minimal modifications. 
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6.3. Results and Discussion 
Sintered and biomimetic calcium phosphates have long been used in bone regeneration 
applications.[19,20] Despite biomimetic CaP substrates can better mimic the 
microstructure and composition of the mineral phase of bone than sintered CaP, in 
vitro assays on biomimetic materials are often more challenging.[21,22] The rough 
microstructure that results from the precipitation of nano/submicron crystals compared 
to the smoother textures of the high-temperature processed materials can have great 
impact on cell behavior. When challenged with osteoclasts the role of surface 
topography is particularly relevant, as osteoclastic resorption is dependent on the 
formation of an actin-rich sealing zone that precedes degradation.[23,24] In vitro studies 
had shown that too rough textures can hinder the formation of a proper sealing zone, 
impairing material degradation.[6,25] 
The possibility offered by FIB, to closely look at the cell-substrate interface can help 
shedding new light on the evaluation of resorption events on challenging biomimetic 
substrates compared to traditional sintered substrates. But FIB is a complex technique 
that requires accurate setting of the processing parameters to minimize the generation 
of artifacts during sectioning. Only artifact-free sections will allow drawing accurate 
conclusions. FIB tomographic studies have successfully been performed to analyze at 
different depths the delicate nature of biomimetic CaP consisting of an interlocked 
network of thin plate-like crystals, proving that artifact-free sections can be 
obtained.[26]The situation is more complex, however, when FIB is used to section cells 
cultured on these substrates. Drobne et al., as well as other authors, extensively 
described the potential of FIB milling to process biological samples and shed light on 
the optimal processing parameters in order to avoid shrinkage, melting effect, Ga+ 
implantation or side-wall artifacts.[18, 27-30] These effects can be effectively reduced by 
a first Pt layer deposition which protects the sample surface against re-deposition of 
ablated atoms, provides mechanical stability and reduces curtain effects. In addition, 
damage can be minimized by working with low ion beam currents and low 
acceleration voltages, especially during the final steps of the cross-section 
polishing.[29] All these strategies have been applied in the present study to investigate a 
series of three apatitic substrates consisting of two biomimetic formulations and a 
sintered material. 
Figure 1 shows the SEM images of the three different substrates in the absence (Figure 
6-1A, C and E) and in the presence (Figure 6-1B, D, F, and G) of cells after 21 days of 
culture. Biomimetic substrates obtained at 37oC, i.e. CDHA-C and CDHA-F, consisted 
of an entangled network of plate-like crystals (Figure 6-1A) and needle-like crystals 
(Figure 6-1C), respectively, whereas sin-HA presented a smoother polyhedral grain 
surfaces (Figure 6-1E) typical of high temperature ceramics. 
FIB-SEM characterization of OC activity on CaPs 
135 
 
 
Figure 6-1. SEM images of the surface of pristine CaP substrates (A, C and E) and cells on the 
substrates (B, D, F and G): CDHA-C (A, B); CDHA-F (C, D) and sin-HA (E, F, G).White arrows 
indicate a resorption pit. 
SEM evaluation of the seeded substrates showed similar cell morphologies consisting 
of flat and well spread cells ranging 20-30µm with various connecting filopodia 
(Figure 6-1B, D, and F). As illustrated in Figure 6-1G, resorption pits were easily 
visualized on some substrates (white arrows), namely sintered HA, where typical 30-
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50µm sized resorption lacunae were observed. In contrast, no clear resorption pits 
were evident on the rough and tortuous surfaces of biomimetic CDHA samples. In this 
case, FIB cuts could provide useful information to assess if any potential osteoclastic 
degradation is taking place locally, at the surface underneath the cell. 
The sequence to obtain the vertical section of a cell and the underlying substrate by 
FIB is shown in Figure 6-2, for biomimetic CDHA-F. No signs of resorption were 
observed in this case in the material under the cell (Figure 6-2D and d), as the needle-
like crystals appeared intact, when compared with the microstructure of the pristine 
material (Figure 6-1C, insert). One possible explanation is that the high roughness of 
the substrate prevented the OC from sealing the substrate, thus hampering the 
degradation process, as described in previous works.[6,25] One aspect worth noticing is 
the fact that the microstructure of the pristine material was revealed intact beneath the 
cell, thus confirming that there was no damage associated to FIB-sectioning.  
 
Figure 6-2. Sequence to obtain vertical sections of a cell (blue colored) on the CDHA-F substrate 
(A-B). No signs of degradation are visible in the material underlying the cell, where the needle-
like crystal morphology can be clearly observed (C and D; the asterisk in the insert indicates the 
region that has been magnified in the image; cell has been colored in blue). 
Interestingly, when on the same substrate a different cell of bigger size and with a 
more spread morphology, compatible with an osteoclastic or macrophage phenotype 
was analyzed, FIB/SEM images revealed that resorption was taking place in the 
underlying material (Figure 6-3). Thus, acid etching was evident in the subjacent 
microstructure where the needle-like crystals were no longer visible (Figure 6-3B* and 
C). Few needle-like crystals were only visible in the outer part of the cell (Figure 
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6-3D). The presence of both, resorptive and non-resorptive cells could evidence the 
multiple and reversible macrophage phenotype.[31] 
 
Figure 6-3. FIB-SEM images of a well spread cell (blue colored) on CDHA-F substrate with the 
insert showing the FIB cut performed (A). Higher magnification of the cell section and the 
subjacent area (B). A region with degraded crystals, marked with * in B is shown at a higher 
magnification (C), whereas non-degraded crystals in the periphery of the cell, marked with + in 
B are shown at a higher magnification (D). 
FIB-SEM images for the CDHA-C substrate are shown in Figure 6-4. As for CDHA-F, 
no resorption pits were found on the surface, and no signs of degradation even 
underneath the cells were detected by FIB cuts (Figure 6-4C and D), as revealed by the 
presence of the original plate-like crystals in the areas subjacent to the cell (*). As 
observed by traditional SEM imaging, numerous resorption pits and several flat and 
spread cells were observed on the sin-HA substrate (Figure 1F and G). Previous works 
have shown the resorptive capacity of osteoclast-like cells derived from mice bone 
marrow on similar substrates.[32,33] However, the study of osteoclast activity using 
primary human cells is less common, despite providing a closer understanding of the 
physiology of human bone resorption. FIB-SEM images of a cell on sin-HA are shown 
in Figure 6-5. Figure 6-5A shows a few cavities on the substrate at low magnification, 
corresponding to osteoclastic resorption pits (white arrows) clearly different from the 
intrinsic porosity of the material (+). Intergranular dissolution of the ceramic was 
displayed just under the cell (Figure 6-5C), with excavated cavities penetrating several 
micrometers into the substrate. This preferential dissolution in the grain boundaries is 
a frequently observed phenomenon, due to the higher reactivity of these regions that 
have a high free energy. Moreover, the surface of the polyhedral grains under the cells 
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presented a rougher aspect compared to the smoother appearance of the pristine 
ceramic, consistent with an acidic etching process (Figure 6-5C and D).  
 
Figure 6-4. FIB-SEM images of a cell (blue colored) on CDHA-C. The FIB section (B-D) show 
that the pristine microstructure, consisting of plate-like crystals, was not degraded under the cell 
(C and D, marked with *). 
 
Figure 6-5. SEM image showing various resorption pits (arrows) and intrinsic pores marked 
with + on sin-HA (A). FIB sections at higher magnification are shown (B-D), illustrating the 
underlying microstructure. Rougher grains are visible in (C) and (D) compared to the smooth 
original grains visible in (B), marked with *. 
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6.4. Conclusions 
The FIB-SEM technique has been shown to be a useful technique to assess the in vitro 
cell resorption activity, even at early stages of the process. The present study on 
different calcium phosphate substrates proved the potential of this technique to 
evaluate both the cell morphology and the microstructure of the substrate underneath. 
Indeed, this technique may disclose the initial activity of resorbing cells when not 
evident yet using other analytical methods, or may confirm and support morphological 
and biochemical evidences of osteoclast degradation capability in vitro. Sintered HA 
surfaces showed visible resorption pits and FIB cuts across the cell demonstrated the 
initial degradation of the ceramic as a consequence of acid etching promoted by the 
cells, which resulted in intergranular dissolution and roughening of the grain surface. 
In contrast, in low temperature biomimetic HA substrates, where no clear signs of 
degradation on the surface were visible by standard SEM imaging, possibly due to the 
higher roughness of these materials, different situations were found by FIB cuts. For 
some cells, no signs of degradation of the underlying material were observed, probably 
due to the lack of a sealing actin ring and a resorbing lacuna formation. However, at 
different sites where large flattened cells and more spread cells were observed, signs of 
degradation were clearly seen in the material underneath the cells, with the etching of 
the needle-like crystals. These findings underline the potential of the FIB-SEM 
technique to evaluate cell-mediated resorption in rough, irregular or coarse substrates. 
Indeed, FIB milling of resorbing cells allows exploring their underlying structure to 
unravel early degradation processes at stages when resorption pits have not yet 
occurred or are virtually impossible to detect. 
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7. GENERAL CONCLUSIONS 
This thesis was devoted to gaining insight into some strategies that can be 
implemented to enhance the performance of calcium phosphate bone grafts, focusing 
specifically on tuning some intrinsic physicochemical properties and on the surface 
functionalization with heparin. The effect on in vitro degradation and the response of 
relevant cell types was addressed, reaching the following conclusions: 
 
Chapter 2. In vitro degradation of calcium phosphates: effect of multiscale 
porosity, textural properties and composition 
 Microstructure, composition, specific surface area and porosity of CaPs 
modulated the materials’ degradation in acidic medium to different extents. 
Biomimetic CDHA with high SSA and low crystallinity presented the highest 
degradation rates, exceeding even the more soluble β-TCP. 
 The effect of SSA on degradation was dependent on the porosity and pore size, 
which conditioned the extent of acid penetration within the sample. 
 The combination of SSA and porosity (nano-, micro-, and macro) resulted in an 
exponential increase in degradation for high SSA substrates, but to a linear 
increase in sintered materials with low SSA. 
 Textural properties were shown to be crucial to modulate the degradation 
behavior, even outweighing the effect of other features such as the solubility of 
the compounds. 
Chapter 3. Carbonation of low temperature macroporous calcium phosphates 
 Carbonation of biomimetic CDHA foams can be achieved through different 
methods, either performing the setting reaction of α-TCP in a carbonate-
containing solution in biomimetic conditions or applying an hydrothermal 
treatment. Alternatively, the hydrothermal treatment in presence of carbonate 
solution can also be applied in pre-set CDHA foams. 
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 The biomimetic setting in presence of carbonate solution prolonged the 
hydrolysis reaction of α-TCP and allowed high levels of mainly B-type 
carbonate substitution (12.3%wt.) 
 Hydrothermal carbonation during the setting reaction of the foams was 
accomplished in 30min and it also resulted in high levels of carbonate 
incorporation (13%wt.). The product was however a mixture of CaPs (BCP). 
 Hydrothermal carbonation after setting of the foam did not alter the material 
composition but was the least efficient, allowing a very limited incorporation of 
carbonate of 2.5%wt. 
 The macrostructure of the foams was preserved in all carbonation methods but 
the nanostructure and SSA varied due to the different crystal morphologies 
formed during synthesis. 
Chapter 4. Heparinization of beta-tricalcium phosphate: immunoregulatory 
effects and osteogenic potential 
 Two different methods were successfully used for the incorporation of heparin 
onto CaP. Physisorption and chemisorption yielded different heparin grafting 
densities. Chemisorption performed through two step functionalization 
improved considerably the amount of heparin grafted. Especially, heparin 
density on β-TCP surface increased when longer silanization times were used, 
providing a higher degree of amines on surface to consequent attachment of 
heparin through carboxylates. Additionally, heparin immobilization did not 
alter the intrinsic textural properties of the substrate. 
 Heparinized β-TCP demonstrated to down-regulate ROS release and pro-
inflammatory cytokine release compared to pristine β-TCP. β-TCP-H yielded 
10% lower ROS than β-TCP, together with the down-regulation of TNF-α and 
IL-1β. 
 The pro-healing effect of heparin β-TCP was assessed also through the 
macrophage phenotype. Macrophage morphology was prone to evolve towards 
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elongated shapes in contact with heparinized surfaces which is consistent with a 
pro-healing macrophage phenotype. 
 The osteogenic potential of heparinized β-TCP was demonstrated by its 
interaction with rat MSC. β-TCP-H promoted rat MSC proliferation and 
additionally, enhanced the differentiation towards osteogenic lineage at earlier 
times than pristine β-TCP and the TCPS control. 
 
Chapter 5. Effect of heparinization on the inflammatory response and 
osteoclastogenesis of biomimetic CDHA 
 The amount of heparin immobilized on the surface was significantly increased 
on high specific surface area substrates such as biomimetic CDHA compared 
to sintered β-TCP substrates (Chapter 4). The amount of grafted heparin 
increased 10-fold on CDHA-H compared to β-TCP-H. As shown in the 
previous chapter 4, the heparinization preserved the nanostructural features of 
the substrates were preserved after heparinization. 
 The anti-inflammatory effect on heparinized CDHA was similar to pristine 
CDHA. However, ROS levels showed a substantial reduction compared to β-
TCP. CDHA-H showed a down-regulation of 70% of ROS compared to 
control TCPS. 
 Biomimetic CDHA substrates supported adhesion and proliferation of OC 
precursors. Interestingly, heparinized CDHA clearly promoted OC fusion at 
earlier time-points than pristine CDHA, demonstrating an enhancement of 
osteoclastogenesis. 
 Even if TRAP activity did not show clear differences amongst substrates, 
degraded zones due to OC activity were clearly observed by SEM on 
heparinized CDHA. 
 The osteogenic potential of CDHA-H was assessed in a pilot study using rat 
MSC cultures through gene expression analysis. Higher expression of 
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osteogenic markers such as COLL, ALP and ON was found on CDHA-H at 
earlier times than CDHA and TCPS.  
Chapter 6. Focus Ion Beam-Scanning Electron Microscopy Characterization 
of Osteoclastic Resorption of Calcium Phosphate Substrates 
 The evaluation of resorption by FIB-SEM imaging allowed the observation of 
early resorptive stages which are usually overlooked by other techniques. 
 Smooth surfaces such as those of sintered HA enhanced the resorption by OC, 
which was associated to the greater ease in creation of a sealing ring typical 
from these cells. 
 The nanostructure demonstrated to influence as well OC resorption. Needle-
like crystals were more effectively resorbed than plate-like crystals probably 
due to the high roughness of plates which hampered OC sealing zone creation. 
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8. FUTURE PERSPECTIVES 
The results obtained in the present thesis represent a promising platform for the field 
of tissue engineering and regenerative medicine. The novel platform to immobilize 
organic motifs onto CaPs offers a broad range of unknown interactions which need 
further characterization, and are likely to be enlightening. Understanding the 
interactions of this platform with different tissue involved in bone remodeling could be 
interesting to shed further light on the biological interactions occurring at bone-
biomaterials interface. 
The in vivo osteogenic properties of the macroporous biomimetic CDHA, and biphasic 
CaP materials developed in this thesis have been investigated to understand their 
inherent capacity to induce new bone formation in an animal study (in vivo) in 
collaboration with the Veterinary Faculty at Universitat Autònoma de Barcelona, 
Spain. The first results analyses have shown that nanostructured macroporous 
materials boosted the osteoinductive potential of these substrates. 
Regarding the development of macroporous scaffold, the implementation of heparin 
functionalization on such scaffold could be a great benefit for bone grafting. 
Macroporous foams have shown to improve substantially the degradation; hence 
further fostering with heparin immobilization can enhance their biological response. 
Stability measurements of heparin grafted are necessary to understand the potential of 
this functionalization. Heparin stability in solution has been previously studied due to 
their use as anticoagulant. Heparin can be stored in isotonic conditions over 24h, 
however, no stability studies upon grafting were performed. It could be interesting to 
know the extent of heparin activity over time. 
Additionally, heparin effects could be measured by its interactions with specific 
proteins. The binding affinity of heparin and different proteins involved in bone 
remodeling process could explain the mechanisms of heparin activity. 
According to the anti-inflammatory effects of heparin, more experiments should be 
performed in order to understand the modulatory effects of heparin. In the present 
work, three cytokines were analyzed, combining pro-inflammatory and anti-
inflammatory ones. However, other important cytokines play crucial roles during 
inflammation and could be interesting to know the extent of modulation over a wider 
range of cytokines. 
The osteogenic potential of GAGs has been investigated by several authors. 
Nevertheless, studies have focused on the mere interactions of GAGs and not of them 
in combination with CaP substrates. Further characterization by PCR is required to 
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understand the process by which mesenchymal cells are differentiated into osteoblasts 
by heparin. 
Interestingly, the interactions of heparin with different cell lineages might be 
beneficial to gain knowledge on the complex interactions of different cells. For 
instance, heparin has shown to have a great influence on endothelial cells which allow 
extravasation of blood cells to injured site by signals mediated by GAGs. The 
biological evaluation of heparin modified CaPs using endothelial cells can help 
understanding the effects during angiogenesis. In vitro testing culturing endothelial 
cells on heparinized substrates could help to compose a larger picture of what is the 
biological response of such substrates. 
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